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ABSTRACT 
All cells in a human body are constantly exposed to environmental fluctuations to which the 
cells must respond. Most of the cellular responses are mediated by proteins that are 
specifically regulated according to the distinct requirements of the cell. Among various 
protein regulatory mechanisms, modulation by post-translational modifications (PTMs), 
such as phosphorylation or sumoylation, provides an efficient and rapid means to alter protein 
function. PTMs have an incredibly vast selection of target substrates and thus are involved 
in nearly every aspect of cells´ life. The fast modulation of cellular response pathways is 
particularly important during stress, which often poses a threat to cell survival unless 
mitigated appropriately. One of the most extensively studied cellular stress response 
pathways is called the heat shock response, which is initiated upon exposure to protein 
damaging conditions. Heat shock response is mediated by heat shock transcription factors 
(HSFs), which assist in the restoration of protein homeostasis, by activating the transcription 
of genes encoding for molecular chaperones. Of the mammalian HSFs, HSF1 is considered 
the main regulator of heat shock response. During its activation-attenuation cycle, HSF1 is 
extensively modified by PTMs, which accompany the acquisition of transcriptional activity. 
For this, the modifications are considered as a prerequisite for HSF1 activity, though their 
exact importance has not been conclusively examined. Due to its ability to potently enhance 
cell survival during stress, HSF1 is regarded as a powerful enabler of carcinogenesis and 
high HSF1 expression has been detected in multiple human cancer types. HSF2, on the other 
hand, is mainly recognized as an important regulator of other differentiation and 
developmental programs, but its role in proteotoxic stress and in human malignancies is 
currently uncharacterized.  
 
In the first study of this thesis, I focus on sumoylation as a post-translational regulator of 
protein function and describe a novel method to examine sumoylated proteins in vivo in cells. 
The method is based on engineered human SUMO1 and can be utilized in the identification 
of novel sumoylation substrates. The second study examines HSF1 phosphorylation and aims 
at understanding the importance of this modification as a regulator of HSF1 activity. The 
results presented in this thesis show that hyperphosphorylation is not required for HSF1 
activity, but functions more as a fine-tuning mechanism for heat shock response. In the third 
study, we aimed at expanding our understanding on the role of HSFs in human malignancies. 
The study demonstrates that in contrast to oncogenic HSF1, HSF2 functions as a suppressor 
of prostate cancer invasion and shows that HSF2 downregulation promotes metastatic 
behavior of prostate cancer cells. Finally, the fourth study examines the role of HSF2 in 
proteasome inhibition-induced prolonged proteotoxic stress and establishes HSF2 as an 
essential cell survival factor in these conditions. Moreover, the work identifies HSF2-
dependent expression of cadherins as a key determinant of cellular sensitivity to proteotoxic 
stress and thus greatly expands our knowledge regarding HSFs as factors promoting cell 
survival. Taken together, the work presented in this thesis elaborates on HSF-mediated 
cellular survival pathways and lays a ground for future studies regarding HSFs as important 
regulators of human physiology and disease. 
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TYÖN TIIVISTELMÄ (ABSTRACT IN FINNISH) 
Jokainen elimistömme solu elää jatkuvasti erilaisten stressitekijöiden ympäröimänä. 
Säilyäkseen elossa vaihtelevassa ympäristössä, solun on kyettävä tunnistamaan suuri määrä 
erilaisia viestejä ja osattava käynnistää kulloiseenkin viestiin sopiva solunsisäinen vaste. 
Solunsisäiset vasteet ovat usein proteiinien eli solun valkuaisaineiden välittämiä, joiden 
toimintaa säädellään muun muassa erilaisten translaation jälkeisten muokkausten, kuten 
fosforylaation tai sumolaation, välityksellä. Translaation jälkeisillä muokkauksilla on 
soluissa lukuisa joukko kohdeproteiineja ja niiden kautta voidaankin säädellä lähes jokaista 
solun toimintaa. Useiden proteiinien yhtäaikainen säätely on erityisen tärkeää erilaisten 
solustressien aikana, jolloin solun on nopeasti käynnistettävä useita solua suojelevia 
geeniohjelmia. Eräs tärkein solujen stressivasteista on nimeltään lämpösokkivaste, ja sen 
tehtävä on suojella solua sen altistuessa proteotoksisille eli proteiineja vahingoittaville 
ympäristötekijöille, kuten korkeille lämpötiloille tai raskasmetalleille. Lämpösokkivastetta 
säädellään lämpösokkitekijöiden (engl. heat shock factors, HSFs) välityksellä, jotka 
aktivoituvat proteotoksisen stressin seurauksena ja käynnistävät solua suojelevien 
esiliinaproteiinien geenien luennan. Esiliinaproteiinit estävät vahingoittuneiden proteiinien 
virheellisen laskostumisen ja siten varmistavat solujen elossa säilymisen stressistä 
huolimatta. Ihmisellä esiintyvistä lämpösokkitekijöistä HSF1:n ajatellaan olevan tärkein 
esiliinaproteiinien ilmenemistä säätelevä tekijä. Aktivoitumisen yhteydessä HSF1 käy läpi 
useita translaation jälkeisiä muokkauksia. Näistä merkittävin on fosforylaatio, jonka 
ajatellaan vaikuttavan HSF1:n kykyyn säädellä esiliinaproteiinien ilmenemistä, vaikka 
tarkkaa tutkimusaineistoa tästä ei vielä ole. Säätelemällä esiliinaproteiinien ilmenemistä 
vaikeissakin olosuhteissa HSF1:llä on erinomainen kyky suojella solua ohjelmoidulta 
solukuolemalta. Tämä solua suojeleva ominaisuus heijastuu HSF1:n taipumukseen edistää 
syövän etenemistä poikkeavissakin olosuhteissa ja HSF1:n yli-ilmeneminen onkin havaittu 
useissa ihmisen syöpätyypeissä. Jokainen ihmisen syöpäsolu ilmentää kuitenkin myös 
HSF2:ää, joskin se toiminta syövässä on vielä täysin tuntematon. 
 
Tämän väitöskirjan ensimmäisessä osatyössä tarkastelen sumolaatiota proteiinien toimintaa 
säätelevänä tekijänä ja kuvailen uuden menetelmän sumoloituneiden proteiinien tutkimiseen 
soluissa. Menetelmä perustuu ihmisen SUMO1-muunnelmaan, jota voidaan tehokkaasti 
hyödyntää uusien sumolaation kohdeproteiinien tunnistamisessa. Väitöskirjan toinen osatyö 
keskittyy fosforylaatioon ja sen merkitykseen HSF1:n säätelyssä. Työ osoittaa aikaisempien 
käsitysten vastaisesti, että fosforylaatio ei määrää HSF1:n aktiivisuutta vaan toimii 
pääasiassa lämpösokkivasteen voimakkuuden hienosäätelyssä. Kolmas osatyö tarkastelee 
HSF2:n merkitystä eturauhassyövässä ja osoittaa, että toisin kuin syöpäsoluja suojeleva 
HSF1, HSF2 hidastaa eturauhassyövän etenemistä. Työssä osoitetaan, että alhainen HSF2:n 
määrä edistää eturauhassyövän etenemistä. Väitöskirjan neljännen ja viimeisen työn 
tarkoitus on ollut määritellä HSF2:n tehtävät proteotoksisissa stresseissä. Työssä selvisi, että 
HSF2 säätele soluissa kadheriinien ilmenemistä ja siten on tärkeä solujen elinkykyä 
määrittävä tekijä pitkäkestoisen proteasomi-inhibition yhteydessä. Kaiken kaikkiaan tässä 
väitöskirjassa esitetyt osatyöt laajentavat merkittävästi tuntemustamme 
lämpösokkitekijöiden säätelystä ja tehtävistä erilaisissa fysiologisissa ja patofysiologisissa 
konteksteissa ja siten toimii tärkeänä pohjana tuleville jatkotutkimuksille.  
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SAMMANFATTNING (ABSTRACT IN SWEDISH) 
Varje cell i människan är konstant utsatt för olika stressförhållanden. För att kunna överleva 
varierande omgivningar, måste cellen ha förmågan att reagera och anpassa sig till varierande 
miljöer och initiera försvarsmekanismer när det behövs. De flesta cellskyddande 
signalräckorna är styrda av proteiner som är reglerade via olika mekanismer beroende på 
cellens behov. Ett av de snabbaste sätten att påverka proteinernas funktion är genom 
posttranslationella modifieringar, såsom fosforylering eller sumoylering. Posttranslationella 
modifieringar har en stor mängd målproteiner och följaktligen framträder i majoriteten av 
cellbiologiska program. Reglering av proteiners funktion genom posttranslationella 
modifieringar är speciellt viktig under cellulär stress som kräver en snabb aktivering av 
skyddsprogrammen. En utav de viktigaste försvarsmekanismerna kallas för 
värmechockresponsen, som aktiveras vid proteinskadande stress. Värmechockresponsen är 
karakteriserad av stressinducerad aktivering av värmechockfaktorer, vilka styr genuttrycket 
av molekylära chaperoner som i sin tur hjälper andra proteiner att upprätthålla sin struktur 
och funktion. Utav de fyra värmechockfaktorerna som förekommer hos däggdjur (HSF1-4), 
är HSF1 den viktigaste för värmechockresponsen. Under aktiveringen av 
värmechockresponsen utsätts HSF1 för omfattande fosforylering, vilket ansetts krävas för 
dess aktivering, fast obestridbart bevis ännu saknas. Med tanke på att HSF1 kan skydda celler 
i varierande omgivningarna, kan cancerceller utnyttja denna egenskap i syfte att anpassa sig 
till cellulärstress och hög HSF1 uttryck har upptäckts i många cancertyper. Funktionen av 
HSF2 i cancer är dock ännu okänd även om det har rapporterats att HSF2 kan också modulera 
värmechockresponsen. 
 
 
I den första studien av denna avhandling, har jag fokuserat på sumoylering som en 
posttranslationell regulerare av proteinfunktion och beskriver hur ett specifikt konstruerat 
SUMO1-protein uttrycks i cellen och kan användas för identifiering av nya målproteiner för 
sumoylering in vivo. I den andra studien undersökte jag fosforylering som en 
regleringsmekanism för HSF1:s aktivitet. I motsatts till de tidigare rapporterade resultaten, 
visar denna studie att fosforylering inte är nödvändig till HSF1:s aktivering, utan 
modifikationen styr tröskelvärdet för aktivering av värmechockresponsen. Den tredje studien 
fokuserade på att karakterisera HSF2:s funktion i prostatacancer. Resultaten visar att i 
motsats till den cellskyddande inverkan av HSF1, har HSF2 en hämmande effekt på 
tumörutveckling och nedreglering av HSF2 uttrycket ökar cancercellernas invasion. Den 
fjärde studien undersöker HSF2:s funktion under proteasominhibition, vilket förorsakar 
proteinskadande stress. Studien visar att HSF2 är en essentiell faktor under kronisk 
proteinskadande stress och den styr uttrycket av cellulära adhesionsmolekyler, kadheriner, 
som kan skydda celler mot stress. Resultaten som presenteras i denna avhandling ökar vår 
förståelse om värmechockfaktorernas funktion i olika fysiologiska och patofysiologiska 
förhållandena och utgör grunden till vidare undersökningar i framtiden. 
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INTRODUCTION 
The human body is a collection of tissues and organs that are all composed of different types 
of cells. Regardless of the tissue type, cells are continuously surrounded by diverse 
environmental signals that, for example, direct the maintenance of distinct tissue phenotypes. 
Sometimes the environmental signals are damaging to the cells and can severely compromise 
cell survival. In such cases, the damaged cell initiates a survival response, which aims at 
restoring cellular homeostasis. Nearly every cellular survival response is characterized by 
activation of distinct DNA-binding proteins that translocate to the nucleus and induce the 
production of specific mRNA species in a process called transcription. The mRNA is 
subsequently exported from the nucleus to the cytoplasm, where the RNA-code is translated 
into a peptide chain that functions as the building material for new proteins. The newly 
produced proteins then assist in repairing the damage and prevent the induction of cell death. 
As proteins are the key factors mediating cellular functions, cells are particularly vulnerable 
to signals that damage the proteins. Accordingly, cells have acquired a variety of survival 
responses that can be launched to protect the proteome. Adequate regulation of survival 
pathways is essential, as their misregulation can lead to severe human diseases, including 
cancer, type II diabetes, and neurodegenerative disorders.  
 
This thesis focuses on the cellular responses that are elicited particularly upon protein 
damaging stresses. The first study examines a specific post-translational modification, called 
sumoylation, which can be used as a rapid regulatory mechanism to steer protein function 
during stress and other conditions. The study presents a novel method to analyze sumoylated 
proteins in cells and thus promotes our understanding on the complexity of sumoylation as a 
regulator of diverse cellular functions. The second study begins the exploration of a distinct 
cellular survival pathway, called the heat shock response. Heat shock response is activated 
in response to cytosolic protein damage and it is directed by heat shock transcription factors 
(HSFs). In response to stress, HSFs accumulate in the nucleus and activate the transcription 
of their target genes. The canonical HSF target genes encode molecular chaperones that by 
restoring the intracellular protein folding environment promote cell survival during stress.  
 
This thesis investigates how HSF1 and HSF2 are regulated in proteotoxic stress conditions. 
The second study reveals that in contrast to previous assumptions, post-translational 
modification of HSF1 with phosphorylation is not required for HSF1 activity but rather fine-
tunes the threshold of HSF1-mediated stress response. Due to the ability to promote cell 
survival during stress, HSF1 is considered as a strong enabler of cancer progression. 
However, the importance of HSF2 in cancer progression has remained unknown. Thus, the 
third study aimed to elucidate whether HSF2 has an impact on cancer progression. 
Intriguingly, the study shows that, unlike HSF1, HSF2 suppresses prostate cancer 
development via genes that are related to invasion and metastasis formation. In contrast to 
HSF1, which is essential for cell survival during acute stress, HSF2 has been shown to be 
dispensable to acute heat shock response and its role in proteotoxic stresses has remained 
enigmatic. In the fourth study of this thesis, HSF2 is presented as an essential survival factor 
during prolonged proteotoxic stress, such as that induced by long-term proteasome inhibition. 
The study shows that HSF2 protects cells against proteotoxicity by maintaining cadherin-
mediated cell-cell adhesion and thus defines a completely novel HSF2-dependent 
transcriptional program in cell protection. Taken together, this thesis provides novel 
information regarding the regulation of cellular survival responses and implicate distinct 
roles for HSF1 and HSF2 in human physiology and disease. 
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REVIEW OF THE LITERATURE 
1 POST-TRANSLATIONAL MODIFICATIONS 
The life of a cell is characterized by the plasticity of its proteome, which is achieved through 
multilevel protein regulation. For example, the existence of a protein can be regulated at the 
level of transcription or translation, through which the cell can shift its protein composition. 
More rapid way to generate functional diversity is, however, regulation through post-
translational modifications (PTMs), where already existing proteins are modified by 
covalently conjugated chemical groups or small proteins or subjected to other structural 
changes. Perhaps the most well-known examples of chemical modifications are 
phosphorylation, acetylation, and methylation, whereas conjugation of ubiquitin-like (UBL) 
proteins is a classic example of protein post-translational modifications. Phosphorylation is 
by far the most common PTM and it has been estimated that the human proteome contains 
over 230 000 distinct phosphorylation sites (Vlastaridis et al., 2017). Not surprisingly, the 
importance of phosphorylation has been demonstrated in a vast variety of cellular signaling 
pathways, all the way from cell division to cell death. Acetylation and methylation [also with 
thousands of target sites (Khoury et al., 2011)], are specifically recognized for their role as 
histone modifications affecting gene expression, whereas ubiquitination is the main 
modification regulating protein degradation. Signaling through PTMs is often mediated by a 
selection of effector proteins, which recognize the modification via modification-specific 
interaction domains. For example, SH2 (Src homology domain 2) and Polo-box domains can 
bind phosphorylated tyrosine and serine/threonine residues, respectively, and thereby 
transduce the signal forward in the signaling pathway. Common to all the above-mentioned 
modifications is, that they are all covalently conjugated to substrates via specific enzymes 
that mediate the attachment in an ATP-dependent manner. Moreover, these modifications are 
almost exclusively transient in their nature and their deconjugation from substrates is 
biologically equally essential as their conjugation. 
 
In this section of 1 Post-translational modifications, I will first describe ubiquitin and the 
ubiquitin conjugation pathway. After that I will proceed with the small ubiquitin-like 
modifier, SUMO, which is in the center of the first original publication (I). Moreover, I will 
briefly describe the best-studied chemical modification, phosphorylation, which has a key 
role in the second original publication (II). Finally, the interplay between sumoylation and 
ubiquitination will be reviewed, as that was the focus of my early PhD work and will be 
presented in the Results and discussion. 
 
1.1 Ubiquitin  
In 1975, Gideon Goldstein and co-workers isolated a novel polypeptide from bovine thymus 
that had thymocyte-differentiating properties (Goldstein et al., 1975). Curiously, the same 
protein appeared to be expressed in all possible tissues they studied and could be identified 
from phylogenetically distant organisms such as mammals and plants. Inspired by these 
findings, Goldstein and co-workers courageously ended the article by proposing that the 
polypeptide is a universal feature of a living cell. And they were right. Goldstein and co-
workers had isolated ubiquitin, a 76-amino acid protein, which is highly conserved all across 
the Eukaryota (Hochstrasser, 2009). Intriguingly, analogously functioning prokaryotic 
ubiquitin-like (Pup) protein has been identified in Eubacteria, which as an example of 
convergent evolution, further highlights the importance of ubiquitin in biological systems 
(Delley et al., 2017). 
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In humans, ubiquitin is encoded by a multigene family, composed of UBB, UBC, UBA52, 
and RPS27A, from which it is transcribed and translated as a precursor protein polyubiquitin 
or as a protein fusion with ribosomal proteins. From these precursors, single ubiquitin 
moieties are cleaved by endopeptidases and folded to their natural conformation in the cell. 
Ubiquitin is structurally characterized by a -grasp fold, where antiparallel -sheets fold 
around the central -helix (Figure 1). This structure, also called the ubiquitin fold, is common 
to all ubiquitin-like (UBLs) proteins and ubiquitin-like domains (ULDs) (Winget & Mayor, 
2010). More specific to ubiquitin itself, is a hydrophobic patch on the surface of the protein, 
which is generated by the closely landing hydrophobic amino acids in the globular state of 
the protein. This patch mediates many of the protein-protein interactions and hence is 
essential for the correct function of ubiquitin. 
 
 
 
 
Figure 1. Ubiquitin molecule. (A) 
Ubiquitin is a globular protein where 
antiparallel -sheets (1-5) 
surround the core -helix (1). (B) 
Hydrophobic patch on the surface of 
ubiquitin is formed by the proximity 
of hydrophobic amino acids. 
Adapted from (Winget & Mayor, 
2010). 
 
1.1.1 Ubiquitin conjugation pathway 
Ubiquitin is covalently conjugated to its target proteins through a stepwise enzymatic cascade 
that consists of E1-activating enzyme, E2-conjugating enzyme and E3-ligase (Figure 2). The 
current literature estimates that the human genome encodes two E1-activating enzymes, 40 
E2-conjugating enzymes, and at least 600 E3-ligases (Bett, 2016). The large number of 
enzymes creates enormous functional diversity, as specific combination of enzymes can be 
utilized to induce ubiquitination in response to distinct stimuli. In the activation step, 
ubiquitin first forms an adenylate intermediate via E1 in an ATP-dependent reaction after 
which it is linked to the active site cysteine on E1 in a reaction that releases AMP. In the 
conjugation step, activated ubiquitin is transferred from the E1 to the active site cysteine on 
the E2-conjugating enzyme. Finally, the E3-ligases responsible for substrate selection 
mediate the conjugation of the ubiquitin moiety to the target lysine on the substrate. The 
isopeptide linkage conjugating ubiquitin to the substrate is formed between the carboxyl 
group of the C-terminal glysine residue (G76) on ubiquitin and the -amino group of the 
target lysine of the substrate. Recurrent repetition of the cascade creates a ubiquitin chain on 
the substrate protein, which dictates the biological outcome of the modification. Ubiquitin 
can be removed by deubiquitinating enzymes (DUBs), which function as isopeptidases and 
break the linkage between the substrate and the ubiquitin or ubiquitin moieties in a ubiquitin 
chain. After this, ubiquitin is recycled and can enter yet another round of conjugation.  
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Figure 2. Ubiquitin conjugation 
pathway. Ubiquitin (U) is 
conjugated to target proteins 
through an enzymatic cascade that 
consists of E1-activating enzyme, 
E2-conjugating enzyme and E3-
ligase. Ubiquitin is first activated by 
E1 in an ATP-dependent reaction 
after which it is transferred to E2 and 
conjugated to the target lysine with 
the assistance of substrate-
recognizing E3 ligases. 
Deubiquitinating enzymes, DUBs, 
deconjugate ubiquitin from the 
target proteins and mediate the 
recycling of ubiquitin in the cell. 
 
1.1.2 The ubiquitin code 
Ubiquitination was originally identified as a modification regulating protein degradation by 
Avram Hershko, Aaro Ciechanover, and Irwin Rose, who in 2004 were awarded with a Nobel 
Prize in Chemistry for their discovery on the essential cellular degradation pathway, the 
ubiquitin-proteasome system (UPS). Since their original observations, it has become evident 
that the ubiquitin signal, here also referred to as ubiquitin code, is extremely versatile and 
regulates several cellular pathways in addition to protein degradation. The molecular 
diversity of the ubiquitin code is based on the notion that ubiquitin can function as a signaling 
moiety in practically every conformation that it occurs in a cell. For example, 
monoubiquitination, multi-monoubiquitination, and polyubiquitination all function as 
specific signaling signatures with distinct biological roles (Figure 3, Table 1). Moreover, 
polyubiquitin chains can adopt diverse linkage type dependent conformations (Figure 3), 
which increases significantly the complexity of the ubiquitin code. Ubiquitin can also signal 
as free chains or even as free diubiquitin, which also can adopt several different 
conformations and thus influence the signal that it mediates (Ye et al., 2012). Similar to all 
PTMs, versatile signaling through ubiquitination requires recognition of the modification by 
specific ubiquitin binding motifs (UBDs) on larger effector proteins, which transform the 
covalent modification to molecular actions (Hurley et al., 2006). 
 
The structural basis for the ubiquitin signal variety is the amino acid sequence of ubiquitin 
itself, which contains multiple target sites for additional PTMs (Swatek & Komander, 2016). 
For example, ubiquitin has seven internal lysine residues (K6, K11, K27, K29, K33, K48, 
and K63) and an N-terminal methionine (M1), which can all function as acceptor amino acids 
for ubiquitin moieties enabling the formation of polyubiquitin chains (Figure 3). These chains 
can be either homogeneous (only one linkage type) or heterogeneous (multiple linkage types) 
and thus they can generate chains with diverse conformations and branched structures (Figure 
Cys
E2
E1
Cys
ATP
PPi
DUB
AMP
AMP
E1 Cys
Substrate
E2
E2 E3
Substrate
E1
E3
Substrate
E3
Lys
LysSubstrate
U
U
U
U
U U U U
 Review of the Literature  
 12
3). The variability in the linkage types is, however, only one layer of the ubiquitin code as 
ubiquitin can be modified also by other PTMs. For example, many of the recent mass 
spectrometric screens have identified ubiquitin as a target protein for other ubiquitin-like 
modifiers, such as SUMO or NEDD8, and thereby have provided evidence for the existence 
of mixed UBL-chains (Hendriks et al., 2014; Lamoliatte et al., 2014). Moreover, ubiquitin 
is also modified with small chemical modifications, such as acetylation and phosphorylation 
(Swatek & Komander, 2016), indicating that ubiquitin signaling is far more complex than 
originally expected. Indeed, it appears that the linkage type, chain length, conformation, and 
decoration, altogether provide an essentially unlimited spectrum of signal combinations 
relaying the biological effects of ubiquitination according to the specific cellular 
requirements. 
 
 
 
Figure 3. Ubiquitin code diversity. Ubiquitin is a 76-amino acid protein that together with other 
PTMs creates enormous signal diversity. Target substrates (grey ovals) can be monoubiquitinated or 
polyubiquitinated by ubiquitin chains with different linkage types and conformations. Ubiquitin chains 
can also be formed via heterogeneous linkages and can be branched. Furthermore, other PTMs, 
such as other ubiquitin-like proteins (e.g. SUMO, turquoise pentagon) can further modify ubiquitin 
chains. Modification through acetylation (red) and phosphorylation (green) has also been reported. 
Free ubiquitin chains, or modified free ubiquitin chains, have also cellular signaling functions. 
Altogether, these modifications can create essentially an unlimited number of signal variation when 
mixed according to the requirements of the cell.  
 
The differentially linked ubiquitin chains are the most extensively studied form of ubiquitin 
code variation. As identified in the original studies, many of the differentially linked 
ubiquitin chains target proteins to proteasomal degradation, which still is the best examined 
function of polyubiquitination. Typically, the degradation signal is composed of K48-linked 
ubiquitin chains, though K6-, K11-, and K29-linked chains can also direct proteins to the 
proteasome in specific circumstances (Swatek & Komander, 2016). For long, the central 
dogma of the field proposed that K48-linked tetraubiquitin chains are the minimal 
requirement for proteasomal recognition. However, recent discoveries questioned the 
prevalent view by showing that diubiquitin chains distributed in multiple lysine residues are 
more efficient degradation signals than the tetraubiquitin, indicating that versatile 
determinants can regulate the decision of protein degradation (Lu et al., 2015). In addition to 
K48-linked chains, K63-linked polyubiquitin chains are considered as the second canonical 
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ubiquitin chain type. K63-linked chains are not directly involved in protein degradation, but 
function in other important cellular processes of which regulation of the NF-B (nuclear 
factor κB) signaling and DNA repair are probably the most extensively studied (Swatek & 
Komander, 2016).  
 
All the other chain linkage types (M1, K6, K11, K27, K29 and K33) are often referred to as 
“atypical” ubiquitin chains and only a few specific cellular functions are known to require 
formation of these atypical chains. For example, similar to K63-linked chains, the M1-linked 
ubiquitin chains have an important role in the NF-B-signaling, where they regulate the 
formation of a signaling hub eventually leading to the phosphorylation and subsequent 
degradation of the NF-B inhibitor IB (Iwai et al., 2014). K6-linked ubiquitin chains are 
involved in the mitochondrial quality control, whereas K11-linked ubiquitin chains are 
especially important during cell cycle progression (Matsumoto et al., 2010). Interestingly, 
the mitotic regulator APC/C (metazoan anaphase promoting complex/cyclosome) utilizes the 
only known K11-specific E2 enzyme, UBE2S, to generate K11-linked chains on specific 
proteins, which appear to function as additional degradation signals enhancing the 
proteasomal destruction of the targets (Wickliffe et al., 2011). The K27-linked chains are the 
least understood ubiquitin chain type. Few of the recent studies suggests that K27-linked 
chains are involved in the epigenetic regulation of DNA damage response through histone 
ubiquitination and together with K29-linked chains might be involved in the neuronal 
protection in Parkinson´s disease (Gatti et al., 2015; Nucifora et al., 2016). K29-linked chains 
have also been shown to be negative regulators of the Wnt-signaling pathway by creating 
non-degradable ubiquitin chains that disrupt the interaction between Wnt and its co-receptors 
(Fei et al., 2013). Finally, K33-linked chains appear to be relevant for TCR (T-cell antigen 
receptor) and AMPK (AMP-activated protein kinase) signaling as well as intracellular 
protein trafficking (Akutsu et al., 2016). The importance of mixed ubiquitin chains is only 
emerging and at least mixed K48/K11-chains have been reported to be extremely efficient 
proteasomal degradation signals (Meyer & Rape, 2014). The current knowledge regarding 
the physiological role of various ubiquitin chain types is summarized in the table below 
(Table 1). 
 
Table 1. Ubiquitin code diversity specifies the physiological impact of ubiquitin conjugation. 
Table generated according to (Akutsu et al., 2016) and (Swatek & Komander, 2016). 
 
 
 
Ubiquitin linkage type Physiological role
Monoubiquitination Gene expression; protein interaction; autophagy; trafficking
Multimonoubiquitination Endocytosis 
K6 DNA damage response; Parkin-mediated mitophagy; proteasomal degradation
K11 Cell cycle control; proteasomal degradation
K27 Nuclear translocation; DNA dmage response
K29 Ub-fusion degradation; Wnt/b-catenin signaling; proteasomal degradation
K33 TCR signaling; post-Golgi trafficking; AMPK-related kinase signaling
K48 Proteasomal degradation
K63 Endocytosis; protein trafficking; innate immunity; NF-kB signaling; DNA repair
M1 Innate immunity; NF-kB signaling; angiogenesis; selective autophagy
Unanchored chains Second-messenger-like signaling
Mixed chains K48/K11 in proteasomal degradation; K63/M1 in scaffolding; Lys11/K63 endocytosis
 Review of the Literature  
 14
1.2 Small ubiquitin-like modifier, SUMO 
As the name directly implies, the 12 kDa SUMO belongs to the superfamily of ubiquitin-like 
(UBL) proteins that resemble ubiquitin in their structure, function, and conjugation pathway. 
Similar to all the family members, SUMO is characterized by the globular -grasp fold and 
the C-terminal di-glycine motif required for the covalent attachment. The SUMO protein was 
initially found in yeast two-hybrid assays as a binding partner of seemingly unrelated proteins 
associated with acute promyelocytic leukemia (Boddy et al., 1996), apoptosis (Okura et al., 
1996), and DNA repair (Shen et al., 1996). Almost simultaneously with these findings, the 
covalent attachment of SUMO was discovered by two separate laboratories, who both 
identified it as a modification regulating the localization of RanGAP1 to nuclear pores 
(Matunis et al., 1996; Mahajan et al., 1997). Today, nearly 20 years after the initial 
discoveries, SUMO conjugation, or sumoylation, has been connected to an extensive number 
of essential biological processes such as DNA replication and repair, chromatin organization, 
transcription, ribosome biogenesis and protein degradation (Pichler et al., 2017). Moreover, 
recent advancements in substrate identification methods have revealed thousands of novel 
sumoylation substrate proteins, further highlighting the biological importance of this 
modification in diverse cellular functions (Hendriks et al., 2014).  
 
The human genome encodes five distinct SUMO isoforms (SUMO1-5), that differ in their 
amino acid sequences, target selection, and tissue distribution. In most contexts, SUMO2 and 
SUMO3 are collectively called SUMO2/3 since they share 97% sequence homology (Figure 
4) and cannot be experimentally separated with the current methodologies. SUMO1 on the 
other hand, shares only 47% sequence similarity with SUMO2/3 and is considered as an 
independent SUMO paralog (Figure 4). Intriguingly, only SUMO2 is essential to mouse 
development, whereas SUMO1 and SUMO3 are dispensable (Evdokimov et al., 2008; Zhang 
et al., 2008). SUMO1-3 proteins are ubiquitously expressed in a wide range of tissue types, 
whereas SUMO4 and SUMO5 have been cloned only from specific tissues (Guo et al., 2004; 
Liang et al., 2016). Moreover, it has not been conclusively shown that SUMO4 or SUMO5 
would be translated to functional proteins in cells and hence their biological relevance 
remains elusive (Pichler et al., 2017).  
 
 
 
Figure 4. SUMO sequence alignment. Homologous sequences between human SUMO isoforms 
are indicated with green. The diglycine motifs required for SUMO conjugation are highlighted in red.  
 
Due to the sequence variation, SUMO1 and SUMO2/3 have both common and unique 
selection of substrate proteins and thus are biologically partially different (Saitoh & Hinchey, 
2000; Vertegaal et al., 2006). For example, RanGAP1 is preferentially sumoylated with 
SUMO1, whereas SP100 nuclear antigen prefers SUMO2/3 (Saitoh & Hinchey, 2000; 
Vertegaal et al., 2006). One of the most striking structural differences is the presence of 
sumoylation consensus motif (discussed below) on the SUMO2/3 N-terminus, which enables 
efficient formation of SUMO2/3 chains through K11 both in vitro and in vivo conditions 
(Matic et al., 2008; Tatham et al., 2001). Upregulation of SUMO2/3 chain formation is 
detected upon a variety of cell stress conditions and it is widely considered as a modification 
SUMO1 1 MSDQEAKPSTEDLGDKKEG- EYI KLKVI GQDSSEI HFKVKMTTHLKKLKESYCQRQGVPMNSLRFLFEGQRI ADNHTPKE 79 
SUMO2   1 MADE- - KP- - - KEGVKTENNDHI NLKVAGQDGSVVQFKI KRHTPLSKLMKAYCERQGLSMRQI RFRFDGQPI NETDTPAQ 75 
SUMO3 1 MSEE- - KP- - - KEGVKTEN- DHI NLKVAGQDGSVVQFKI KRHTPLSKLMKAYCERQGLSMRQI RFRFDGQPI NETDTPAQ 74 
SUMO1 80 LGMEEEDVI EVYQEQTGGHSTV – 101 
SUMO2 76 LEMEDEDTI DVFQQQTGGVY 95 
SUMO3 75 LEMEDEDTI DVFQQQTGGVPESSLAGHSF 103
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promoting cell survival during stress (Saitoh & Hinchey, 2000; Blomster et al., 2009; 
Golebiowski et al., 2009). Although SUMO1 is mainly recognized for its role as a cap 
regulating SUMO2/3 chain elongation, it can also form chains through non-consensus lysine 
residues (Matic et al., 2008). Unlike the diverse signaling mediated by versatile ubiquitin 
chain types, analogous functions for SUMO chains have not been reported.  
 
1.2.1 SUMO conjugation pathway 
The SUMO conjugation pathway resembles closely the ubiquitin conjugation pathway as it 
similarly consists of E1-activating enzyme, E2-conjugating enzyme and E3-ligase (Figure 5) 
(Gareau & Lima, 2010). Prior to conjugation, the immature SUMO precursors are cleaved 
from their C-terminal end by SUMO-specific proteases (SENPs) revealing the diglycine 
motif (GG) required for covalent substrate attachment. After maturation, SUMO is activated 
by the E1-activating enzyme, which in an ATP-dependent reaction first forms an adenylate 
intermediate with SUMO and then binds to the cleavage-exposed C-terminal glycine residue 
through a high-energy thioester bond. The SUMO pathway utilizes only one heterodimeric 
E1-activating enzyme, which in humans is composed of subunits SAE1 and SAE2 (Aos1-
Uba2 in yeast). After activation, SUMO is transferred to the E2-conjugating enzyme Ubc9, 
which further transfers the SUMO to the target lysine residues. Distinct to the ubiquitination 
pathway, where dozens of E2-conjugating enzymes have been identified, Ubc9 is the only 
known SUMO E2 enzyme. Ubc9 is essential to sumoylation and to organismal development 
as Ubc9 knock-out is lethal to most eukaryotes (Hayashi et al., 2002; Nacerddine et al., 2005; 
Nowak & Hammerschmidt, 2006). Interestingly, and also opposite to hundreds of substrate-
recognizing ubiquitin E3-ligases, Ubc9 can be solely responsible for recognizing the 
sumoylation target lysine (Bernier-Villamor, Sampson, Matunis, & Lima, 2002). However, 
the substrate-Ubc9-SUMO complex needs to be stabilized to enable efficient SUMO 
conjugation and this stabilization can be mediated by SUMO-specific E3 ligases or additional 
Ubc9-binding (Revievewd in Pichler et al., 2017). Finally, the covalent isopeptide bond is 
formed between the G97 of SUMO and the -amino group on the target lysine. The fast 
SUMO deconjugation is mediated by SUMO-specific proteases (SENPs), which hydrolyze 
the covalent isopeptide bond between the substrate and the SUMO, maintaining the free pool 
of SUMO in the cell (Figure 5).  
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Figure 5. SUMO-conjugation 
pathway. Before entering the 
conjugation pathway, precursor-SUMO 
(S) is cleaved by SUMO-specific 
proteases, SENPs, to reveal the C-
terminal GG-motif. After that, SUMO is 
activated by heterodimeric E1 in an 
ATP-dependent manner. From E1, 
SUMO is transferred to the catalytic 
cysteine residue on the E2-conjugating 
enzyme Ubc9. With the assistance of 
E3-ligating enzymes, SUMO is 
covalently conjugated to the target 
lysine residues on the substrate 
protein. SUMO can be removed from 
substrate proteins by SENPS, after 
which SUMO can re-enter the 
conjugation pathway.  
 
1.2.2 Sumoylation consensus motif and SUMO-interaction motif 
The sumoylation target lysine on substrate proteins, is often embedded in the sumoylation 
consensus motif (SCM), denoted by KxE/D ( is a hydrophobic residue, often I or V). 
This consensus motif is found in approximately half of the identified sumoylation substrates. 
The SCM is directly recognized by Ubc9 (Bernier-Villamor et al., 2002) and the interaction 
can mediate E3-independent sumoylation in vitro. However, in cells this interaction requires 
additional stabilization, which can be acquired through multiple ways. Such stabilizing 
mechanisms are, for example, the SCM-extensions that provide additional interface between 
the substrate and Ubc9 thereby enhancing the affinity. In 2006, we identified in human heat 
shock transcription factor 1 the first SCM-extension, the phosphorylation-dependent 
sumoylation motif (PDSM) (Hietakangas et al., 2006). The characterized motif consists of 
the consensus tetrapeptide and an adjacent phosphorylatable serine residue at position +5 
from the target lysine (KxExxSP) and was identified from many transcriptional regulators. 
Subsequently, an analogous motif, termed negatively charged amino acid-dependent 
sumoylation motif (NDSM), was described, where negatively charged amino acids, such as 
glutamic acid (E) or aspartic acid (D), were identified adjacent to the sumoylation target 
lysine (KxExx(E/D)4) (Yang et al., 2006). Mechanistically these motifs function similarly, 
as the negative charge provided by the phospho group or the amino acids E and D, enhance 
the affinity to the basic patch on Ubc9  and thereby stabilize the interaction (Yang et al., 
2006; Mohideen et al., 2009). Notably, biologically these extensions are distinct as the 
transient nature of phosphorylation and subsequent sumoylation provides additional 
flexibility to the complex stabilization and thus can be regulated according to cellular 
requirements.  
 
Although many of the identified sumoylation targets contain the sumoylation consensus 
tetrapeptide, it is important to note that sumoylation can also occur on non-consensus binding 
sites or inverted sumoylation motifs (ExK). In these cases, the structural environment 
surrounding the sumoylation target lysine, determines the occurrence of the modification. An 
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example of such regulation is the sumoylation of ubiquitin ligase E2-25K on non-consensus 
lysine 14, which only occurs in the context of specific -helix (Pichler et al., 2005). 
Similarly, a specific loop structure on the DNA-binding domain of human heat shock factor 
1 (HSF1) restricts the sumoylation of a nearby consensus lysine though the same lysine in 
different structural environment can be efficiently sumoylated (Anckar et al., 2006). 
Interestingly, non-consensus sumoylation seems to respond to cell environmental changes, 
since stress conditions, such as heat shock, are known to increase specifically non-consensus 
sumoylation.  
 
In addition to covalent non-consensus/consensus sumoylation, SUMO can exert its 
regulatory effects also through non-covalent protein-protein interactions. These interactions 
are conveyed by hydrophobic core regions called SUMO-interaction motifs (SIM), which are 
characterized by an array of V/I-V/I-x-V/I or V/I-x-V/I-V/I amino acids flanked by acidic 
residues (Song et al., 2004). The SIMs are analogous to the ubiquitin binding domains 
(UBDs), but instead of multiple well-defined UBDs, only one type of SIM has currently been 
identified. SIMs are embedded in a highly versatile set of host proteins, including 
sumoylation enzymes, sumoylation target substrates, and other SUMO-binding proteins 
(Gareau & Lima, 2010), and hence can mediate multiple biological effects.  
 
1.2.3 Identification of sumoylation sites 
Since sumoylation is widely accepted as an essential modification in a multitude of biological 
processes, the growing interest in characterizing the whole mammalian sumoylated 
proteome, or sumoylome, is not surprising. After identification of the sumoylation consensus 
motif (SCM), analysis of protein amino acid sequence was used as the primary method to 
identify novel sumoylation target substrates. However, existence of the motif is insufficient 
to determine the susceptibility for SUMO-modification, as the general structural environment 
created by the surrounding amino acids is also essential (Anckar et al., 2006). Furthermore, 
as sumoylation can also occur on non-consensus sumoylation sites, it is obvious that more 
advanced methods to identify in vivo sumoylation sites are mandatory.  
 
Sumoylation is a very similar modification to ubiquitin and therefore the experimental 
approaches to study sumoylated proteins are also highly similar. Like ubiquitination, global 
sumoylation of cellular proteins is often studied through proteomics, which currently is the 
most reliable method for such analysis. A typical SUMO proteomics experiment utilizes 
Histidine-tagged (His6 or His10) exogenous SUMO, which is enriched from the cells with 
metal-affinity resins based on divalent cations (e.g. Ni2+ or Co2+) (Hendriks & Vertegaal, 
2016a). Subsequently, the purified sample is digested, and the peptides are analyzed with 
mass spectrometry, which ionizes the peptide sample and sorts the ions according to their 
mass-to-charge ratio. The challenge in this kind of approach is the nature of the branched 
SUMO remnants that yield complex fragmentation patterns and thus are complicated to 
analyze. A common way to overcome this is to generate additional tryptic digestion site to 
the C-terminus of SUMO proteins (e.g. T95R on human SUMO1), which truncates the long 
peptide remnant and consequently alleviates the analytical challenge (Hendriks & Vertegaal, 
2016a). Moreover, sumoylation is a very transient and low-stoichiometry modification, 
which further challenges the purification and detection sensitivity. Thereby the sample 
preparation usually requires inhibition of desumoylating enzymes, e.g. with NAM (N-
ethyilmaleimide), which enhances the accumulation of sumoylated proteins inside the cell.  
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1.3 Interplay between SUMO and ubiquitin 
Though being independent modifications, SUMO and ubiquitin pathways are known to 
converge in a variety of ways (Denuc & Marfany, 2010). For example, SUMO and ubiquitin 
can have antagonistic effects on protein function through shared lysine residues or SUMO 
can modify enzymes in the ubiquitination pathway. Sumoylation of a protein can also 
cooperatively stimulate ubiquitination and direct proteins to degradation. An example of 
antagonistic SUMO and ubiquitin effects is the regulation of NF-κB, a key factor involved 
in immune responses and cell survival. To become activated, NF-κB requires efficient 
function of the ubiquitination machinery that promotes the degradation of its inhibitor IκBα. 
However, the ubiquitinated lysine (K21) on IκBα can also be sumoylated by SUMO-1, which 
inhibits IκBα degradation and consequently results in the inactivation of NF-κB signaling 
(Desterro et al., 1998). Examples of  ubiquitination enzymes regulated by SUMO are E2-
25K (ubiquitin conjugating enzyme) (Pichler et al., 2005) and USP25 (ubiquitin-specific 
protease 25) (Meulmeester et al., 2008), which both are inhibited by sumoylation. 
Furthermore, the cooperative crosstalk is best exemplified by the function of SUMO-targeted 
ubiquitin ligases (STUBLs), which recognize polysumoylated proteins through SIMs and 
ubiquitinate the target through a separate ubiquitin E3 ligase domain. Most extensively 
studied STUBL is RNF4 (RING finger protein 4), which was identified as the first enzyme 
mediating SUMO-dependent degradation of the oncogenic PML-RAR fusion in acute 
promyleocytic leukemia (APL) (Lallemand-Breitenbach et al., 2008; Tatham et al., 2008). 
RNF4 has two N-terminal SIMs through which it recognizes sumoylated PML, whereas a 
separate C-terminal RING ubiquitin E3 ligase domain mediates the ubiquitination and 
subsequent degradation of PML. APL is mainly treated with arsenic trioxide, which RNF4-
dependently stimulates PML-RAR degradation and consequent differentiation of the 
leukemic cells, often resulting in clinical remission of the patients. Interestingly, STUBLs 
can also ubiquitinate SUMO itself (Tatham et al., 2008), which further increases the 
versatility of the SUMO-ubiquitin crosstalk. 
 
Despite the above-mentioned observations regarding SUMO and ubiquitin crosstalk, there is 
only mass spectrometric evidence regarding direct regulation of ubiquitin by SUMO i.e. 
sumoylation of ubiquitin. Since SUMO-1 can regulate SUMO-2/3 chain length by acting as 
a cap in the end of the chain (Matic et al., 2008), the possibility that it could also regulate 
ubiquitin chains should not be excluded. Considering that ubiquitin chains have a central role 
in multiple cellular pathways, the hypothesis that SUMO could regulate ubiquitin biology is 
intriguing and will be addressed in more detail in this thesis in the chapter 1.2 Sumoylation 
of ubiquitin in Results and discussion. 
 
1.4 Phosphorylation 
Protein phosphorylation is the most common PTM and used to regulate proteins in all 
organisms, including animals, plants, fungi, bacteria, and archaea (Khoury et al., 2011). 
Phosphorylation refers to a chemical modification of a protein, where negatively charged 
phosphate group is conjugated to the target amino acid on the substrate proteins. Usually the 
modification is targeted to serine (S), threonine (T), or tyrosine (Y) residues, although basic 
amino acids such as histidine (H), lysine (K), and arginine (R) have been also reported to 
undergo phosphorylation (Cieśla et al., 2011). Similarly to other PTMs, phosphorylation is 
ATP-dependent (though in some cases other nucleoside triphosphates can also provide the 
phosphate) and regulated by specific enzymes, called kinases and phosphatases that mediate 
the phosphorylation and dephosphorylation events, respectively. Mechanistically, the kinases 
function by transferring the terminal phosphate group from ATP to the target amino acid on 
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the substrate, whereas the removal of the phosphorylation is catalyzed by phosphatase-
mediated hydrolysis.   
 
From the cellular point of view, protein phosphorylation is an essential PTM that is involved 
in an extensive amount of regulatory pathways and thereby affects nearly every aspect of a 
cells´ life (Cohen, 2000). Phosphorylation of a protein can modulate protein function in a 
variety of ways, such as changing the conformation of the protein or by altering its activity, 
localization, or stability. Phosphorylation can also create novel interaction sites for diverse 
phosphopeptide binding motifs on effector proteins and thus can regulate the whole 
interactome of the protein. Phosphorylation-regulated signaling pathways typically function 
through step-wise kinase cascades, where the modification and subsequent activation of a 
kinase is sequentially repeated. One example of such kinase cascades, is the MAP-kinase 
cascade, which is activated by external stimuli of transmembrane receptors and leads to 
activation of MAP3K (e.g Raf) that activates MAP2K (e.g MEK1/2) that activates MAPK 
(e.g ERK1/2) that finally activates the effector proteins, which transform the signal to, for 
example, transcriptional response (Keshet & Seger, 2010). Many of the transcriptional 
effectors undergo multi-site phosphorylation (i.e. phosphorylation of multiple amino acids 
on the same target protein), and thereby can integrate various signaling inputs before 
transforming the modification into biological action. Moreover, phosphorylation often 
interplays with other post-translational modifications, which further increases the signal 
diversity. Interestingly, a very recent study by Hendriks and co-workers revealed that 
especially sumoylation is often preceded by phosphorylation (Hendriks et al., 2017), 
suggesting that these modifications are closely connected in various cellular signaling 
pathways.   
 
  
 Review of the Literature  
 20
2 CELLULAR RESPONSES TO PROTEOTOXIC STRESS 
Every cell in the human body is dependent on the correct function of its proteins. When 
encountering environmental variations disturbing protein homeostasis (or proteostasis), the 
cell responds to the stress by initiating specific transcriptional programs to counteract the 
damage. Depending on the type and location of the damage, the transcriptional selection of 
genes is optimized according to the requirements of the cell. For example, accumulation of 
misfolded proteins in the endoplasmic reticulum or mitochondria initiates an unfolded 
protein response (erUPR or mtUPR, respectively) that activates genes leading to 
normalization of organelle homeostasis (Haynes and Ron, 2010; Walter and Ron, 2011). 
However, when the protein damage occurs in the cytosol, the counteractive response is called 
the heat shock response and it leads to induction of molecular chaperones, which help to 
mitigate the damage by restoring the cytosolic protein folding environment. The importance 
of maintaining proteostasis is highlighted by multiple human diseases, such as Huntington´s 
disease, Alzheimer´s disease, or cancer, which all stem from imbalances in protein 
homeostasis (discussed in more detail in section 3 HSFs in pathologies).  
 
In this section of 2 Cellular responses to proteotoxic stress, I will first focus on the cytosolic 
proteotoxic stress response, the heat shock response, and introduce the heat shock 
transcription factors that mediate this response. After that, I proceed with a more detailed 
description of HSF1 and the PTMs regulating its activity, a key question addressed in the 
second study of this thesis (II). I will end this section by reviewing the current knowledge 
about HSF2, as that is in the main focus in the third and fourth study of this thesis (III and 
IV).  
 
2.1 Heat shock response 
In 1962, an Italian geneticist Ferruccio Ritossa accidentally discovered the heat shock 
response, while studying the chromatin structure of the salivary gland polytene chromosomes 
of fruit fly Drosophila busckii (Ritossa, 1962). During one of the experiments, the fly cells 
were non-intentionally cultured at elevated temperatures, which resulted in appearance of 
specific chromosomal puffs associated with newly synthesized RNA (Ritossa, 1962). Nearly 
a decade later, this heat-inducible RNA synthesis was shown to coincide with the synthesis 
of specific proteins, which consequently were designated as the heat shock proteins (Hsps) 
(Tissières et al., 1974). Yet another decade later, genomic mapping and comparative 
sequence analysis of the puffed loci led to the identification of a common promoter element, 
the heat shock element (HSE), which was shown to be essential for the heat-induced 
activation of the loci (Mirault et al., 1982; Pelham, 1982). Subsequently, the HSE, consisting 
from inverted nGAAn pentamers, was used as a bait to purify the HSE-binding proteins, 
eventually leading to the identification of heat shock transcription factors, HSFs, first from 
Drosophila (Parker et al., 1984; Wu, 1984) and later on also from yeast (Sorger & Pelham, 
1987) and human cells (Kingston et al., 1987). Hence, though not knowing it himself, Ritossa 
had serendipitously described a phenomenon that together with the subsequent studies 
defined the fundamental attributes of heat shock response; namely the heat-inducible 
activation of specific factors, which through distinct genomic elements regulate the mRNA 
synthesis of heat shock proteins.  
 
Despite originally identified in the fly, the heat shock response is an evolutionarily extremely 
well conserved stress protective mechanism that is activated upon exposure to variable 
environmental stresses (Figure 6). In fact, the ability to respond to proteotoxic stress is so 
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vital to an organism, that analogous protective pathways have been identified in every living 
organism, all the way from unicellular bacteria and yeast to multicellular plants and animals. 
And as one of the pioneers of the modern stress biology, Susan Lindquist, once said “It may 
be that some creature living in the depths of the ocean does not have a heat shock response, 
but that is doubtful” (Lindquist, 1986). In all studied organisms, the response is characterized 
by a transcription factor (or factors), which stress-inducibly binds to its target promoters and 
activates the transcription of its target genes. Most of these target genes code for molecular 
chaperones, such as the heat shock proteins, which are essential in promoting protein 
homeostasis in both unstressed and stressed cells (Hartl et al., 2011). The superfamily of 
molecular chaperones consists of six major Hsp subfamilies: HSPH (Hsp110), HSPC 
(Hsp90), HSPA (Hsp70), DNAJ (Hsp40), HSPB (Small Hsps), and chaperonins HSPD/E 
(HSP60/10) and CCT (TRiC) (Kampinga et al., 2009). In non-stressed cells, the main role of 
these chaperones is to assist in the folding of newly synthesized polypeptides and it is the 
HSPCs, HSPAs (especially the constitutively expressed HSPA8) and CCT chaperonins that 
are mainly responsible for this de novo folding. These chaperones function by forming 
multiprotein complexes with co-chaperones and utilize ATP to assist the acquisition of 
correct 3D conformation. The mechanism by which chaperones recognize their target, is 
based on their ability to bind hydrophobic amino acid residues exposed either on the nascent 
polypeptide chain or on the stress-inducibly unfolded proteins.  
 
 
 
Figure 6. Heat shock response is activated in a variety of conditions. During stress or specific 
pathologic conditions, cytosolic HSFs are activated, trimerized and localized to the nucleus. In the 
nucleus, HSFs bind to their target elements and activate the transcription of the target genes. Many 
of the target genes encode molecular chaperones, such as the heat shock proteins (Hsps), which 
ameliorate the toxicity of damaged proteome. 
 
The majority of the chaperone superfamily proteins are upregulated during proteotoxic stress, 
but by far the best characterized is the massive upregulation of the HSPA (Hsp70) family 
proteins, such as HSPA1A, HSPA1B, and HSPA6. During stress, these chaperones prevent 
the aggregation of damaged proteins and help the refolding of unfolded proteins. The ATP-
bound HSPAs bind to non-native proteins with the help of DNAJ co-chaperones, which 
deliver the substrates to HSPAs and stimulate the ATPase activity. With further help of 
additional co-factors such as a nucleotide exchange factor (NEF), Bcl2-associated 
athanogen-1 (Bag1), or Hsp70-binding protein 1 (Hspbp1), ADP and the client substrate are 
released and the machinery can enter yet another round of folding cycle. The ATP-
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independent HSPBs, the small Hsps, are also essential for the heat shock response, as they 
bind with high affinity to exposed hydrophobic patches and form soluble protein deposits 
inside the cell. With the assistance of Hsp70 and/or Hsp90 machineries, these aggregates are 
resolved and refolded back to their native conformations or directed to protein degradation 
machineries (Richter et al., 2010). 
 
2.2 Mammalian heat shock transcription factor family 
One of the most striking features of the heat shock response is the extremely rapid 
transcriptional activation of genes required for cellular survival. Both in prokaryotes and 
eukaryotes, the rapid activation is achieved through specific transcription factors that regulate 
gene expression in a signal dependent manner. In the bacteria Escherichia coli, this stress-
inducible transcription factor is called 32, which can heat-inducibly activate transcription of 
DnaK, a prokaryotic homologue of Hsp70 (Grossman et al., 1984). In yeast Saccharomyces 
cerevisiae, nematode Caenorhabditis elegans, and fruit fly Drosophila melanogaster, the 
heat shock response is mediated by a single heat shock factor (ScHSF, CeHSF, and DmHSF, 
respectively), whereas multiple HSFs exist in fish, birds, mammals and plants. In fact, the 
existence of several HSFs was primarily reported in Lycopersicon peruvianum (tomato), 
which led to the hypothesis that more than one HSF exists also in other organisms (Scharf et 
al., 1990). 
 
The mammalian HSF family consists of seven members (HSF1-5, HSFX, and HSFY), of 
which HSF1 and HSF2 are the most extensively studied. Cloning of these factors from human 
cells was reported simultaneously in 1991 by two independent studies, both utilizing a probe 
produced according to the conserved amino acids in the DNA-binding domain of fly and 
yeast HSFs. The first study screened a human B cell lymphoma cDNA library and identified 
human HSF1 (Rabindran et al., 1991). The second study isolated two distinct HSF cDNAs, 
with significant homology to the conserved HSF-regions, from HeLa cells and thus indicated 
for the existence of another HSF in human cells (Schuetz et al., 1991). These factors were 
named HSF1 and HSF2 and already in that original study, the factors were hypothesized to 
have separate functions in human cells (Schuetz et al., 1991). Later on, homologous factors 
were also cloned from mouse liver (mHSF1 and mHSF2) (Sarge et al., 1991) and chicken 
(cHSF1, cHSF2, cHSF3) (Nakai & Morimoto, 1993), which conclusively confirmed the 
existence of multiple HSFs in different vertebrates.  
 
HSF1 is the most studied member of the mammalian HSFs and the main factor regulating 
inducible gene expression during stress (McMillan et al., 1998). HSF1 is the functional 
counterpart of ScHSF, CeHSF, DmHSF, and the avian HSF3, and essential for the cellular 
and organismal protection against heat-induced damage (McMillan et al., 1998). Similarly 
to HSF1, HSF2 has the ability to bind DNA stress-inducibly, though its role in the stress 
response is considered modulatory (Östling et al., 2007). Instead, HSF2 is especially 
important in specific developmental processes, such as gametogenesis and corticogenesis, 
and it has been implicated in neuronal migration and fetal alcohol spectrum disorder (FASD) 
(El Fatimy et al., 2014). Both HSF1 and HSF2 will be discussed in more detail in the 
forthcoming chapters.  
 
The third member of the mammalian HSFs, HSF3, was discovered relatively late, and 
currently, it has been identified only in mouse (Fujimoto et al., 2010). In the experiments 
conducted by Fujimoto and co-workers, exogenously expressed mHSF3-GFP (green 
fluorescent protein) did accumulate in the nucleus in response to stress, but failed to activate 
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the Hsp70 promoter. However, mHSF3 appeared to be important in the regulation of non-
classical heat shock genes, such as PDZK1 and PROM3 (Fujimoto et al., 2010), indicating 
that the protein can function as an active transcription factor. Interestingly, overexpression 
of mHSF3 in Hsf1-/- MEFs partially restores the cellular resistance to heat shock, suggesting 
that mHSF3 might be important during inducible heat shock response. Similarly to HSF2, 
HSF4 is also highly important in differentiation and developmental processes and more 
specifically in the development of mammalian sensory organs. In humans, a point mutation 
in the HSF4 DBD leads to cataract, linking HSF4 directly to human diseases (Bu et al., 2002). 
Studies performed with HSF4 knock-out mice have revealed that the cataract is at least 
partially caused by decreased expression of -crystallins and increased expression of 
fibroblast growth factors (FGFs) that leads to accumulation of inclusions and premature 
differentiation of the lens epithelial cells, respectively (Fujimoto et al., 2004). Lastly, the 
biological importance of HSF5, HSFX and HSFY is currently uncharacterized, but they are 
all hypothesized to be involved in gametogenesis (Widlak & Vydra, 2017). 
 
2.2.1 Structural features of HSFs 
All HSF family members are characterized by functional domains that contain both common 
and unique features. The most conserved domain is the N-terminal winged helix-turn-helix 
DNA-binding domain (DBD) (Figure 7), which is present in all eukaryotic HSFs (Vuister et 
al., 1994). The crystal structure of DBD was reported in 1994 by Harrison and co-workers, 
who by studying the yeast Kluyveromyces lactis revealed the core structure of the domain: 
four-stranded antiparallel -sheet capping three -helices (Harrison et al., 1994). More 
recently, the mammalian DBD was co-crystallized with DNA, uncovering the positioning of 
DBD and the remaining HSF on the opposite sites of the DNA strand in a so called DNA-
embracing structure (Jaeger et al., 2016; Neudegger et al., 2016). Furthermore, Jaeger and 
co-workers extended the structural knowledge by crystallizing also the DBD wing-domain 
from human HSF2 (Jaeger et al., 2016). This wing-structure is distinct among other winged 
helix-turn-helix transcription factors, as it is not in contact with the DNA minor groove or 
with the DNA backbone (Littlefield & Nelson, 1999). In addition, the wing-domains between 
hHSF1 and hHSF2 differ both structurally and functionally and provide essential isoform-
specific protein-protein interaction sites important for DNA-binding affinity and binding-
specificity in distinct cellular states (Ahn et al., 2001; Jaeger et al., 2016). 
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Figure 7. Heat shock factor family. Out of the seven mammalian HSFs (HSF1-5, HSFX and HSFY) 
HSF1, HSF2, and HSF4 are expressed ubiquitiously in human and mouse, whereas expression of 
HSF3 is only detected in mouse. The chicken HSF3 is depicted only to highlight the structural 
similarity between hHSF1, mHSF1 and the cHSF3 that likely results in the detected functional 
similarity of these proteins in acute stress responses. Domain abbreviations: DBD, DNA-binding 
domain; HR-A/B/C heptad repeat domains required for oligomerization; RD, regulatory domain; TAD, 
transactivation domain. Adapted from Dayalan Naidu & Dinkova-Kostova (2017).  
 
Unlike many other transcription factors that often exist as dimers, HSFs are trimerized upon 
activation, which is thought to improve the DNA-binding affinity. This intermolecular 
oligomerization is mediated by overlapping arrays of hydrophobic leucine-zipper-like heptad 
repeats (HR-A/B) located directly adjacent to the DBD (Sorger et al., 1989) (Figure 7). In 
addition to the highly conserved DBD, this region is also largely similar between the HSF 
isoforms. Indeed, already in the initial studies that recognized multiple HSF isoforms in 
mammalian cells, the region was hypothesized to provide an “inter-isoform” interaction site 
and thus suggested for the existence of HSF heterotrimers. Excitingly, this hypothesis was 
later confirmed experimentally (Östling et al., 2007; Sandqvist et al., 2009) and is currently 
considered as one of the mechanisms enabling cell- and developmental-state specific HSF 
target gene selection. Yet another heptad repeat (HR-C) resides closer to the C-terminus and 
exists only in specific HSF isoforms. This domain confers an intramolecular interaction site 
and represses spontaneous oligomerization and subsequent acquisition of DNA-binding 
activity. Interestingly, neither mammalian HSF4 nor ScHSF contains HR-C, resulting in 
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constitutively trimeric and DNA-binding competent forms of these HSFs (Sorger et al., 1987; 
Nakai et al., 1997).  
 
Though trimerized and DNA-bound, HSFs do not necessarily induce target gene expression 
(Hensold et al., 1990; Jurivich et al., 1992). For that they require the C-terminal 
transactivation domain (TAD), which provides an interaction site for co-factors and 
chromatin remodelers thus potentiating transcription (Sullivan et al., 2001; Boellmann et al., 
2004). In the absence of stress, the TAD is negatively regulated by a centrally located 
regulatory domain (RD) (Shi et al., 1995, Zuo et al., 1995). The RD is self-sufficient in its 
heat-sensing capability and can provide heat-sensitivity also to heterologous activatory 
domains (Newton et al., 1996). The RD is subjected to multiple PTMs, such as 
phosphorylation, sumoylation, and acetylation, but the exact role of these modifications is 
still partially unknown. 
 
2.2.2 HSE, target sequence for HSF binding 
Similarly to many other sequence-specific transcription factors, HSFs act through a 
conserved upstream regulatory DNA-element, known as the heat shock element, HSE (Amin 
et al., 1988). These elements consist of inverted repeats of the pentameric nGAAn consensus 
sequence and are highly variable in their primary sequences, length, and orientation 
(Mendillo et al., 2012; Riva et al., 2012; Vihervaara et al., 2013). A typical HSE contains 
two to six inverted nGAAn repeats and heat-responsive promoters harbor often more than 
one HSE (Littlefield & Nelson, 1999). Since HSFs bind DNA as trimers, the optimal HSE 
consists of three consecutive inverted nGAAn repeats, to which all the HSF subunits can be 
in contact with. This is not, however, always required and HSF oligomers can also bind HSEs 
with only two repeats, presumably maintaining one subunit unattached to the DNA. 
Mechanistically this sequence-specific binding of HSFs occurs through hydrogen bonding 
between a conserved arginine residue (R63 in human HSF2) in the recognition -helix (3 
in the DBD core structure) and the guanine nucleotide (nGAAn) located in the major groove 
of DNA (Jaeger et al., 2016).  
 
Due to the inverted nature of the element, two contiguous nGAAn repeats can exist either in 
so called head-to-head orientation (nGAAnnTTCn) or in tail-to-tail orientation 
(nAAGnnCTTn) (Jaeger et al., 2014). Consequently, in HSEs with more than two repeats, 
the orientation of contiguous nGAAn repeats can vary. This orientation variability can result 
in a complex HSF binding patterns where affinity of the trimers, orientation of trimer 
subunits and interactions between adjacent trimers can be affected. For example, HSFs can 
recognize the orientation of the nGAAn repeats and bind with higher affinity to head-to-head 
oriented repeats (Bonner et al., 1994). Because of the conserved binding mechanistic 
described above, the orientation of the repeat also affects the HSF monomer orientation, as 
the DBD always forms a contact with the consensus guanine. Furthermore, HSEs with 
several repeats often promote cooperative binding of multiple HSF trimers, and depending 
on the orientation of distinct repeats the adjacent trimers can interact and create specific 
interfaces for additional regulatory inputs (Jaeger et al., 2014). Altogether, these HSE 
features result in variations in HSF binding to specific promoters, which likely is reflected in 
the observed differences in HSF target gene selection between stress (Vihervaara et al., 
2013), cancer (Mendillo et al., 2012), and neurodegenerative diseases (Riva et al., 2012).  
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2.3 Heat shock factor 1, HSF1 
Mammalian HSF1 is the functional counterpart of single HSF found in yeast, nematode and 
fruit fly and the best characterized member of the HSF family. During stress, HSF1 is the 
fundamental and irreplaceable activator of Hsp gene expression and hence generally accepted 
as the master regulator of the heat shock response. The expression of HSF1 among tissues is 
ubiquitous (Fiorenza et al., 1995) and as evidenced by Hsf1-/- mice studies, the factor is 
essential for acquisition of both cellular and organismal thermotolerance as well as protection 
against heat-induced apoptosis (McMillan et al., 1998; Xiao et al., 1999). In addition to 
elevated temperatures, HSF1 is activated in response to a vast repertoire of proteotoxic stress 
signals, proposing a key role for the factor in the overall cellular response to damaged 
proteins.  
 
The first step in the HSF1 activation-attenuation pathway (Figure 8) is the conversion of inert 
HSF monomers to DNA-binding competent trimers. In the absence of stress, HSF1 
monomers shuttle between the cytoplasm and the nucleus, whereas upon stress the nuclear 
export is restricted, which leads to accumulation of HSF1 monomers in the nucleoplasm and 
thereby enables oligomerization (Budzyński & Sistonen, 2017). Trimerization increases 
HSF1 affinity for DNA and precedes transcriptional activation, which leads to Hsp 
production. Transcriptional attenuation occurs in response to stress withdrawal or in 
prolonged stress conditions and involves repression of transcriptional activity through 
negative feedback from Hsps as well as decrease in the DNA-binding affinity due to DBD 
acetylation (Westerheide et al., 2009). Despite still being under a debate, the current view 
proposes that rather than being reverted back to monomers, the attenuated trimers are 
subjected to ubiquitin-mediated proteasomal degradation, which ends the stress induced 
HSF1 activation-attenuation pathway (Budzyński & Sistonen, 2017). During the whole 
pathway, HSF1 is subjected to multiple PTMs, such as phosphorylation, sumoylation and 
acetylation, which will be discussed in more detail in the following section 2.3.2 Post-
translational regulation of HSF1. 
 
 
Figure 8. HSF1 activation-attenuation pathway. In the absence of stress, HSF1 exists primarily as 
monomers in chaperone-bound inactivated state. Heat shock and other forms of stress, induce HSF1 
oligomerization, accumulation in the nucleus and DNA-binding activity. Simultaneously, HSF1 is 
extensively modified by phosphorylation and sumoylation. Transcriptional activation of HSF1 co-
occurs with acetylation of specific sites and leads to upregulation of molecular chaperones, such as 
the Hsps. Transcriptional attenuation is regulated through acetylation of the DBD, which releases 
HSF1 trimers from target DNA. Subsequently, acetylated HSF1 trimers are ubiquitinated and directed 
to proteasomal degradation.  
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The role of HSF1 as the master regulator of heat shock response has evoked large interest 
towards the sensory mechanisms that recognize the stress and regulate stimulus-dependent 
HSF1 activity. Interestingly, HSF1 itself appears to be one such molecular sensor as it has 
an intrinsic ability to sense stress and can form DNA-bound trimers when subjected to 
versatile proteotoxic stresses in vitro (Mosser et al., 1993; Goodson & Sarge, 1994; Larson 
et al., 1995). Recently, particularly the RD and the HR-C were shown to undergo 
temperature-dependent conformational alterations (Hentze et al., 2016). However, in cells 
this property is suppressed by negative regulators, which maintain HSF1 monomers in 
inactive state and inhibit spontaneous trimerization and subsequent DNA binding. Perhaps 
the best known of such regulators is Hsp90, which interacts with HSF1 in the absence of 
stress and retains it monomeric (Figure 8) (Zou et al., 1998). During proteotoxic stress, 
accumulation of denatured proteins sequester Hsp90 and the interaction between HSF1 and 
Hsp90 rapidly decreases, thereby allowing HSF1 trimerization and induction of HSF1 DNA-
binding and transcriptional activities (Zou et al., 1998, Guo et al., 2001). Upon recovery from 
the stress, upregulated Hsps restore the protein homeostasis, which leads to Hsp liberation 
from their substrates and re-association with HSF1. Thus, Hsp90 provides the cell with a 
negative feedback mechanism sensitive for the cellular folding state.  
 
In addition to regulating the initial monomer-to-trimer transition, Hsps interact also with the 
trimeric HSF1 during stress and the interaction is considered as one of the mechanisms 
important for the response attenuation. For example, the Hsp90-FKBP2-p23 chaperone 
complex has been reported to interact with the HSF1 regulatory domain, which appears to be 
required for the appropriate transcriptional attenuation, as inhibition of the interaction 
prolongs HSF1 DNA-binding activity (Bharadwaj et al., 1999; Guo et al., 2001). Moreover, 
trimeric HSF1 can also interact with Hsp70 and its co-chaperone Hsp40, which in contrast 
to Hsp90-mediated regulation of HSF1 DNA-binding activity, seems to be more important 
in the regulation of its transcriptional activity (Shi et al., 1998). Indeed, already in 1982, 
DiDomenico and co-workers reported that accumulation of Hsp70 is required for the 
transcriptional repression of the heat shock response (DiDomenico et al., 1982). Therefore, 
though not functioning directly as the initial sensor for the stress, Hsp interaction with the 
trimeric HSF1 can generate an essential self-regulating step during the heat shock response, 
which helps to coordinate HSF1 activity according to the requirements of the cell. 
 
2.3.1 Post-translational regulation of HSF1 
Phosphorylation of HSF1 
HSF1 is a stress-inducible transcription factor that undergoes multiple PTMs during its 
activation-attenuation pathway. The significance of PTMs in HSF regulation was revealed 
already in 1987 by Zimarino and Wu, who studied the heat shock response kinetics by 
analyzing HSF binding in Drosophila cells and revealed that the inducible HSF binding is 
not dependent on newly synthesized proteins. Simultaneous translation inhibition and heat-
treatment did not hamper the heat shock response, indicating that the HSF must pre-exist in 
Drosophila cells and undergo stimulus-specific PTMs to gain its activity (Zimarino & Wu, 
1987). Later during the same year, Sorger and co-workers studied the properties of human 
and yeast HSFs, and observed that in contrast to heat-inducible binding of human HSF1, the 
yeast HSF is constitutively DNA-bound and exhibits stress-specific migration pattern on a 
polyacrylamide gel. Treating the heat-shocked yeast cells with calf intestinal phosphatases 
eliminated the pattern difference, demonstrating that the factor was phosphorylation in 
response to stress (Sorger et al., 1987). Following year, also the human HSF1 was reported 
to undergo heat-inducible phosphorylation (Larson et al., 1988), altogether confirming that 
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the post-translational modification of HSFs through phosphorylation is a general 
phenomenon in eukaryotic cells.  
 
  
Figure 9. Schematic overview of identified post-translational modification sites on human 
HSF1. HSF1 is phosphorylated on multiple serine (S) and threonine (T) residues, mainly located in 
the regulatory domain (RD). DNA-binding domain (DBD) and the oligomerization domain (HR-A/B) 
harbor most of the acetylatable and sumoylatable lysine (K) residues. HSF1 is also ubiquitinated, but 
the exact lysine residues are not thus far identified. Additional abbreviations: C-terminal heptad repeat 
domain (HR-C) and transactivation domain (TAD).  
 
Today, altogether 23 phosphorylatable serine (S) and threonine (T) residues have been 
identified on human HSF1, of which most reside within the RD (Guettouche et al., 2005,  
(Figure 9). Although the prominent hyperphosphorylation is strongly induced upon heat 
shock and coincides with the acquisition of DNA-binding and transcriptional activities (Cotto 
et al., 1996), most of the studied phosphorylation sites are in fact repressive. For example, 
MAPK (mitogen-activated protein kinase) -driven phosphorylation of S303, GSK3 
(glycogen synthase kinase 3 beta) -driven phosphorylation of S307, and PKC (protein kinase 
C) -driven phosphorylation of S363 have all been shown to repress HSF1 activation in non-
stress conditions (Chu et al., 1996; Knauf et al., 1996; Kline & Morimoto, 1997; Chu et al., 
1998). Moreover, pro-inflammatory protein kinase MAPKAPK2 (MAPK-activated protein 
kinase 2) inhibits HSF1 transcriptional activity through phosphorylation of S121, which 
promotes HSF1-Hsp90 interaction and consequently inhibits HSF1 trimerization and DNA-
binding activity (Wang et al., 2006). More recently, AMPK-mediated phosphorylation of 
S121 was shown to suppress proteotoxic stress response specifically during metabolic stress, 
suggesting that HSF1 repression via phosphorylation is important not only in the absence of 
proteotoxic stress but also during specific cellular stress conditions (Dai et al., 2015).  
 
Besides repressing spontaneous HSF1 activation, phosphorylation appears to repress HSF1 
function also by regulating its degradation during stress. As shown by Kourtis and co-
workers, the ubiquitin ligase FBXW7 (a substrate-targeting subunit of the Skp1-Cul1-F box 
E3 ubiquitin ligase) interacts with HSF1 in a phosphorylation-dependent manner, resulting 
in proteasomal degradation of the factor (Kourtis et al., 2015). Interestingly, mutation of 
S303/307 on HSF1 abolished the interaction with FBXW7 and prolonged heat shock 
response, indicating that the degradation is required for proper attenuation of the response. 
Moreover, inhibition of GSK3 and MEK kinases decreased the interaction between FBXW7 
and HSF1, proposing that the previously identified kinases are responsible for S303 and S307 
phosphorylation and subsequent degradation of HSF1 (Kourtis et al., 2015). More recently, 
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Gomez-Pastor and co-workers elegantly confirmed these results by showing that 
CK2´(casein kinase II alpha prime) -mediated HSF1 phosphorylation promotes HSF1 
interaction with FBXW7 in Huntington´s disease, which leads to abnormal HSF1 
degradation and supports the disease phenotype (Gomez-Pastor et al., 2017). 
 
In addition to somewhat counterintuitive repressive phosphorylation sites, HSF1 is also 
subjected to activatory phosphorylation events. The best-known example among activating 
phosphorylation sites is S326, which is generally accepted as a hallmark of HSF1 activation 
(Boellmann et al., 2004; Guettouche et al., 2005; Shah et al., 2016) and has been shown to 
be the target amino acid for MEK and p38 MAPK kinases (Tang et al., 2015, Dayalan Naidu 
et al., 2016). Furthermore, stress-inducible phosphorylation of S230 by CaMKII 
(calcium/calmodulin-dependent protein kinase II) similarly potentiates HSF1 transactivation 
capacity, as evidenced by decreased Hsp70 levels in cells expressing mutant HSF1 with 
S121A substitution (Holmberg et al., 2001). Yet another type of activating phosphorylation 
signals are conveyed by PKA (pleiotropic protein kinase A) and PLK1 (polo-like kinase 1), 
which through S320 and S419 phosphorylation, promote the nuclear accumulation of HSF1 
upon heat stress (Kim et al., 2005; Murshid et al., 2010). Interestingly, during mitosis PLK1 
phosphorylates S216, which has been shown to be important for mitotic progression by 
contributing to HSF1 ubiquitination and degradation (Lee et al., 2008). Despite a wealth of 
studies examining the importance of single phosphorylation sites in the regulation of HSF1, 
the role of hyperphosphorylation still remains to be elucidated and will be assessed in the 
second study of this thesis. 
 
Sumoylation and acetylation of HSF1 
In addition to phosphorylation, HSF1 is also stress-inducibly sumoylated, which was initially 
described as a modification required for proper DNA-binding and induction of Hsp genes 
(Hong et al., 2001). Soon after, the importance of sumoylation was, however, contradicted 
by another report, which showed that HSF1 sumoylation is dispensable for the induction of 
heat shock response (Hietakangas et al., 2003) and thereby suggested that the biological 
outcome of the modification might be context-dependent. According to both of the original 
studies, HSF1 is mainly sumoylated on lysine 298, though an additional minor sumoylation 
site on lysine 126 was also identified (Hong et al., 2001, Hietakangas et al., 2003). The HSF1 
sumoylation target lysine resides within an extended SCM, called phosphorylation-
dependent sumoylation motif (PDSM) (discussed in more detail in 1.2.2 Sumoylation 
consensus motif and SUMO-interaction motif), where phosphorylation of the nearby S303 is 
a prerequisite for the SUMO-modification on K298 (Hietakangas et al., 2006). The PDSM 
has also been identified in various other transcription factors (Hietakangas et al., 2006) and 
appears to be a common mechanism to integrate different intracellular signaling pathways. 
Reporter gene assays and RT-PCR analysis of HSF1 target genes, have demonstrated that 
sumoylation is a negative regulator of HSF1 transactivation capacity during proteotoxic 
stress (Hietakangas et al., 2006), albeit the mechanistic understanding of this process is still 
scarce. Interestingly, Hendriks and co-workers recently identified 14 putative sumoylation 
sites on HSF1, mainly residing on the DBD and the HR-A/B domains (Hendriks et al., 2017) 
(Figure 9), further highlighting the requirement of future work regarding HSF1-SUMO 
interactions.  
 
HSF1 is acetylated on 12 lysine residues that appear to be important in different phases of 
the HSF1 activation-attenuation pathway (Westerheide et al., 2009; Raychaudhuri et al., 
2014). In non-stressed cells, HSF1 is acetylated by histone acetyl transferase EP300 on three 
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individual lysine residues (K118, K208 and K298), of which K208 and K298 are essential 
for HSF1 stabilization by preventing the proteasomal degradation of the factor 
(Raychaudhuri et al., 2014). Interestingly, though lysine residues are subjected to 
ubiquitination, blocking ubiquitination seems not to be the main mechanism behind 
acetylation-mediated stabilization, since only acetylation-mimicking mutation K208Q, but 
not K208R, prevents HSF1 degradation (Raychaudhuri et al., 2014). In contrast to the 
stabilizing effect in untreated cells, increased HSF1 acetylation upon HS contributes to 
attenuation of heat shock response, through at least two acetylatable lysine residues in the 
DBD (K80, K118) (Westerheide et al., 2009; Raychaudhuri et al., 2014). Acetylation of 
DBD during stress releases HSF1 from the DNA, which is generally accepted as a key step 
required for the response attenuation. The acetylation status of the K80 can be regulated by 
the deacetylase SIRT1 as well as histone deacetylases HDAC7 and HDAC9, which all have 
been shown to deacetylate HSF1 and prolong the heat shock response (Westerheide et al., 
2009; Zelin & Freeman, 2015). 
 
It is worth mentioning that the novel sumoylation sites identified by Hendriks and co-workers 
raise an important question about the interplay between distinct PTMs, as many of the 
identified lysine residues appear to be subjected to both sumoylation and acetylation. Most 
of those residues are located in DBD and HR-A/B, and it is tempting to speculate that 
alternating lysine modification could provide a cell state-specific mechanism to regulate 
oligomerization or the DNA-binding activity of HSF1. Particularly intriguing residue is 
lysine 298 in the RD, which is the only lysine within a PDSM consensus extension and has 
been implicated in the regulation of HSF1 transactivation capacity. Previous studies have 
demonstrated in two distinct PDSM-containing substrates, MEF2A (myocyte enhancer factor 
2A) and tumor suppressor HIC1 (hypermethylated in cancer 1), that acetylation and 
sumoylation of the same lysine within a PDSM provides a regulatory switch, where 
acetylation of the lysine blocks sumoylation and thereby counteracts the repressing effect of 
SUMO conjugation (Shalizi, 2006; Stankovic-Valentin et al., 2007). Therefore, future 
studies on post-translational regulation of HSF1 should perhaps not only focus on single 
modifications, but examine the combinatorial effect of various HSF1 PTMs. 
 
2.3.2 HSF1 in physiological context 
In addition to its prominent role in the heat shock response, HSF1 is essential also in multiple 
physiological processes, such as development, immune responses and organismal aging 
(Figure 10). For example in yeasts, the single HSF is absolutely essential for cell viability 
already in normal growth conditions, as genetically disrupted cells lacking HSF are unable 
to produce viable spores (Sorger & Pelham, 1988; Gallo et al., 1993). Although the yeast 
HSF has been reported to bind multiple gene loci in non-stressed conditions, the lethal knock-
out phenotype can be rescued with overexpression Hsp70 and Hsp90, implying that the main 
role of yeast HSF is the maintenance of proteostasis (Solis et al., 2016). In contrast to yeast, 
the DmHSF is not required for adult fly viability, but is essential for larval development and 
oogenesis (Jedlicka et al., 1997). Intriguingly, larval lethality and impaired oogenesis is not 
caused by defective Hsp expression, indicating that unlike in yeast, HSFs in multicellular 
organisms maintain an additional genetic program essential for organismal development. 
Supporting the view, Li and co-workers recently revealed that CeHSF targets a distinct 
selection of genes during nematode development and regulates a genetic program different 
from heat shock response (Li et al., 2016). Intriguingly, the developmental activation of 
CeHSF was shown to depend on binding of another transcription factor E2F, proposing that 
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the stimulus specific HSF activation might be regulated at the level of complex transcription 
factor interplay. 
 
In mammals, HSF1 is expressed in a variety of tissue types, and though not directly required 
for the survival of the organism, Hsf1-/- mice have severe developmental defects (Xiao et al., 
1999). One of the most visible alterations detected in Hsf1-/- mice is the reduced body and 
organ size of both female and male mice. Intriguingly, by showing that interaction between 
HSF1 and JNK (c-Jun N-terminal kinase) is required for the maintenance of mTORC1-
governed translation, it was proposed that the reduced body size is at least partially caused 
by hampered translation in Hsf1-/- mice (Su et al., 2016). In addition to reduced size, the Hsf1-
/- female mice suffer from multiple reproductive shortcomings, such as placental 
insufficiency and infertility, which appear to be caused by deficiencies in zygotic divisions 
(Xiao et al., 1999; Christians et al., 2000). These deficiencies are not solely caused by 
alterations in the basal Hsp expression (Xiao et al., 1999). Although Hsp90 does support 
the meiotic maturation of the oocytes (Metchat et al., 2009), HSF1 also regulates genes 
associated with synaptonemal complex, cohesin, and spindle assembly checkpoint (Le 
Masson et al., 2011). The Hsf1-/- male mice produce less sperm and show disorganized 
layering of the seminiferous epithelium (Salmand et al., 2008), which surprisingly does not 
result in infertility (Izu et al., 2004). However, HSF1 is required for brain development as 
both female and male mice exhibit enlarged ventricles, neurodegeneration, demyelination, 
astrogliosis and accumulation of ubiquitinated proteins in the brain (Santos & Saraiva, 2004; 
Homma et al., 2007). Interestingly, the developing mouse brains are considered normal until 
E18.5 (Xiao et al., 1999), which indicates that the abnormalities likely occur postnatally and 
that HSF1 activity is regulated in a developmental stage-specific manner.  
 
 
 
 
Figure 10. Versatile functions of human 
HSF1. The role of HSF1 is not restricted to 
its essential function in the cellular stress 
response, but it is important also in other 
physiological and pathophysiological 
contexts. Involvement of HSF1 in cancer 
and neurodegeneration will be discussed in 
more detail in section 3 HSFs in 
pathologies.   
 
 
HSF1 provides protection also at the organismal level through modulation of immune 
responses. Accordingly, Hsf1-/- mice exhibit increased mortality during pathological 
challenges, partly caused by exaggerated production of pro-inflammatory cytokine TNF- 
(Xiao et al., 1999). Moreover, the mice have significantly lower constitutive expression of 
cytokines and chemokines, as well as impaired induction of serum immunoglobulins, such 
as IgG2a, all important for proper immune responses (Inouye et al., 2004). Organismal 
protection is also demonstrated by HSF-mediated life-span regulation, which was originally 
demonstrated in C. elegans (Garigan et al., 2002). By using a RNAi-screen to search for 
factors affecting the animal life-span, CeHSF was identified as one of the proteins important 
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for preserving youthfulness (Garigan et al., 2002). The following year CeHSF was reported 
to promote life together with a forkhead family transcription factor Daf-16 (Hsu et al., 2003), 
previously well-recognized for enhancing nematode longevity (Kenyon et al., 1993). Upon 
activation of the insulin/IGF-1-like receptor Daf-2, Daf-16 is phosphorylated and retained in 
the cytoplasm, which prevents it from activating its anti-aging target genes (Hsu et al., 2003). 
However, when the signaling is impaired for example by RNAi-mediated downregulation of 
the transmembrane Daf-2 receptor, Daf-16 localizes to the nucleus together with HSF1 and 
initiates a transcriptional program required for life-span extension (Hsu et al., 2003; Morley 
& Morimoto, 2004). The cooperation between Daf-16 and HSF1 is essential, as 
downregulation of either of the factors suppresses the longevity phenotype (Hsu et al., 2003; 
Morley & Morimoto, 2004). Interestingly, these transcription factors share a selection of their 
target genes, such as hsp-12 and hsp-16 encoding for small Hsps. Though downregulation of 
these target genes reduce longevity, the effect is minor compared to downregulation of 
CeHSF (Morley & Morimoto, 2004), suggesting that CeHSF promotes life-span extension 
through a more complex transcriptional network. Moreover, inactivation of IGF-1R, a mouse 
homologue of Daf-2, results in 26% increase in the animal life-span, indicating that the 
insulin/IGF-signaling is crucial also in the regulation of mammalian aging (Holzenberger et 
al., 2003). However, it remains to be examined, whether the mammalian HSF1 plays any 
role in promoting longevity in an analogous manner.  
 
2.4 Heat shock factor 2, HSF2 
Already at the time of its discovery in 1991, HSF2 was found profoundly different to its close 
homologue HSF1. For example, albeit both factors were able to bind consensus HSE 
sequences, they exhibited distinct binding preferences and differential activation in response 
to stress. Unlike HSF preferring arrays of four to five nGAAn consensus pentamers, HSF2 
favors HSEs with two to three repeats, which results in negligible cooperativity between 
adjacent trimers upon DNA-binding (Kroeger et al., 1993; Kroeger & Morimoto, 1994). 
Moreover, in contrast to prominent heat-inducible activation of HSF1, HSF2 is DNA-binding 
competent already in non-stressed conditions (Sarge et al., 1991) and shows constitutive 
DNA-binding in mouse embryonic carcinoma cells (Murphy et al., 1994) and during mouse 
embryogenesis (Mezger et al., 1994a; Mezger et al., 1994b; Rallu et al., 1997). More 
importantly, constitutive HSF2 binding appears to be uncoupled from the classical activation 
of Hsp gene expression, suggesting that the factor is not necessarily important for the acute 
heat stress responses (Mezger et al., 1994a; Mezger et al., 1994b; Rallu et al., 1997 Eriksson 
et al., 2000). Consistently, in vitro transcription assays have revealed that HSF1 is a more 
potent transcriptional activator of Hsp70 promoter than HSF2 (Kroeger et al., 1993). 
Prominent HSF2 binding can, however, be detected during hemin-induced differentiation of 
K526 cells (Sistonen et al., 1992) or proteasome inhibition (Mathew et al., 1998; Rossi et 
al., 2014), suggesting that the factor is perhaps more important during differentiation and 
development or in other types of proteotoxic stresses. 
 
Unlike monomeric HSF1, HSF2 exists primarily as cytosolic dimers in non-stressed cells, 
whereas upon appropriate stimuli, it trimerizes and associates with DNA (Sistonen et al., 
1994; Mathew et al., 1998). Interestingly, in contrast to HSF1, only exogenously expressed 
hHSF2 is constitutively trimerized in yeast and can functionally complement the viability 
defects detected in S. cerevisiae lacking the HSF gene (Liu et al., 1997). HSF1 on the other 
hand, can complement the defects only when HR-C is disrupted, indicating that the 
trimerization is an essential regulatory step in HSF activation. Though the regulatory 
mechanism behind the trimerization difference is not fully elucidated, it is at least partially 
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dictated by the distinct structural features of HSF1 and HSF2. In HSF1, the DBD resident 
wing-domain accounts for the temperature-dependent trimerization of HSF1 and defines the 
target gene selectivity (Ahn et al., 2001). Intriguingly, when transposed to HSF2, the wing-
domain confers analogous stress-responsiveness and DNA-binding specificity, suggesting 
that the structural features provide an essential stress-sensing mechanism differentially 
regulating HSF1 and HSF2 activation in specific cellular contexts.  
 
2.4.1 Regulation of HSF2 activity 
In contrast to the prominent PTMs that regulate HSF1 transcriptional activity, HSF2 activity 
is mainly regulated on the level of its expression. HSF2 is a very short-lived protein, with 
half-life of approximately 60 min (Mathew et al., 1998) and shows diverse tissue type, cell 
type, stress stimulus, and cell cycle phase dependent expression patterns (Sarge et al., 1994; 
Fiorenza et al., 1995; Mathew et al., 1998, Elsing et al., 2014). High HSF2 expression in 
cells and tissues correlates with prominent HSF2 DNA-binding activity (Mathew et al., 1998; 
Sarge et al., 1994), suggesting that the activity is indeed mainly dependent on HSF2 
expression levels. In further support of the prevalent view, overexpression of HSF2 has been 
shown to activate Hsp70 reporter constructs and endogenous genes (Sarge et al., 1993; 
Sandqvist et al., 2009). Moreover, treatments such as hemin or proteasome inhibition lead to 
concomitant upregulation of HSF2 protein expression and DNA-binding activity. (Sistonen 
et al., 1994; Mathew et al., 1998, Rossi et al., 2014). 
 
As the levels of HSF2 are important in the regulation of its activity, cells have developed 
efficient mechanisms to modulate HSF2 expression according to their specific requirements. 
For example, when exposed to elevated temperatures, HSF2 is ubiquitinated by the E3-
ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C), which leads to HSF2 
degradation in the proteasome (Ahlskog et al., 2010). During heat shock, APC/C co-factor 
cdc20 and the proteasome subunit 2 localize to the Hsp70 promoter, which engages HSF2 
in proteasome-mediated degradation and allows for prominent Hsp70 expression during 
stress. Although the importance of this type of regulation remains to be fully elucidated, it 
seems that HSF2 degradation is required to direct selective target gene expression during 
stress in freely cycling (Ahlskog et al., 2010) and in mitotic (Elsing et al., 2014) cells. The 
stress-specific ubiquitination sites on HSF2 have not been experimentally validated, but five 
lysine residues have been identified as ubiquitination target sites in unbiased mass 
spectrometric screens (Kim et al., 2011; Wagner et al., 2011) (Figure 11), though their 
regulatory functions remain to examined. In testis, HSF2 expression is regulated at the 
mRNA level by a specific microRNA, miR-18, which belongs to the Oncomir-1 or miR-
17~92 cluster of microRNAs (Björk et al., 2010). During spermatogenesis, miR-18 is 
expressed in a cell-type specific manner and downregulates HSF2 expression through 
binding to the HSF2 mRNA 3´-UTR (Björk et al., 2010). Specific downregulation of HSF2 
results in decreased expression of testis-specific HSF2 target genes, Speer4 and Ssty 
(Åkerfelt et al., 2008), suggesting that by targeting HSF2, miR-18 orchestrates stage-specific 
gene expression during spermatogenesis. Altogether, these regulatory mechanisms provide 
elegant examples on how HSF2 expression can be modulated during stress and in 
development. 
 
Similarly to HSF1, HSF2 is also subjected to post-translational modification by sumoylation, 
which appears to be important in controlling HSF2 DNA-binding ability. Sumoylation of 
HSF2 was initially proposed by Goodson and co-workers, who detected interaction between 
HSF2 and Ubc9 in yeast-two-hybrid studies and subsequently identified lysine 82 as the main 
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sumoylation site on HSF2 (Goodson et al., 2001). K82 resides in the HSF2 DBD (Figure 11) 
and was first reported to be required for efficient HSF2 DNA-binding both in vitro and in 
vivo in Xenopus laevis (Goodson et al., 2001; Hilgarth et al., 2004). Later on, however, our 
laboratory re-examined HSF2 sumoylation and contradicted the previous studies by showing 
that sumoylation of K82 in fact inhibits HSF2 DNA-binding ability (Anckar et al., 2006). 
The results have been later confirmed by other laboratories (Tateishi et al., 2009; Feng et al., 
2016) and HSF2 sumoylation is generally considered as an inhibitory modification. When 
contemplating the putative explanations for the observed differences, it is important to note 
that all the previous studies regarding HSF2 sumoylation have been conducted either with 
exogenous overexpression constructs (of HSF2 and SUMO1 or SUMO2/3) or in diverse in 
vitro assays, which greatly underestimates the delicate biology of a living cell. Indeed, when 
Hendriks and co-workers utilized mass spectrometry based identification methods to study 
protein sumoylation in cells, they identified 20 novel sumoylation sites on HSF2 DBD and 
HR-A/B (Figure 11), suggesting that the post-translational regulation of HSF2 by SUMO is 
perhaps much more complex than originally expected (Hendriks et al., 2016). Thus, it is 
possible that the previously observed contradictions are in fact caused by secondary-site 
sumoylation events, which were not fully detectable with the methods used at that time. 
Moreover, as K82 resides within the HSF2 wing-domain, suggested to be involved in the 
regulation of HSF-specific protein interaction network and target-gene selectivity (Jaeger et 
al., 2016), over-expression of the regulatory components can result in biased observations 
regarding the functional role of HSF2 sumoylation. Thereby, it would be of great interest to 
re-examine HSF2 sumoylation in biologically more relevant contexts.  
 
 
 
 
 
Figure 11. Schematic overview of identified post-translational modification sites on human 
HSF2. HSF2 is sumoylated on multiple lysine (K) residues, mainly located in the DNA-binding domain 
(DBD) and oligomerization domain (HR-A/B). Ubiquitination of five lysine residues has been reported. 
Additional domain abbreviations: C-terminal heptad repeat domain (HR-C), regulatory domain (RD) 
and transactivation domain (TAD).  
 
2.4.2 HSF2 as a developmental regulator 
The significance of HSF2 in biological processes other than stress responses (Figure 12), was 
initially proposed by demonstrating that HSF2 activity increases during hemin-induced 
differentiation of K562 erythroleukemia cells (Sistonen et al., 1992). Subsequently, 
spatiotemporally variable HSF2 expression was detected in multiple mouse tissues in both 
developing and adult animals, which further supported the emerging view of HSF2 as a 
developmentally important transcription factor. However, it was not until the generation of 
Hsf2-/- mouse by three independent research laboratories, which finally provided compelling 
evidence for the involvement of HSF2 in developmental processes (Kallio et al., 2002; 
McMillan et al., 2002; Wang et al., 2003). In none of these studies, disruption of HSF2 gene 
led to robust morphological abnormalities of the animals. However, two laboratories 
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observed nearly identical phenotypic defects, mainly related to corticogenesis and 
gametogenesis in both genders (Kallio et al., 2002; Wang et al., 2003). The lack of similar 
observations in the third mouse model is likely due to the selection of different genetic 
approaches to disrupt the HSF2 gene as well as utilization of distinct mouse strains as the 
knock-out background. 
 
 
 
Figure 12. Versatile functions of human 
HSF2. In contrast to the prominent role of 
HSF1 in stress, HSF2 is mainly related to 
differentiation and developmental 
processes. Moreover, HSF2 is important in 
specific human pathologies, such as fetal 
alcohol spectrum disorder (FASD) and 
neurodegeneration (will be discussed in 
more detail in 3 HSFs in pathologies).
 
During mouse embryogenesis, HSF2 expression is mainly detected in the central nervous 
system and more specifically in the ventricular layer containing the highly proliferating 
neural precursors (Rallu et al., 1997; Kallio et al., 2002, Wang et al., 2003). In adult Hsf2-/- 
mice both lateral and third ventricles are significantly dilated (Kallio et al., 2002, Wang et 
al., 2003), indicating that developmentally regulated expression of HSF2 might be important 
in the tissue homeostasis during ventricle formation. Interestingly, when analyzing the 
expression of specific Hsps during embryogenesis, Wang and co-workers observed 
equivalent Hsp levels in both Hsf2-/- and wild-type mice, suggesting that the neuronal defects 
are not caused by misregulated Hsp expression. In addition to ventricular defects, the Hsf2-/- 
mice display neuronal mispositioning at the cortical layers of the brain (Chang et al., 2006). 
Neuronal migration is architecturally supported by two different cell types, namely the radial 
glia cells and the Cajal-Retzius cells, which both are less abundant in the Hsf2-/- mouse brain. 
Moreover, in search of the molecular mechanism behind the defective neuronal migration, 
p35 was identified as a novel HSF2 target gene in brain (Cheng et al., 2006). p35 is a well-
established activator of Cdk5 (cyclin-dependent kinase 5), which is one of the essential 
factors required for cortical lamination. In Hsf2-/- mice, p35 expression and subsequently also 
Cdk5 activity is reduced, suggesting that the observed migratory defects are at least partly 
mediated by lack of HSF2 target gene expression (Chang et al., 2006). Interestingly, HSF2 
binding to the p35 promoter is inhibited during fetal alcohol exposure, which results in 
neuronal migratory defects similar to those detected in the children diagnosed with fetal 
alcohol spectrum disorder (FASD) (El Fatimy et al., 2014). Altogether, these studies imply 
that HSF2 is an essential regulator of neuronal migration, which could potentially function 
as a target molecule in the development of novel strategies to prevent fetal brain damage. 
 
Among all the studied tissue types, HSF2 is most prominently expressed in adult testes (Sarge 
et al., 1994, Fiorenza et al., 1995) and particularly in the pachytene spermatocytes as well as 
round spermatids (Sarge et al., 1994; Alastalo et al., 1998; Björk et al., 2010). Consequently, 
the Hsf2-/- mice display multiple testicular defects, including reduced testis size, 
morphologically abnormal seminiferous tubules, and increased apoptosis of the 
spermatocytes, which does not affect male fertility (Kallio et al., 2002, Wang et al., 2003). 
Hsf2-/- female mice are also challenged with reproductive insufficiencies, as they show 
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increased embryonic lethality and reduced fertility caused by defective ovulation, meiotic 
problems, and diverse hormonal abnormalities (Kallio et al., 2002). During spermatogenesis, 
HSF2 occupies the male-specific region of the mouse Y chromosome long arm (MSYq) and 
is required for the transcriptional induction of the MSYq-resident multicopy genes, such as 
Ssty2, Sly, and Slx (Åkerfelt et al., 2008). Altered expression of multicopy genes leads to 
conformational abnormalities in the sperm heads, suggesting that HSF2 is involved in the 
quality control of male gametes. Interestingly, the combined disruption of both HSF1 and 
HSF2 exacerbates the Hsf2-/- phenotype and the double knock-out mice are infertile due to 
stalled spermatogenesis at the pachytene stage (Wang et al., 2004). By examining HSF1 and 
HSF2 DNA-binding sites in mouse testes with ChIP-seq (Chromatin immunoprecipitation 
combined with sequencing), Korfanty and co-workers revealed that these factors indeed 
share target binding sites during spermatogenesis (Korfanty et al., 2014), suggesting that 
HSF1 and HSF2 cooperatively regulate gene expression during sperm development.  
 
2.4.3 HSF2 regulates gene expression together with HSF1 
Due to the significant homology of the oligomerization domains, the existence of HSF1-
HSF2 heterotrimers was hypothesized already in the first study that identified the factors in 
human cells (Schuetz et al., 1991). Quite a few years later, the direct interaction between 
HSF1 and HSF2 was revealed by co-immunoprecipitation analyses and was shown to be 
dependent on the oligomerization domain of HSFs (Alastalo et al., 2003; He et al., 2003). 
HSF1 and HSF2 were also demonstrated to co-localize on the clusterin gene promoter 
containing only one HSE with three nGAAn repeats, which strongly suggested that the 
factors bind DNA as a heterotrimer (Loison et al., 2006). Finally, by utilizing the nuclear 
stress bodies (nSBs, discussed more below) as a model system to study HSF1-HSF2 
interplay, it was revealed that the factors can indeed bind DNA in a heterotrimeric complex 
(Sandqvist et al., 2009). Experimental manipulation of the relative abundance of HSF1 and 
HSF2 affected the transcriptional properties of the trimers, indicating that the composition 
of heterotrimers might serve as an integrator of cellular signals and assist in the fine-tuning 
of HSF-mediated transcription (Sandqvist et al., 2009).  
 
The interplay between HSF1 and HSF2 has been shown to modulate stress-induced activation 
of transcription. Although both HSF1 and HSF2 occupy nearly identical loci during heat 
shock (Vihervaara et al., 2013), HSF2 localization to the hsp promoters is dependent on 
HSF1 and affects transcription gene-specifically (He et al., 2003; Östling et al., 2007). For 
example, lack of HSF2 in mouse embryonic fibroblasts results in impaired heat-induced 
expression of hsp70 and hsp25, whereas hsp40 and hsp110 are induced in the absence of 
HSF2 (Östling et al., 2007). However, in stressed and mitotic K562 cells, HSF2 interferes 
with HSF1 binding and subsequent transcriptional activation of the hsp70 promoter (Elsing 
et al., 2014), suggesting that the effect of HSF1-HSF2 heterotrimers depends on cell type 
and growth conditions.  
 
In addition to regulating the transcription of protein coding genes, HSF1 and HSF2 jointly 
participate in the regulation of the non-coding SatIII-transcripts, produced from the 9q12 
locus during proteotoxic stresses (Sandqvist et al., 2009). Accumulation of HSF1 and HSF2 
to the locus produces characteristic nuclear structures, termed nuclear stress bodies (nSBs), 
which only appear in the primate cells (Jolly et al., 2002). The structures were initially 
identified already in the early 90s, by demonstrating that HSF1 stress-inducibly localize to 
specific nuclear granules (Sheldon & Kingston, 1993). Later on, the sites were reported to be 
transcriptionally active and separate to hsp70 and hsp90 loci (Jolly et al., 1997), which led 
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to the identificaiton of specific repetitive satellite III transcripts (Jolly et al., 2002). Upon 
exposure to elevated temperatures, HSF2 localization to nSBs is HSF1-dependent and lack 
of HSF2 results in increased heat-inducible expression of the SatIII-transcripts (Sandqvist et 
al., 2009). However, experimental upregulation of HSF2, mimicking the high HSF2 
expression during development, activates SatIII loci in the absence of stress, indicating that 
the biological consequence of HSF1-HSF2 interplay is dependent on the relative amount of 
the factors. Intriguingly, a recent study by Goenka and co-workes demonstrated that the 
SatIII-transcripts are involved in stress-dependent transcriptional repression and required for 
cellullar protection against damaging conditions (Goenka et al., 2016). Since the mechanisms 
behind the heat-induced transcriptional repression are not elucidated, it is tempting to 
speculate that through non-coding transcription sites, HSFs could participate in the 
comprehensive transcriptional reprogramming of the cell during stress. Moreover, as the 
importance of heterotrimers in developmental processes is currently unknown, it remains to 
be established whether HSF2 could function as the main driver of gene expression in specific 
developmental processes.  
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3 HSFs IN PATHOLOGIES 
The obvious importance of HSFs as regulators of protein homeostasis and cell survival has 
evoked large interest towards their putative roles in severe human pathologies such as cancer 
and neurodegenerative diseases. Intriguingly, these two diseases (or rather umbrella terms 
for highly variable groups of diseases) represent two extreme opposites of misregulated tissue 
homeostasis. Cancers are usually described by unrestrained cell growth leading to neoplasms 
(for more details see 4 Cancer), whereas neurodegenerative diseases are always associated 
with aberrant cell death and tissue damage. Such diversity undeniably poses specific 
challenges to the cellular survival mechanisms, which from the organismal point of view are 
too active in cancer and malfunctional during degeneration. 
 
In this section of 3 HSFs in pathologies I first review the current knowledge regarding the 
roles of HSFs in human cancers as that is the main topic further examined in the third study 
of this thesis (III). After that, I will describe the contributions of HSFs in protein aggregation 
diseases and neurodegeneration, since the final study of this thesis (IV) might have 
implications relevant to such conditions.  
 
3.1 HSF1 in cancer 
Upregulation of Hsps is an evolutionarily conserved stress protective mechanism that guards 
the cellular proteome in times of damage. In cancer, the proteotoxic damage is caused by 
both intrinsic and extrinsic factors, as the tumor cells characteristically harbor multiple 
genetic mutations and maintain growth in adverse environments. Due to the unstable 
proteome, abnormally high expression of Hsps has been reported in a wide range of human 
cancers and is currently considered as a general feature of neoplastic cells (Whitsell and 
Lindquist, 2000). However, it was not obvious in the beginning whether the increased 
expression of Hsps is the cause or the consequence of malignant transformation. In the 1990s, 
the question was examined by multiple individual research laboratories, who provided 
several lines of evidence supporting the causality between Hsps and tumorigenicity. For 
example, ectopically induced overproduction of Hsp70 or Hsp27 was reported sufficient to 
promote metastatic potential of cancer cells in host organisms (Jäättelä, 1995; Garrido et al., 
1998). Moreover, it was demonstrated that abnormally high Hsp70 expression can induce 
malignant transformation and metastatic T-cell lymphoma in transgenic mice (Seo et al., 
1996). Furthermore, overproduction of Hsp70 in immortalized Rat-1 cells resulted in features 
characteristic to oncogenic transformation, including loss of contact inhibition, growth on 
soft agar, and tumor formation in nude mice (Volloch & Sherman, 1999). Altogether, these 
results indicated that overproduction of molecular chaperones is sufficient to drive 
tumorigenesis and sustain cancer progression. 
 
Though Hsp levels in normal cells are maintained by various transcription factors (Stephanou 
& Latchman, 2011), in stress HSF1 is the primary factor responsible for inducible expression 
of Hsps. Thus, after recognizing the importance of Hsps in cancer formation, it became 
simply impossible to ignore the putative role of HSF1 in the malignant transformation. The 
relationship between HSF1 and cancer begun to emerge through few important studies 
published in the early 2000s. First, analysis of the differentially expressed genes in metastatic 
variants of prostate adenocarcinoma cell lines, PC-3 and PC-3M, revealed that HSF1 is 
strongly upregulated in the more metastatic PC-3M line (Hoang et al., 2000). A few years 
later, expression of dominant negative HSF1 (DN-HSF1) was reported to inhibit aneuploidy 
in the same PC-3 model system (Wang et al., 2004), suggesting that HSF1 could be involved 
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in regulating genomic instability. HSF1 was also related to cancer-specific growth 
phenotypes by demonstrating that heregulin 1 (HRG1), an oncogenic growth factor, 
HSF1-dependently promotes anchorage-independent growth and inhibits apoptosis in breast 
and cervical carcinoma cell lines (Khaleque et al., 2005). HSF1 was also related to the 
migratory behavior of cells by showing that MEFs lacking HSF1 display reduced migration 
upon EGF stimulation (O´Callaghan-Sunol & Sherman, 2006).  
 
It was not until the two groundbreaking studies from the Mivechi and Lindquist laboratories 
in 2007, when the door for HSF1-related cancer research finally became wide open. By 
utilizing Hsf1-/-p53-/- (Min et al., 2007) and Hsf1-/-p53R172H/+ (Dai et al., 2007)   mouse models 
both laboratories demonstrated that loss of HSF1 protects mice from spontaneous tumor 
formation often associated with p53-deficiency (Min et al., 2007; Dai et al., 2007). The p53 
R172H mutation (missense mutation affecting the p53 DBD structure) had been found from 
many types of spontaneously arising human tumors (Olive et al., 2004), which already then 
highlighted the putative clinical relevance of the findings by Dai and co-workers. Moreover, 
the protective effect of HSF1-deficieny was not limited to p53-mutant background, as Hsf1-
/- mice exposed to mutagenic dimethylbenzanthracene (DMBA) and tumor promoting 12-O-
tetradecanoylphorbol-13-acetate (TPA), were also shown less susceptible to skin 
carcinogenesis induced by the chemicals (Dai et al., 2007). Chemical-induced tumors are 
often associated with activating H-RAS mutations and interestingly all sampled tumors from 
WT and Hsf1-/- mice harbored H-RAS mutations. These results indicated that HSF1 provides 
protection independently of the oncogenic driver identity. The observation was further 
supported by studies in cell culture systems, which demonstrated that Hsf1-/- MEFs are more 
resistant against spontaneous transformation when transfected with either H-RAS or PDGF-
B proto-oncogenes (Dai et al., 2007). To study the importance of HSF1 in maintaining the 
transformed phenotype, Dai and co-workers depleted HSF1 with shRNA from a wide 
selection of well-established human cancer cell lines and measured the cell viability after 
four days in culture. Intriguingly, nearly every malignant cell type exhibited reduced cell 
viability at the experimental endpoint altogether proposing that HSF1 is not only required for 
the cancer initiation but supports the transformed cell phenotype independently of the 
underlying genetic defects. Thereby, it appeared that HSF1, conventionally considered as a 
survival factor, had an opposite role in cancer; as a strong supporter of the malignant 
phenotype, it challenges the survival of the organism. 
 
Due to the original findings, the ability to maintain high Hsp expression was generally 
considered as one of the key mechanisms by which HSF1 enhances cancer cell survival. The 
concept is often presented as “chaperone addiction” model, underlining the requirement of 
chaperones as buffers against genetic instabilities. However in 2012, Mendillo and co-
workers demonstrated that the transcriptional program that HSF1 regulates in malignant 
cells, is in fact surprisingly diverse and extends far beyond the molecular chaperones 
(Mendillo et al., 2012). By comparing the HSF1 binding sites in heat shocked and 
transformed mammary epithelial cells, the study revealed that HSF1 is not only activated 
during transformation but occupies promoters distinct from the heat shock response. The 
genes regulated by HSF1 in malignant cells were shown to be related to translation, energy 
metabolism, adhesion, immune processes, and cell cycle, suggesting that HSF1 
comprehensively impacts the physiology of the cancer cell (Figure 13). Similar gene 
occupancy was detected in a variety of established human cancer cell lines and human patient 
material, indicating that HSF1 has a specific transcriptional cancer signature (Mendillo et al., 
2012). Importantly, this HSF1 cancer signature was associated with reduced survival in 
breast, colon and lung cancer patients (Mendillo et al., 2012). 
 Review of the Literature  
 40
 
Reflecting the previous results, the molecular mechanisms by which HSF1 promotes cancer 
progression have been reported to be versatile and follow closely the proposed repertoire of 
cancer hallmarks (Hanahan & Weinberg, 2011) (Figure 13). One of the key features of cancer 
cells is, for example, their ability to avoid apoptotic signals and HSF1 participates in this 
process by inducing the expression of Hsp70 co-chaperone BAG3 (Bcl-2-associated 
athanogene domain 3), which stabilizes the anti-apoptotic Bcl-XL, Mcl-1, and Bcl-2 proteins 
(Jacobs & Marnett, 2009). Moreover, HSF1 transcriptionally represses the expression XAF1 
(XIAP associated factor 1), a factor antagonizing the cytoprotective XIAP (X-linked 
inhibitor of apoptosis) (Wang et al., 2006). Another feature of cancer cells is the acquisition 
of metastatic behavior, which allows the cells to escape from the original tumor site and 
colonize distant tissues (see 4 Cancer for more details). Intriguingly, an unbiased screen 
identified HSF1 as one of only six essential drivers of melanoma invasion (Scott et al., 2011). 
HSF1 has also been shown to reduce adherence and enhance metastatic spread of other cell 
types in vivo in mice (Khaleque et al., 2005; Toma-Jonik et al., 2015). The role of HSF1 in 
angiogenesis was demonstrated by studying the slowly growing tumors in Hsf1-/- mice and 
HSF1-depleted MCF7 xenografts that were both found to exhibit reduced angiogenesis 
associated with suppressed HIF-1 40  expression (Gabai et al., 2012). Moreover, HSF1 
appears to be important in reprogramming the cellular energy metabolism that is required to 
fuel the uncontrolled proliferation characteristic to neoplastic growth. By reshaping the 
transcriptional network upon alterations in translational flux, HSF1 functions as an integrator 
of translational and transcriptional inputs and supports the malignant anabolic state 
(Santagata et al., 2013). HSF1 has been also shown to control chemoresistance in MCF7 and 
RKO cells by enhancing cytoprotective autophagy via upregulation of ATG7 and 
p62/SQSTM1 expression in response to carboplatin and Hsp90 inhibitors, respectively 
(Desai et al., 2013; Samarasinghe et al., 2014). Importantly, HSF1 is an essential downstream 
effector protein of mitogenic signaling pathways and thereby is required for e.g. HER2-
related tumorigenesis (Xi et al., 2012). 
 
 
 
Figure 13. In cancer HSF1 
drives a transcriptional 
program distinct to the 
classical heat shock 
response. In addition to 
regulating the chaperone 
expression, HSF1 binds to 
several other genes and 
affects their expression both 
negatively (blue) and positively 
(purple).  Modified from 
(Mendillo et al., 2012).  
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Malignant cancer cells in a tumor are often surrounded by extensive tumor stroma, which 
consists of other cell types, such as cancer associated fibroblasts (CAFs), endothelial cells, 
and immune cells, as well as extracellular matrix components. Signaling between the cancer 
cells and the stroma is continuous and currently considered as one of the cancer hallmarks 
required to support tumor progression and metastasis (Hanahan &Weinberg, 2011). 
Intriguingly, by examining mouse xenografts composed of breast cancer cells and either 
HSF1 WT or HSF1-null MEFs, it was demonstrated that HSF1 impacts the signaling between 
stromal and cancerous cells and lack of HSF1 in CAFs significantly reduces tumor growth 
(Scherz-Shouval et al., 2014). Comparison of the transcriptional programs induced in cancers 
cells co-cultured with either WT or HSF1-null MEFs revealed that HSF1-expressing CAFs 
promote expression of genes associated with extracellular matrix (ECM) organization and 
adhesion. In contrast, lack of HSF1 in CAFs resulted in upregulation of genes encoding pro-
inflammatory cytokines (Scherz-Shouval et al., 2014). Observed gene expression alterations 
were shown to be mediated by CAF-secreted TGF- (transforming growth factor ) and 
SDF1 (stromal-derived factor 1), of which SDF1 was identified as a direct HSF1 target gene. 
Altogether the results indicated that the tumor progression is affected by HSF1-regulated 
chemokine signaling in the heterogeneous tumor cell population. Importantly, the study 
established that HSF1 is upregulated in stromal cells in a selection of human cancers (lung, 
skin, esophageal, colon, gastric, prostate cancers) and that high HSF1 expression in stroma 
is associated with poor outcome in breast and lung cancer patients (Scherz-Shouval et al., 
2014).  
 
What then causes HSF1 activation in cancer? The pathways regulating HSF1 activation are 
not fully elucidated even in the contexts of heat shock response and thereby our knowledge 
regarding cancer-specific HSF1 regulation is also limited. However, several oncogenic 
pathways have been reported to alter HSF1 activity, which suggests that the regulation can 
be mediated through multiple signaling mechanisms. For example, activation of HER2 
receptor tyrosine kinase (also known as Erbb2 and Neu) has been shown to increase HSF1 
trimer formation and protein expression in MCF7 and MDA-MB-435 breast cancer cell 
variants (Zhao et al., 2009), whereas activation of RAS/RAF/MAPK signaling pathway 
results in increased HSF1 activity in transformed human embryonic kidney cells (HEK293T) 
(Tang et al., 2015). Also HSF1 protein levels seem to be deregulated in cancer. In a panel of 
melanoma cell lines (WC00125, WM3862, WM39) ubiquitin ligase FBXW7-deficiency 
resulted in stabilization of nuclear HSF1 and promoted activation of invasion-supportive 
HSF1 transcriptional program (Kourtis et al., 2015). Furthermore, in the same study, negative 
correlation between FBXW7 and HSF1 nuclear localization was observed in metastatic 
melanoma patient samples, indicating that regulation of HSF1 protein stability might be 
essential in HSF1-mediated cancer progression (Kourtis et al., 2015). These results are 
further supported by the observations of Santagata and co-workers, which conclusively 
showed that high expression and nuclear localization of HSF1 in a cohort of breast cancer 
samples derived from the Nurses´ Health Study (NHS) correlate with poor patient outcome 
(Santagata et al., 2011).  
 
Lastly, though the role of HSF1 in various human malignancies begins to be well-
acknowledged and the mechanisms leading to HSF1 activation are emerging, the role of other 
HSFs in these processes is completely unknown. For example, the expression of HSF2 in 
tumor samples has not been examined in any of the above-mentioned studies and the 
importance of HSF2 for cancer progression is thus far unknown. Therefore, the role of HSF2 
in cancer is examined in the third study of this thesis (III) and further discussed in the Results 
and Discussion. 
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3.2 HSFs in neurodegenerative diseases 
Neurodegenerative diseases, such as Alzheimer´s disease (AD), Parkinson´s disease (PD), 
and amyotrophic lateral sclerosis (ALS), are all characterized by toxic intracellular protein 
aggregates that disturb neuronal homeostasis and eventually lead to cell death. Toxic protein 
aggregates are caused by misfolding of distinct diseases-specific proteins, such as Amyloid-
 or Tau in the case of AD or -synuclein in the case of PD, that associate with important 
cellular effectors and thereby disturb normal cell physiological functions (Sweeney et al., 
2017). In healthy cells, misfolding-induced proteomic imbalances are counteracted by 
molecular chaperones as well as the ubiquitin-proteasome and autophagy systems, which 
regulate protein folding and degradation in order to maintain proteostasis. In 
neurodegenerative diseases, many of these regulatory pathways are misregulated and the 
diseases typically exhibit overall decline in the protein quality control pathways, which 
results in proteostasis collapse and subsequent propagation of the disease.  
 
Several lines of evidence have suggested that enhancing the protein folding capacity via 
increased expression of molecular chaperones can prevent proteostasis collapse and thus 
have neuroprotective effects. For example, overexpression of Hsp70 and other chaperones, 
has been shown to suppress aggregation related toxicity in mouse models of PD (Klucken et 
al., 2004), spinocerebellar ataxia type 1 (Cummings et al., 2001), amyotrophic lateral 
sclerosis (Nagy et al., 2016), and AD (Magrane et al., 2004). Moreover, similar results have 
been observed in various D. melanogaster, C. elegans, S. cerevisiae, and in vitro models for 
neurodegeneration and amyloid formation (Warrick et al., 1999;  Muchowski et al., 2000; 
Auluck et al., 2002; Takeuchi et al., 2002; Nollen et al., 2004; Evans et al., 2006), altogether 
indicating that chaperones are important regulators of toxic aggregates. Due to the 
importance of HSF1 as a regulator of chaperone gene expression, its role in 
neurodegenerative diseases has rightfully been hypothesized. One of the first unbiased 
evidence regarding HSF1 as an important suppressor of aggregation was provided by a 
genome-wide RNAi screen in a polyQ expressing C. elegans, which identified CeHSF1 as 
one of the factors required to suppress age-related protein aggregation (Nollen et al., 2004). 
In Hsf1-/- MEFs, lack of HSF1 was shown to result in increased accumulation of ubiquitinated 
proteins and polyQ-aggregates and similar observations were made in Hsf1-/- mice (Fujimoto 
et al., 2005; Homma et al., 2007). The importance of HSF1 in specific diseases was 
confirmed more recently by showing that ectopically expressed HSF1 suppresses the disease 
phenotypes of Alzheimer´s disease as well as spinal and bulbar muscular atrophy (Jiang et 
al., 2013; Kondo et al., 2013). Consequently, HSF1 activation via e.g. Hsp90 inhibitors or 
small HSF1 activating molecules (HSF1-A1) has been documented to have positive effects 
in several cell culture models of neurodegenerative diseases as well as in fly and mouse 
models of PD, SCA (spinocerebellar ataxia), and Huntington´s disease (Bose & Cho, 2017).  
 
Albeit proposing for prominent therapeutic potential, increasing HSF1 activation with small 
molecules might not be sufficient to rescue the degenerative disease phenotypes. As 
evidenced by two recent studies, HSF1 expression levels are specifically downregulated 
during aggregate accumulation, suggesting that also HSF1 stability is affected in 
neurodegenerative diseases. By examining -synuclein aggregation in neuroblastoma cells, 
Kim and co-workers observed aberrant NEDD4-mediated HSF1 ubiquitination, which led to 
HSF1 degradation via the ubiquitin proteasome system (Kim et al., 2016). In both mouse and 
human tissues of -synucleopathy, NEDD4 and HSF1 presented reciprocal expression 
levels, indicating that the whole molecular pathway is misregulated during aggregation (Kim 
et al., 2016). Analogously, FBXW7-mediated HSF1 ubiquitination and degradation was 
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shown to result in decreased HSF1 expression in Huntington´s disease (Gomez-Pastor et al., 
2017). These results propose that regulation of HSF1 stability is of key importance during 
disease progression, to which the current literature presents no therapeutic interventions.  
 
It is not also exactly clear, how HSF1 promotes cell survival during neurodegeneration. 
Active HSF1 has been shown to suppress polyQ-aggregation more efficiently than any 
combination of Hsps (Fujimoto et al., 2005), suggesting that also other HSF1-regulated genes 
are essential in preventing the disease phenotype. In accordance, Pat-10 was identified as a 
novel HSF1-regulated gene in aging C. elegans, which by maintaining cytoskeletal integrity 
was shown to promote stress resistance (Baird et al., 2014). Moreover, HSF1 has been 
demonstrated to protect neurons independently of its trimerization (and thereby also DNA-
binding) capacity, proposing that the factor might have a more extensive role in these 
diseases than originally anticipated. Intriguingly, also HSF2 is implicated as an essential 
factor required to maintain proteostasis against polyQ-aggregation (Shinkawa et al., 2011). 
By crossing the Hsf2-/- mouse with R6/2 Huntington´s disease mouse, it was revealed that 
lack of HSF2 accelerates the accumulation of polyQ-aggregates in mouse brain and shortens 
the organismal lifespan (Shinkawa et al., 2011). The observations were partially attributed 
to the cellular inability to regulate B-crystallin (Hspb5) expression together with HSF1, 
indicating that the interplay between HSF1 and HSF2 can also function as an important 
determinant of neuronal degeneration.  
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4 CANCER 
The tissues in multicellular organisms are composed of organized collections of cells, which 
through constant cell-to-cell signaling regulate the life of their neighbors to maintain proper 
tissue homeostasis. When a cell acquires a capability to escape these surveillance systems it 
may become a cancer cell and function as a foundation for a neoplasm, an abnormal growth 
of new tissue. Such “cell-of-origin”, the last normal ancestor of a neoplasm, can arise in 
whatever adult tissue, which together with an endless amount of mutation combinations 
results in a highly variable disease spectrum called cancer. 
 
Despite the heterogeneity of the disease, a great majority of human cancers are characterized 
by specific features, which in the current literature are referred to as the hallmarks of cancer 
(Hanahan & Weinberg, 2011). One of the most fundamental hallmarks is the ability to sustain 
constant proliferative signaling that can be acquired in a variety of ways. For example, the 
cancer cell might overexpress growth factor receptors, contain activating mutations in the 
downstream effector proteins, or even be able to produce growth factor ligands itself. 
Simultaneously, however, the cell must be able to avoid proliferation inhibiting messages, 
such as those conveyed by TP53 (tumor protein 53; p53) or Rb (retinoblastoma-associated 
protein, pRb). Yet another hallmark of cancer is the ability to escape signals that induce 
programmed cell death, apoptosis. Initiation of apoptosis is controlled by balancing the 
amount of pro- and anti-apoptotic factors, such as those belonging to the Bcl2 (B-cell 
lymphoma 2) -family of proteins (Adams & Cory, 2007). In approximately half of the human 
cancers the anti-apoptotic Bcl-2 is found overexpressed (Weinberg, 2014). In healthy tissues, 
cells with proliferative capacity eventually undergo replicative senescence and cease into a 
state where they no longer can divide. This phenomenon is caused by cell division dependent 
shortening of chromosomal ends, called telomeres, and predisposes the cell to DNA damage 
and subsequent activation of apoptosis. In cancer, replicative senescence is circumvented by 
expression of a specific DNA-polymerase, telomerase, that has the ability to add repetitive 
telomeric sequences to telomeres and thereby induce cell immortalization (Hanahan & 
Weinberg, 2011).  
 
Similarly to all the cells in a human body, cancer cells require nutrients and oxygen to fuel 
their growth and proliferation. In fact, inadequate oxygen supply is one of the key factors 
restricting tumor growth and thus bypassing such limiting barrier, by e.g. inducing 
angiogenesis, is essential for cancer progression (Weinberg, 2014). In this respect, the tumors 
greatly resemble sites of wound healing, where new vasculature is rapidly formed to support 
the regeneration of damaged tissue. Perhaps the most clinically relevant of the cancer 
hallmarks is, however, the cancer cells´ ability to activate invasive migration to the 
surrounding tissues. Acquisition of invasive potential allows cells to intravasate into blood 
or lymphatic microvessels that can transport the cells to distant sites in the human body. At 
these sites, cells may extravasate the microvessels, colonize the tissue, and eventually form 
large macrometastases. This multi-step process is known as invasion-metastasis cascade 
(Talmadge & Fidler, 2010) and approximately 90% of cancer related deaths are caused by 
metastases, evolved via this process (Lambert et al., 2017). 
 
Considering the diversity of the above-mentioned cancer hallmarks, it is hardly a surprise 
that the acquisition of novel features is regulated by a vast variety of molecular pathways. 
Albeit the literature describing these pathways is impressive, in this section of 4 Cancer I 
will only describe the key molecular events regulating cancer cell invasion, since that will be 
in the focus of the third (III) study of this thesis.  
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4.1 Molecular effectors of cancer cell invasion 
Since nearly 80% of diagnosed human cancer are of epithelial origin, that is carcinomas, the 
molecular details regulating carcinoma cell invasion are perhaps the most extensively studied 
(Lambert et al., 2017). In many cases, the initial steps of carcinoma cell dissemination are 
thought involve activation of a key program, called EMT (epithelial-to-mesenchymal 
transition). EMT is a normal developmental program particularly important during 
gastrulation, when epiblasts detach from embryonal ectoderm and migrate to the center of 
the embryo to form the mesoderm (Weinberg, 2014). During EMT, cancer cells, as well as 
the normal epiblasts, lose epithelial cell polarity, cytokeratin expression, and E-cadherin-
mediated adherens junctions, and gain mesenchymal cell properties, such as fibroblast-like 
shape, motility, and expression of vimentin. Many of these alterations are coordinated by a 
selection of so called EMT-transcription factors (e.g. Snail, Slug, Twist, and Zeb1), which 
orchestrate the transition from epithelial to mesenchymal gene expression programs and 
eventually allow the initiation of cell migration (Lambert et al., 2017; Lamouille et al., 2014).  
 
During EMT cells reorganize their cortical actin cytoskeleton (typical for epithelial cells) and 
gain front-to-rear polarity to enable directional actin driven protrusions, such as lamellipodia 
and filopodia (Pollard, 2003; Mayor & Etienne-Manneville, 2016). This actin cytoskeleton 
reorganization is mainly regulated by the Rho-family of small GTPases, which through their 
downstream effector proteins modulate actin polymerization (Parri & Chiarugi, 2010). The 
Rho-family of small GTPases consist of Rho, Rac and Cdc42 subfamilies, of which RhoA, 
Rac1 and Cdc42 are the most well-studied. The general consensus is that the role of RhoA is 
to regulate actin stress fibers and focal adhesions, whereas Rac1 and Cdc42 mainly function 
in formation of lamellipodia and filopodia, respectively (Lamouille et al., 2014). The activity 
of all Rho-GTPases is tightly regulated by various guanine nucleotide exchange factors 
(GEFs), GTPase-activating proteins (GAPs), and guanine nucleotide dissociation inhibitors 
(GDIs) that all modulate GTP-binding status of the GTPases. The GEFs, GAPs, and GDIs 
act downstream of many growth factor receptors and transmembrane adhesion molecules and 
thus can integrate multiple cellular signals into distinct Rho-GTPase activity profiles (Parri 
& Chiarugi, 2010). 
 
The process of cellular movement can be divided into distinct general steps. In the beginning, 
the cell generates finger-like actin-rich structures, called filopodia, which are used to probe 
the cellular surroundings for appropriate growth environment (Jacquemet et al., 2015). This 
step is regulated mainly by Rac, which is compartmentalized to the leading edge through 
lipid anchoring (Parri & Chiarugi, 2010). Once activated, Rac interacts with WAVE-complex 
(member of the Wiskott-Aldrich Syndrome Protein family) and subsequently activates actin 
nucleation through Arp2/3 protein complex (actin-related proteins 2/3). This creates a 
membrane protrusion that pushes the cell forward (Parri & Chiarugi, 2010; Ridley, 2015). 
Simultaneously, the cell forms cell-ECM interactions by nascent integrin attachments, which 
through formation of focal adhesions help to organize actin bundles. It has been suggested 
that Cdc42, acting also in the front of the cell, would assist in the formation of these focal 
adhesions (Weinberg, 2014). In addition, Cdc42 has been shown to be important in regulating 
the cell polarity through Par polarity complex and microtubules (Ridley, 2015). An essential 
element of the cell movement is also the production of ECM-degrading MMPs (matrix 
metalloproteinases) in the front of the cell, which enable the cell movement through the 
ECM. Degradation of the ECM also releases matrix-bound growth factors creating a positive 
feedback loop for the migratory behavior of the cell. The MMPs are produced by the tumor-
surrounding stromal cells as well as the cancer cells, and there are indications that Rac 
activity would be required for adequate MMP production (Parri & Chiarugi, 2010). The final 
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requirement for the cell to move is to create contractile forces in the lagging edge of cell, 
which help to push the cell body forward and assist in the detachment of cell-ECM contacts 
at the rear of the cell. This step is mainly regulated by Rho and one of its effector proteins 
ROCK (Rho-associated serine/threonine kinase) that phosphorylates myosin light chains 
when activated. Moreover, Rho promotes the formation of actin bundles, which together with 
the phosphorylated myosin creates contractile forces.  
 
In addition to their key roles in cell movement, the functions of Rho-family of GTPases in 
cancer extends far beyond the regulation of invasion and involves cellular processes such as 
gene expression, proliferation, and cell survival (Sahai & Marshall, 2002). Interestingly, the 
cancer-specific abnormalities in Rho GTPase function appear to be mainly at the level of 
deregulated expression and activity, rather than at the level of genetic mutations (Sahai & 
Marshall, 2002; Parri & Chiarugi, 2010). Considering the multi-functional nature, Rho 
GTPases are intriguing targets for molecular cancer therapy and therefore detailed 
knowledge about the factors affecting their expression and activity is warranted. A summary 
of observed abnormalities in Rho GTPases in human cancer can be found in the table below 
(Table 2). 
 
Table 2. Aberrant regulation of Rho-family of GTPases in cancer. Table modified from (Sahai & 
Marshall, 2002; Parri & Chiarugi, 2010). 
 
Rho-GTPase subtype Abnormality Cancer type
RhoA High expression, High activity
Liver, skin, colon, ovarian, bladder, gastric, esophageal squamous cell (SCC), 
testicular, breast
RhoB High expression, Low expression Breast (high exp.), lung (low exp.)
RhoC High expression, High activity
Melanoma metastases, breast, squamous cell (SCC), pancreas, liver, ovarian, 
head and neck, prostate, non-small cell lung (NSCLC), gastric cancer
RhoH Rearragement, Mutations Non-Hodgkin´s lymphoma, multiple myeloma
Rac1 High expression, High activity Testicular, colon, breast, squamous cell (SCC)
Rac1B Alternative splicing Colon, breast
Rac2 High expression Head, neck squamous-cell carcinoma (SCC)
Rac3 High expression, High activity Breast (high exp.), lung (low exp.)
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AIMS OF THE STUDY 
At the beginning of this work, the methods that were used to identify novel sumoylation 
substrates mainly relied on protein sequence analysis for the existence of sumoylation 
consensus motifs. Already then, it was well recognized that SUMO can be conjugated to non-
consensus lysine residues, which at that time were laborious to identify. To alleviate the 
experimental challenge, one of the aims in this thesis was to develop a novel biochemical 
method to study sumoylated proteins in cells. Simultaneously, HSF1 had been identified as 
a target for various PTMs, though their regulatory roles were still partially uncharacterized. 
Phosphorylation was considered as the most prominent HSF1 modification, and multiple 
laboratories were interested in the stress-inducible phosphorylation of HSF1, which was 
mainly considered as a prerequisite for HSF1 activation. However, most of the studies had 
focused on single site phosphorylation events, whereas we wanted to conclusively examine 
how hyperphosphorylation affects HSF1 transactivation capacity.  
 
More recently, I have investigated the significance of HSFs, and more specifically HSF2, in 
human malignancies. Prior to this work, only HSF1 had been established as a key 
transcription factor in cancer progression, whereas the role of HSF2 was completely 
unknown. For this reason, this thesis work aimed at investigating if HSF2 has a role in cancer 
progression. Moreover, although the prominent role of HSF1 in cell survival upon 
proteotoxic stress is well-acknowledged, the importance of HSF2 in such conditions has 
remained enigmatic. Since the identification of HSF2, the factor has been considered as a 
dispensable bystander of the stress response with only modulatory role in the regulation of 
heat shock gene expression. However, HSF2 is responsive to distinct types of proteostasis 
alterations, such as those created by proteasome inhibition, suggesting that the factor might 
be important in particular types of stress. Thereby, the final aim of this thesis has been to 
examine the role of HSF2 in prolonged proteotoxic stress conditions. 
 
 
 
The specific aims of this thesis work were to: 
 
 Develop novel methods to identify sumoylated proteins in cells. 
 
 Study the role of phosphorylation in the regulation of HSF1. 
 
 Examine if HSF2 has a function in prostate cancer progression. 
 
 Define the role of HSF2 during proteotoxic stress.  
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EXPERIMENTAL PROCEDURES 
The experimental procedures used in this thesis are provided here in a table format. More 
detailed information about specific methods can be found from the original publications (I-
III). In addition, materials and methods used in the unpublished work included in thesis are 
described in the end of this section. 
 
Table 3. Methods used in this thesis work.  
 
 
 
 
 
 
 
 
 
 
Methods Original work
3D cell culture III, IV
Cation exhange chromatography I
Cell aggregation assay IV
Cell culture I, II, III, IV
Cell viability assay through Calcein IV
Chicken chorioallantoic membrane assay III
Chromatin immunoprecipitation (ChIP) II
CRISPR-Cas9 IV
Cys-tag enrichment I
Electrophoretic mobility shift assay II
HE-staining III
His-purification I
Image analysis I, II, III, IV
Immunofluorescence II, III, IV
Immunohistochemistry III
In  vitro sumoylation assay Results and Discussion
LC-MS/MS I
Luciferace assay II
LysC-digestion I
Microscopy II, III, IV
mRNA Microarray III
Protein dephosphorylation II
Protein turnover analysis II
Quantitative RT-PCR II, III
RNA extraction II, III
RNA interference III
RNA sequencing IV
SDS-PAGE and immunoblotting I, II, III, IV
Site-directed mutagenesis II
Statistical analysis II, III, IV
Transient transfections I, II, III
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Table 4. Cell lines used in this thesis work.  
 
 
 
 
 
Table 5. Plasmids used in this thesis work. These expression plasmids were used to express the 
indicated wild-type and mutant proteins or reporter constructs.  
 
 
 
 
 
 
Cell lines Type Original work
DU145 Human prostate carcinoma III
EP156T Human prostate epithelial III
HeLa Human cervical carcinoma I,II
LNCaP Human prostate adenocarcinoma III
Mef WT Mouse embryonic fibroblast II
Mef Hsf1 -/- Mouse embryonic fibroblast II
PC3 Human prostate carcinoma III
PC3-M Human prostate carcinoma III
PrEC Human primary prostate epithelial III
U2OS WT Human osteosarcoma IV
U2OS 2KO Human osteosarcoma IV
Plasmids Original work
GAL4-luciferase II
Gal4-VP16 II
Gal4-VP16-HSF1 WT II
Gal4-VP16-HSF1 ΔPRD II
HA-CKAP2L K198R I
HA-CKAP2L WT I
His-SUMO1 C52S H75K V87K V90C Q92C T95R I
His-SUMO1 C52S V87K V90C Q92C T95R I
His-SUMO1 E89K T95R I
His-SUMO1 E93C T95R I
His-SUMO1 I88K T95R I
His-SUMO1 Q92C T95R I
His-SUMO1 T95R I
His-SUMO1 V87K T95R I
His-SUMO1 V87K V90C Q92C T95R I
His-SUMO1 V90C T95R I
His-SUMO1 WT I
hsp70-prom-luciferase II
Myc-His-HSF1 WT II
Myc-His-HSF1ΔPRD II
Myc-PARP-1 H53R I
shRNA HSF1 III
shRNA HSF2 III
shRNA res HSF2 III
shRNA scr III
β-galacatosidase II
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Table 6. Antibodies used in this thesis work. Abbreviations ChIP, Chromatin immunoprecipitation; 
IHC, Immunohistochemistry; IP, Immunoprecipitation; WB, Western blotting. 
 
 
 
 
1 In vitro sumoylation  
For in vitro sumoylation reactions, 10 M of monoubiquitin (WT or mutants) or 1 M of 
tetraubiquitin chains were incubated in the presence of 0.14 M Aos1/Uba2 (E1), 0.05 M 
Ubc9 (E2), 0.05 M BP2FG/IR1+M/Pias1 (E3), 10 M SUMO1 or SUMO2, and 10 M 
ATP in final volume of 20 l of sumoylation assay buffer (SAB) [transport buffer (200 mM 
HEPES, 110 mM KOAc, 20 mM Mg(OAc)2, 10 mM EGTA, pH 7.3) containing 10 g/ml 
ovalbumin, 2 % Tween20, 1 g/ml LP (leupeptin/pepstatin), AP (aprotinin), and 1 mM 
DTT]. Samples were incubated at 30˚C for 1 h after which the reaction was stopped by 
boiling the samples in Laemmli-sample buffer before subjecting them in to SDS-PAGE and 
immunoblot analysis. The purified ubiquitin proteins were purchased from Boston Biochem 
[monoubiquitin (WT, K0, K6 only, K11 only, K27 only, K29 only, K33 only, K48 only, K63 
only), K48-linked tetraubiquitin, K63-linked tetraubiquitin] or from Enzo Life Sciences 
(linear tetraubiquitin). The E1 (Aos1/Uba2), E2 (Ubc9), and E3 enzymes (BP2FG, IR1+M, 
Pias1), as well as purified SUMO1, SUMO2 and HA-tagged monoubiquitin were a kind gift 
from Dr. Andrea Pichler (Max-Planck Institute of Immunobiology and Epigenetics, Freiburg, 
Germany).  
 
Since sumoylation is an ATP-dependent reaction, a sample without ATP was prepared to be 
used as a negative control. Additionally, a sample without ubiquitin was used to distinguish 
the unspecific signal from ubiquitin. To study the possibility of E3-independent sumoylation 
of ubiquitin, two samples with high (12.5 M) or low (0.05 M) concentration of Ubc9 
without any E3-ligase, were also prepared. As sumoylation of ubiquitin has not been 
experimentally examined in the literature before, the ubiquitin specific SUMO-ligases have 
not been identified. Therefore, I used three different E3-ligases, with specific properties to 
Antigen Cat#/Clone Company Application Original work
ARHGAP1 HPA004689 Sigma-Aldrich WB III
Actin AC-40 Sigma-Aldrich WB II
Cdc42 ACD03 Cytoskeleton WB III
CDH1 GTX125890 Gentex WB III
CDH2 EPR1792Y Millpore WB III
FK2 PW8810 Biomol International Inc. WB Results and Discussion
GAPDH ab9485 Abcam WB IV
GNA13 HPA010087 Sigma-Aldrich WB III
HA PRB-101C Covance IP, WB I
Hsc70 SPA-815 Stressgen WB I, III, IV
HSF1 SPA-901, AB-4 Stressgen, Thermo Scientific WB II, III
HSF2 HPA031455/3E2 Sigma-Aldrich, Millipore WB III, IV
MMP14 MAB3328 Sigma-Aldrich IHC III
Myc M4439 Sigma-Aldrich WB, ChIP I, II 
PARP-1 sc-8007 Santa Cruz Biotechnology WB IV
Snail2 9585 Cell Signaling WB III
SUMO1 ab58424 Abcam WB I
Tubulin T8328 Sigma-Aldrich WB III, IV
Vimentin 5741 Cell Signaling WB III
VP-16 V4388 Sigma-Aldrich WB II
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study the ubiquitin sumoylation. The BP2FG is a C-terminal fragment of SUMO E3-ligase 
RanBP2 and contains the SUMO E3-ligase activity that has been shown to be sufficient in 
promoting sumoylation in vitro (Pichler et al., 2002). BP2FG further consists of two central 
IR-regions, IR1 and IR2, that are separated by a short M-region. Together with the short M-
region, IR1 (IR1+M) has SUMO-ligase activity. IR1+M lacks completely substrate 
specificity and for that was included in these experiments. As the third ligase, I used full-
length Pias1, which belongs to the SP-RING like family of SUMO E3-ligases that are the 
most studied SUMO-ligases (Pichler et al., 2017). For the experiments studying the SUMO-
isoform specificity of ubiquitin sumoylation, similar samples were prepared where only 
SUMO2 was used instead of SUMO1. To study the sumoylation target lysine on ubiquitin, 
samples were prepared as the IR1+M sample (see table 7), but with different ubiquitin 
constructs (HA-Ub, WT, K0, K6 only, K11 only, K27 only, K29 only, K33 only, K48 only, 
K63 only) as substrates (Table 7). 
 
 
Table 7. In vitro sumoylation sample preparation. In the in vitro reactions, 13 different ubiquitin 
constructs were used as sumoylation substrates. For all the monoubiquitins used (HA-Ub, WT, K0, 
K6 only, K11 only, K27 only, K29 only, K33 only, K48 only, K63 only) the concentration in the reaction 
was 10 M. Tetraubiquitin chains (K48-linked chains, K63-linked chains, linear chains) were used in 
concentration of 1 M. 
 
 
 
 
 
 
  
no ATP no ubiquitin High Ubc9 Low Ubc9 BP2∆FG IR1+M Pias1
Aos1/Uba2 0,14 μM 0,14 μM 0,14 μM 0,14 μM 0,14 μM 0,14 μM 0,14 μM
Ubc9 0.05 μM 0.05 μM 12.5 μM 0.05 μM 0.05 μM 0.05 μM 0.05 μM
BP2∆FG - - - - 0.05 μM - -
IR1+M 0.05 μM - - - - 0.05 μM -
Pias1 - - - - - - 0.05 μM
SUMO1/SUMO2 10 μM 10 μM 10 μM 10 μM 10 μM 10 μM 10 μM
Ubiq. 1 μM/10 μM - 1 μM/10 μM 1 μM/10 μM 1 μM/10 μM 1 μM/10 μM 1 μM/10 μM
ATP - 10 μM 10 μM 10 μM 10 μM 10 μM 10 μM
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RESULTS AND DISCUSSION 
1 IDENTIFICATION OF IN VIVO SUMOYLATION SITES (I) 
Sumoylation is a post-translational modification that targets thousands of substrate proteins 
in eukaryotic cells (Hendriks et al., 2014). Through the versatility of its targets, sumoylation 
has been connected to many essential processes, such as DNA repair, chromatin remodeling, 
and cellular stress responses. Moreover, the importance of sumoylation has been 
demonstrated in severe human diseases like cancer and neurodegeneration, further 
highlighting the fundamental role of sumoylation in organismal health.  
 
The obvious importance of sumoylation has raised the interest in identifying the sumoylated 
proteome in mammalian cells, which is often challenged by the biological nature of the 
modification. For example, low abundance of specific sumoylation substrates complicates 
the detection as classical methods, such as immunoblotting, are not sensitive enough. In 
addition, the dynamic nature of the modification caused by highly active SUMO-
isopeptidases that maintain their activity in a wide range of buffer conditions results in fast 
SUMO deconjugation and thereby hampers the purification of sumoylated substrates. The 
amino acid sequence of the protein itself also poses a challenge. Nearly all current methods 
that are used to study protein sumoylation, rely on different proteomics strategies for the final 
peptide identification. An essential part of that kind of procedure is the cleavage of the 
purified proteins with specific enzymes, such as LysC and trypsin. However, cleavage of 
endogenous SUMO with such enzymes produces a large signature tag on the target lysine 
residues, resulting in such a complex pattern in tandem MS/MS spectra that the target 
peptides are nearly impossible to identify. To that end, we developed a novel method that is 
based on an engineered human SUMO1 and can be used to alleviate the above-mentioned 
issues.  
 
1.1 Generation of engineered SUMO1 
To facilitate the in vivo identification of sumoylated substrates, we generated an engineered 
human SUMO1 protein with various single site mutations in its C-terminus. The aim of these 
mutations was to improve both purification of sumoylated peptides and subsequent target 
site identification. We introduced two cysteine residues at positions V90 and Q92 to enable 
cysteine-targeted affinity purification, a method previously used to examine human plasma 
proteome (Liu et al., 2006). In this method, peptides are enriched with specific affinity beads 
(Thiopropyl-Sepharose 6B in this study) that bind cysteine residues covalently. During the 
development of our method, SUMO1 peptides containing an internal cysteine at position 52 
(C52) were also found to bind to the affinity beads. For that, C52S mutation was included in 
our mutant SUMO1 protein. H75K and V78K were introduced to enhance peptide digestion 
with the endoproteinase LysC, which cleaves proteins specifically on the C-terminal side of 
lysine residues and thus produces shorter peptides required for MS/MS analysis. In most of 
the proteomic approaches, the peptides are further digested with trypsin, a serine protease, 
that cleaves proteins at both lysine and arginine residues. Neither LysC nor trypsin can cleave 
at lysine residues that are post-translationally modified with ubiquitin or ubiquitin-like 
proteins, which results in branched peptides with intact lysine cleavage site and covalent 
attachment of the specific signature tag (Knuesel et al., 2005). In the case of ubiquitin, the 
signature tag consists of two glycine residues (GG), since the 76-amino acid ubiquitin 
contains arginine at position 74 (R74) and thus is cleaved by trypsin at that site. In the case 
of 97-amino acid human SUMO1 the first tryptic digestion site (counting from the C-
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terminus) is lysine 78 (K78), whereas in 93-amino acid human SUMO2/3 the first site is 
arginine 61 (R61). This results in signature tags of 19 or 32 amino acids for SUMO1 and 
SUMO2/3, respectively, and thereby challenges the target identification by generating 
complex mass spectra. Diglycine (GG) increases the mass of the peptide with only 114 Da, 
which can be more readily identified with MS/MS. To facilitate the identification of 
sumoylated peptides, we substituted the threonine at position 95 in SUMO1 with arginine 
(T95R). Such mutation creates an additional tryptic cleavage site to SUMO1 C-terminus (-
RGG) and allows generation of a short diglycine tag at the target lysine after tryptic digestion. 
Importantly, introduction of the T95R mutation has been previously shown to be dispensable 
for SUMO1 conjugation efficiency (Knuesel et al., 2005). Finally, the construct was His6-
tagged to enable metal affinity purification of the sumoylated proteins from cell lysates. 
Metal affinity purification was specifically used, as it tolerates strong denaturing conditions 
(8 M urea in this study) that are required to disrupt all the non-covalent protein interactions. 
Altogether, these mutations resulted in His-SUMO-1C protein with C52S, H75K, V87K, 
V90C, Q92C and T95R substitutions.  
 
The functionality of the generated His-SUMO-1C was examined by co-expressing the mutant 
protein in HeLa cells together with the well-established SUMO-target PARP-1 (Martin et al., 
2009) and analyzing PARP-1 sumoylation with immunoblotting. In this study, we used a 
DNA-binding mutant PARP-1 (Myc-PARP-1 H53R) since it can be sumoylated already at 
normal growth conditions (unpublished observations by Henri Blomster). As evidenced by 
Figure 1C (in I), similar higher molecular weight bands representing the sumoylated PARP-
1 were detected in the samples expressing His-SUMO-1C and SUMO1 WT, indicating that 
His-SUMO-1C can be efficiently conjugated to target substrates.  
 
1.2 Identification of sumoylation sites in cells 
For the in vivo identification of novel sumoylation substrates, His-SUMO-1C was transiently 
expressed in HeLa cells. Cells were lysed and the sumoylated proteins were purified with 
metal affinity purification in denaturing conditions. Purified proteins were digested with 
LysC and the sumoylated peptides were enriched from the sample with cysteine-targeted 
affinity purification. Covalently bound peptides were treated with trypsin, which released the 
diglycine modified peptides (Figure 1B in I). These peptides were then subjected to LC-
MS/MS (liquid chromatography coupled with tandem mass spectrometry) with QSTAR 
Pulsar and LTQ-Orbitrap XL mass spectrometers. The received data were analyzed with 
Mascot against the SwissProt Human database. As a result, 14 sumoylated peptides 
originating from 12 proteins were identified (Table 1 in I). For example, we identified two 
sites (K8 and K524) from RanGAP1 and K11 from SUMO2/3, which all have previously 
been identified as sumoylation target sites (Mahajan et al., 1998: Tatham et al., 2001; Matic 
et al., 2008), thereby confirming the functionality of our method. To further validate the 
method, we examined sumoylation of one of the identified non-consensus targets CKAP2L 
(cytoskeleton-associated protein 2), which had not been previously shown to be sumoylated. 
We mutated the identified lysine (K198) on CKAP2L to arginine, after which the mutant and 
WT CKAP2L proteins together with SUMO1 were expressed in HeLa cells. As shown in 
Figure 2C (in I), mutation of K198 abolished specific bands from the CKAP2L K198R 
migration pattern, demonstrating that CKAP2L is indeed sumoylated on lysine 198. These 
results confirmed that the His-SUMO-1C-based method can be used as a novel tool to study 
sumoylation in cells and is applicable for the identification of both consensus and non-
consensus sumoylation substrates. 
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Albeit presenting a functional tool to identify sumoylated proteins in cells, our method 
significantly suffers from low enrichment efficiency and low number of identified 
sumoylation substrates. This could be caused by utilization of the mutant SUMO1 protein, 
which might not be conjugated to all substrates as efficiently as the endogenous WT SUMO1. 
In our study, the functionality of the protein was only examined with exogenously expressed 
mutant PARP-1 (Myc-PARP-1 H53R), which can serve as an excellent model system to 
study sumoylation, but represents only one mutant example of a sumoylation target. 
Therefore, it is possible that the construct is conjugated only to a specific subset of target 
proteins and thus results in an overall reduced number of sumoylated proteins in the sample. 
In addition, as this method is based on transiently expressed His-SUMO-1C, it is also 
possible that the construct is not sufficiently expressed in HeLa cells. As we did not monitor 
the expression levels of our construct, we cannot exclude the possibility that the low peptide 
yield is due to low protein expression.  
 
Yet another explanation for the low number of identified proteins could be provided by our 
experimental procedure, in which sumoylated proteins are first His-purified and digested 
with LysC, after which the peptides are enriched with cysteine-targeted affinity purification 
and trypsinized when bound to Thiopropyl-Sepharose 6B beads. In contrast, the most 
efficient currently used method uses both fewer experimental steps and inverse order of the 
key purifications (Hendriks et al., 2014). This method is called the K0-method and it is based 
on the His-K0-SUMO2 Q87R mutant protein, where all the internal lysine residues in 
SUMO2 as well as the glutamine at position 87 are substituted with arginines (8K>R/Q87R) 
(Hendriks et al., 2014; Hendriks & Vertegaal, 2016b). Similarly to our approach, this protein 
can be expressed from exogenous plasmid construct, though a cell line stably expressing the 
His-K0-SUMO2 Q87R has been developed (Hendriks et al., 2014). After induction of the 
His-K0-SUMO2 Q87R expression, sumoylated substrates are purified and peptides analyzed 
with MS/MS. They key difference between our and the K0-method is the eight lysine 
mutations (8K>R), which render SUMO2 resistant to the first digestion with LysC. This 
allows digestion of the unpurified whole cell lysate and results in a sample, where all other 
proteins are digested into peptides except for SUMO2 itself. Digestion of the sample into 
peptides considerably reduces the sample complexity, whereas the intact SUMO2 enables 
utilization of efficient metal affinity purification for the sample enrichment. Subsequently, 
sumoylated peptides are trypsinized when bound to the metal affinity resin, which due to the 
C-terminal Q87R mutation results in branched peptides more compatible with MS/MS 
(Hendriks et al., 2014). Thus, in comparison to our method, both the number and order of 
experimental steps in the K0-method is different, which likely results in more efficient 
enrichment of sumoylated peptides. Consequently, the K0-method has been successfully 
used to identify thousands of novel sumoylation substrates (Hendriks et al., 2014) (Table 8) 
and is currently considered the best method to examine sumoylated proteins in cells 
(Hendriks & Vertegaal, 2016). 
 
One obvious drawback of the above-mentioned methods is that they both rely on mutant 
SUMO proteins, which might be differentially regulated than the endogenous SUMOs. For 
example, mutating all SUMO2 lysine residues to arginines in His-K0-SUMO2 Q87R inhibits 
SUMO2 chain formation, which has been shown to promote cell survival during cell stress 
and thus appears essential for the correct function of the protein (Saitoh & Hinchey, 2000; 
Blomster et al., 2009; Golebiowski et al., 2009). To surpass the usage of mutant constructs, 
a method called Protease-Reliant Identification of SUMO Modification (PRISM) has been 
developed, which can be used to identify sumoylated proteins modified with wild-type 
SUMO (Hendriks et al., 2015). In this method, sulfosuccinimidyl acetate (SNHSA) is used 
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to block all free lysine residues in a SUMO-purified sample, after which SUMO is 
enzymatically removed with SENPs. This exposes free lysine residues that are not blocked 
by SNHSA or SUMO, thereby allowing for identification of the lysines with MS/MS. The 
PRISM method still relies on epitope-tagged SUMO (His10-SUMO) for the sample 
purification and thus is not suitable for studying endogenous sumoylation sites. For that, 
Lumpkin and co-workers have recently developed a method called WaLP, which utilizes 
wild-type -lytic protease (WaLP) instead of trypsin to enzymatically digest the protein 
sample into peptides. WaLP can specifically cleave after threonine amino acid residues and 
as all human SUMO isoforms contain threonines directly adjacent to the C-terminal di-
glycine motif (Figure 4), the WaLP-cleavage generates a GG signature tag on target 
substrates. Resulting peptides can subsequently be identified with methods previously 
developed to identify ubiquitinated substrates with GG-tag (Lumpkin et al., 2017). Albeit 
not as efficient as the K0-method, WaLP is the only currently available method that can be 
used to identify endogenous sumoylation sites and is therefore the only method that is 
applicable for the examination of sumoylation on tissue and patient material (Table 8).  
 
Table 8. Various methods used for identification of sumoylation sites. IP, Immunoprecipitation; 
PRISM, Protease-Reliant Identification of SUMO Modification; WalP, wild-type -lytic protease. Both 
NQTGG- and Diglycine-immunoprecipitations are methods where monoclonal antibodies produced 
against the tryptic remnant are used to immnopurify sumoylated peptides from cell samples (Impens 
et al., 2014; Lamoliatte et al., 2014; Tammsalu et al., 2015). Table modified from (Hendriks & 
Vertegaal, 2016a). 
 
 
 
In our study, we found that the majority of the identified peptides were modified on non-
consensus sumoylation sites (i.e. sites with no SCM). Previously, SIM-directed sumoylation 
has been proposed as one of the mechanisms directing non-consensus sumoylation (Zhu et 
al., 2008), and six of the 11 identified non-consensus peptides did contain SIM in close 
proximity to the target lysine (data not shown). The remaining five peptides, however, 
suggested that other determinants can also direct substrate sumoylation. By manually 
inspecting the MS/MS spectrum, we detected that many of the peptides were also modified 
with other PTMs, such as phosphorylation and acetylation (Table 1 in I). Based on this 
finding we hypothesized that perhaps other PTMs are important in directing a subset of 
sumoylation evens. Intriguingly, a recent study examined the peptide profile of 6,747 human 
proteins and defined phosphorylation as one of the key mechanisms directing substrate 
sumoylation (Hendriks et al., 2017). These results indicate that our method could also be 
valid to examine complex PTM interactions directing sumoylation events in cells. 
 
Taken together, we developed a mass-spectrometric method to identify sumoylated proteins 
in cells. The method is based on mutant human SUMO1 protein, which through its specific 
features facilitates both the purification of sumoylated peptides and the identification of 
sumoylation target sites. The results presented in this study validate the utilization of our 
Publication Year Method Mutation Tag Control Stress Total
Tammsalu et al ., 2014 Diglycine IPa T90K His6 - 1002 1002
Impens et al ., 2014 Diglycine IPa T90R His6 295 - 295
Lamoliatte et al ., 2014 NQTGG-IP Q87R/Q88N His6 123 936 954
Hendriks et al ., 2015 PRISM - His10 392 556 751
Hendriks et al ., 2014 K0 8>R/Q87R His10 1069 4317 4361
Xiao et al ., 2015 K0 8>R/Q87R His10 1043 - 1043
Hendriks et al ., 2015 K0 8>R/Q87R His10 755 - 755
Lumpkin et al ., 2017 WaLP - - 1209 - 1209
SUMO sites identifiedSUMO properties
 Results and Discussion  
 56
method in sumoylation research and provide a novel tool to examine both consensus and 
non-consensus sumoylation events in cells.  
 
1.3 Sumoylation of ubiquitin 
In addition to the 14 peptides published in Study I of this thesis, one of the putative non-
consensus sites identified was lysine 48 on ubiquitin. At that time, this lysine was only known 
to serve as a conjugation site for another ubiquitin moiety, but not for SUMO. To examine 
whether ubiquitin can function as a sumoylation target substrate, I performed in vitro 
sumoylation assays and used four different purified ubiquitin constructs as sumoylation 
target substrates; monoubiquitin, K48-linked tetraubiquitin, K63-linked tetraubiquitin and 
linear tetraubiquitin. Ubiquitin constructs were mixed with the sumoylation machinery 
supplemented with ATP and the samples were incubated at 30C for 1 h. The samples were 
resolved in SDS-PAGE and subjected to immunoblotting with ubiquitin-specific antibodies. 
Surprisingly, these experiments revealed that ubiquitin can indeed be sumoylated in vitro in 
the presence of substrate unspecific IR1+M ligase fragment of RanBP2 (Figure 14). 
Importantly, not only monoubiquitin, but also all the tested tetraubiquitin chains were 
sumoylated in vitro, suggesting that SUMO can target ubiquitin in different conformations 
(Figure 14). Furthermore, two higher molecular weight bands were detected with linear 
tetraubiquitin chains (Figure 14). This might be caused by modification of two individual 
lysine residues on the linear ubiquitin chain and result in differential separation on the SDS-
PAGE. 
 
Due to the finding that higher molecular weight ubiquitin signal was only detected in the 
sample with unspecific IR1+M fragment, and not with BP2∆FG fragment or full-length Pias1 
(Figure 14), it is likely that neither RanBP2 nor Pias1 is the cellular SUMO-ligase targeting 
ubiquitin. Sumoylation has been reported to occur independently of an  E3-ligase in vitro in 
high Ubc9 concentrations (Bernier-Villamor et al., 2002). However, I did not detect a higher 
molecular weight signal in the sample with high (12.5 µM) Ubc9 concentration (Figure 14). 
This is likely due to the observation that E3-independent in vitro sumoylation often requires 
the target lysine to be embedded in the SCM (Pichler et al., 2017), whereas none of the lysine 
residues of ubiquitin resides within the consensus motif. These results provide for the first 
time direct evidence for ubiquitin sumoylation and demonstrated that not only monoubiquitin 
but also ubiquitin chains of variable linkage types can be sumoylated in vitro. 
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Figure 14. Monoubiquitin and ubiquitin chains with variable linkages are sumoylated in vitro. 
In vitro sumoylation reactions were performed in the presence of 0.14 M Aos1/Uba2, 0.05 M Ubc9 
or 12.5 M Ubc9 only for the “High Ubc9” sample, 0.05 M BP2FG/IR1+M/Pias1, 10 M SUMO1, 
and 10 M monoubiquitin or 1 M of tetraubiquitin chains in 20 l of reaction volume. Samples were 
incubated at 30C for 1 h after which they were subjected to SDS-PAGE. Ubiquitin was detected with 
specific antibodies (FK2). Representative results from three independent experiments are shown. 
 
Ubiquitin contains seven internal lysine residues as well as the N-terminal methionine, which 
can all serve as conjugation sites for another ubiquitin moiety (Swatek & Komander, 2016). 
By using the WT monoubiquitin or ubiquitin chains as sumoylation substrates, it is 
impossible to separate which one of these lysines is the actual sumoylation target lysine. To 
study the sumoylation site specificity, in vitro reactions were performed in the presence of 
specific ubiquitin constructs, where all except for one lysine was replaced with arginine (e.g. 
K6 only = all the other six lysines are replaced with arginine, only K6 is functional). These 
experiments revealed that lysine 11 (K11) is the predominant target lysine for sumoylation 
(Figure 15). A weak signal at lysine 63 (K63) was also detected, suggesting that it can also 
function as a sumoylation target lysine, albeit to a lesser extent. No higher molecular weight 
signal was detected with the K0-construct, where all the lysines were abolished, indicating 
that the M1 of ubiquitin cannot function as a sumoylation target site. These results are 
consistent with the recent results by Hendriks and co-workers (2017), who revealed in an 
unbiased proteomics screen that K11 and K63 are the main sumoylation target lysines on 
ubiquitin, whereas no M1-targeted sumoylation was detected.  
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Figure 15. Sumoylation of ubiquitin shows site specificity. In vitro sumoylation reactions were 
performed in the presence of 0.14 M Aos1/Uba2, 0.05 M Ubc9, 0.05 IR1+M, 10 M SUMO1, and 
10 M monoubiquitin (HA-Ub, WT, K0 only, K6 only, K11 only, K27 only, K29 only, K33 only, K48 
only, K63 only) in 20 l of reaction volume. Samples were incubated at 30C for 1 h after which they 
were subjected to SDS-PAGE and immunoblotting. Ubiquitin was detected with specific antibodies 
(FK2). 
 
Since the initiation of this project in 2010, multiple MS screens have identified ubiquitin as 
a sumoylation target substrate in cells (Hendriks et al., 2015; Lamoliatte et al., 2014; 
Lumpkin et al., 2017; Xiao et al., 2015). These studies did not directly address the biological 
role of ubiquitin sumoylation, but the obtained results suggested that sumoylation of 
ubiquitin could function as a modification regulating ubiquitin chain formation. Modification 
of K11 on SUMO2/3 by SUMO1 has been shown to limit SUMO2/3 chain elongation (Matic 
et al., 2008), and it is tempting to speculate that SUMO1 could also regulate ubiquitin chain 
elongation. Such a hypothesis could be examined by in vitro reactions assessing ubiquitin 
chain length in the presence of variable SUMO1 concentrations. Increased appearance of 
short ubiquitin chains in samples with high SUMO1 concentrations would suggest a role for 
SUMO1 in the regulation of ubiquitin chain length. Recently, Wauer and co-workers reported 
that phosphorylation of S65 of ubiquitin affects ubiquitin chain structure, chain assembly, 
and hydrolysis (Wauer et al., 2015). Their study confirms that ubiquitin biology is indeed 
regulated by other post-translational modifications and it would be extremely exciting to 
perform analogous experiments with SUMOs to examine the functional role of ubiquitin 
sumoylation.  
 
Although many experiments can be performed in in vitro conditions, the in vivo 
characterization of ubiquitin sumoylation is essential for the biological validation of the 
PTM-interplay. Unfortunately, this appears not to be straightforward. SUMO and ubiquitin 
share a large number of target substrates (Lumpkin et al., 2017), which means that 
immunoprecipitation with e.g. ubiquitin-specific antibodies and immunoblotting with 
SUMO-specific antibodies is not sufficient to examine the phenomenon. For this purpose, 
we generated a selection of mutant ubiquitin proteins that were unable to bind to substrate 
proteins. Most of these constructs contained a G75/76A double mutation, which abolishes 
the ubiquitin C-terminal di-glycines and thereby inhibits ubiquitin conjugation. We predicted 
that such proteins could still function as initiator ubiquitin for chain formation and by 
immunoprecipitating these proteins we would be able to detect ubiquitin sumoylation in vivo. 
Unfortunately, despite multiple efforts, I was not able to detect ubiquitin sumoylation in cells 
and the project was terminated. However, I still find the original in vitro observations very 
intriguing, since sumoylation-mediated ubiquitin regulation has not thus far been reported. 
Moreover, as MS/MS is unable to detect modifications in protein multimers, such as 
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ubiquitin chains, the results presented in this thesis are novel and advocate the continuation 
of this fascinating project. 
 
 
2 POST-TRANSLATIONAL REGULATION OF HSF1 (II) 
During its activation and attenuation pathway, HSF1 undergoes multiple post-translational 
modifications, such as phosphorylation, sumoylation and acetylation (Budzyński & Sistonen, 
2017). By far the most extensively studied of these modifications is phosphorylation which, 
due to its correlation with HSF1 transcriptional activity, has been proposed as the main 
modification regulating HSF1 transactivation capacity. Nearly 70% of the known HSF1 
phosphorylation sites occur within the regulatory domain (RD), which is the domain 
responsible for heat-inducibility and repression of transactivation domain (TAD) in non-
stressed conditions (Shi et al., 1995; Zuo et al., 1995). Previous studies addressing the 
importance of phosphorylation for HSF1 function have mainly utilized single-site HSF1 
mutants, which disregards the existence of prominent multi-site hyperphosphorylation of the 
RD. To elucidate the role of hyperphosphorylation in HSF1 function, we generated a 
phosphorylation-deficient HSF1 mutant and analyzed effect of phosphorylation loss on key 
HSF1 features: stability, DNA-binding activity, transactivation capacity and stress-
inducibility. 
 
2.1 Characterization of the phosphorylation-deficient HSF1 mutant 
To study the importance of hyperphosphorylation on HSF1´s ability to function as a stress-
inducible transcription factor, we generated a human HSF1 mutant, called HSF1PRD, 
where 15 known phosphorylation sites within the RD were mutated to non-phosphorylatable 
alanines. Before proceeding into functional studies, the expression and stability of the mutant 
construct was examined in Hsf1-/- MEFs. These cells were used throughout the study to 
exclude the interference of the results by endogenous HSF1. HSF1 WT and HSF1PRD 
constructs were transfected in Hsf1-/- MEFs and expression of the proteins in control and 
upon a 30-min heat shock was analyzed by immunoblotting. These experiments 
demonstrated that HSF1PRD is expressed in Hsf1-/- MEFs and migrates faster on SDS-
PAGE in both control and stress conditions than HSF1 WT (Figure 1C in II). Observed 
migration differences were abolished by treating the cell lysates with lambda protein 
phosphatase (PP) (Figure 1C in II), confirming that the proteins are differentially 
phosphorylated in both control and heat shock conditions. The stability of HSF1PRD in 
relation to WT HSF1, was examined by treating the HSF1 WT and HSF1PRD transfected 
Hsf1-/- MEFs with eukaryotic translation inhibitor cycloheximide (CHX). The protein levels 
of both constructs remained stable throughout the CHX time course, indicating that the 
phosphorylation within the RD does not regulate HSF1 turnover in MEFs treated with CHX 
(Figure 1D in II). It is plausible that this result reflects the finding by Raychaudhuri and co-
workers, who showed that HSF1 is stabilized through EP300-mediated acetylation, not 
phosphorylation (Raychaudhuri et al., 2014). However, our observations could also be cell 
type dependent, as it has been shown that phosphorylation of serines 303 and 307 (both sites 
mutated in HSF1PRD) precedes HSF1 degradation in medium spiny neurons of 
Huntington´s disease mouse model and in HEK293 cells (Kourtis et al., 2015; Gomez-Pastor 
et al., 2017). This suggests that lack of phosphorylation might stabilize HSF1 in specific cell 
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types and possibly also during distinct stresses. Thereby, it would be interesting to examine 
whether HSF1PRD would be more protected against degradation in such conditions.  
 
To be able to induce transcription, HSF1 must accumulate in the nucleus and gain DNA-
binding capacity. To examine whether HSF1 hyperphosphorylation is required for the 
nuclear localization and DNA-binding of HSF1, we analyzed the appearance of nuclear stress 
bodies (nSBs) in HSF1 WT and HSF1PRD transfected HeLa cells using indirect 
immunofluorescence. nSBs are primate-specific subnuclear structures that are formed at 
satIII-repeats during heat shock and correspond to active transcription at these sites 
(Biamonti & Vourc’h, 2010). Localization of HSF1 to satIII-repeats depends on HSF1´s 
ability to trimerize and bind DNA (Jolly et al., 2002) and thus nSBs can be used as an 
indicator of HSF1 DNA-binding ability. In our experiments, both HSF1 WT and 
HSF1PRD localized to the nucleus and formed nSBs upon stress (Figure 2 in II), 
indicating that the phosphorylation within the RD is not required for the stress-induced 
accumulation of HSF1 to the nucleus or for HSF1´s ability to bind DNA. Considering the 
notions that HSFs form trimers while binding to DNA and that these experiments were 
performed in HeLa cells, it is possible that the detected nSBs could be formed by 
heterotrimeric HSF consisting of both exogenous and endogenous HSF1 monomers. To 
exclude the possibility of interference by endogenous HSF1, we examined the HSF1PRD 
DNA-binding ability in Hsf1-/- MEFs. Hsf1-/- MEFs were transfected with HSF1 WT and 
HSF1PRD and the heat-induced binding of the proteins to the endogenous HSPA1A/B and 
HSPB1 promoters was assessed with chromatin immunoprecipitation (ChIP). As shown in 
figure 3A (in II), both HSF1 WT and HSF1PRD equally occupied the HSPA1A/B and 
HSPB1 promoters after a 30-min heat shock, indicating that phosphorylation within the RD 
does not affect HSF1´s ability to bind chromatin upon acute stress.  
 
The DNA-binding activity of HSF1 has been previously shown to depend on stress duration 
(Sarge et al., 1993). To be able to examine the DNA-binding activity of HSF1 WT and 
HSF1PRD in more prolonged stress conditions, we used electrophoretic mobility shift 
assay (EMSA), which is technically more suitable than ChIP for such experiments. Hsf1-/- 
MEFs were transfected with HSF1 WT and HSF1PRD and treated with 60 M CdSO4 for 
times indicated in Figure 3B (in II). Hsf1-/- MEFs are highly sensitive to continuous heat 
stress (unpublished observations) and for that we used cadmium for the induction of 
prolonged stress conditions. Moreover, cadmium has been previously shown to induce HSF1 
DNA-binding activity and Hsp expression (Koizumi et al., 2007). After cadmium treatments, 
whole-cell lysates were incubated with 32P-labeled oligonucleotides containing the proximal 
HSE from the HSPA1A promoter and the protein-DNA complexes were visualized with 
autoradiography. At the 9-h time point, both HSF1 WT and HSF1PRD showed equal in 
vitro binding capacity to the radiolabeled oligonucleotides (Figure 3B in II) and thus 
suggested that the phosphorylation within the RD is not required for HSF1 DNA-binding 
activity during acute or prolonged stress conditions. 
 
Considering the notion that DNA-binding activity of HSF1 WT and HSF1PRD was only 
studied with a distinct set of target promoters and with pure DNA in the form of 
oligonucleotides, it is plausible that hyperphosphorylation impacts HSF1 DNA-binding on a 
subset of target promoters. HSF1 has a versatile selection of target genes, which varies 
depending on the cell type and growth conditions (Mendillo et al., 2012; Riva et al., 2012.; 
Vihervaara et al., 2013). A specific PTM signature has been frequently proposed as one of 
the mechanisms regulating HSF1 target gene selection, though the question has not been 
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directly addressed in mammalian cells. In yeast S. cerevisiae, the importance of 
phosphorylation on target gene selection was recently examined by comparing the genome-
wide binding of WT ScHSF and phosphorylation-deficient ScHSFpo4 mutant in control 
and heat shock conditions with ChIP-seq (Zheng et al., 2016). The obtained results 
demonstrated that the heat stress-induced chromatin occupancy of ScHSF is not affected by 
lack of phosphorylation (Zheng et al., 2016), suggesting that hyperphosphorylation does not 
regulate HSF1 binding to specific promoters during stress.  
 
2.2 Lack of phosphorylation potentiates HSF1 transactivation capacity 
Activation of the mammalian HSF1 is a multistep process evidenced by the observation that 
HSFs can localize to the nucleus and bind DNA without activating transcription (Hensold et 
al., 1990; Jurivich et al., 1992). Acquisition of HSF1 transactivation capacity coincides with 
the inducible hyperphosphorylation, which has been suggested as an elementary step in the 
initiation of transcription (Cotto et al., 1996). To establish whether hyperphosphorylation 
within the RD is required for HSF1 transactivation capacity, we transiently transfected Hsf1-
/- MEFs with HSF1 WT and HSF1PRD and measured the steady-state mRNA levels of 
HSPA1A/B and HSPB1 upon heat stress with qRT-PCR. At control conditions, neither 
expression of HSF1 WT nor HSF1PRD induced upregulation of mRNA levels of the 
studied genes, indicating that the proteins are not constitutively active (Figure 4A and B in 
II). Upon exposure to acute heat stress (30 min or 60 min at 43C) both proteins induced 
prominent increase in HSPA1A/B and HSPB1 mRNA levels (Figure 4 A in II). Intriguingly, 
HSF1PRD exceeded the transactivation capacity of WT HSF1 by inducing even higher 
mRNA levels at both time points (Figure 4A in II). These results show that the stress-
inducible hyperphosphorylation does not define HSF1 transactivation capacity during heat 
stress. To examine whether the observed results are stress type dependent, we performed the 
same experiments in the presence of heavy metal cadmium (60 M CdSO4). Similarly to heat 
shock, HSF1PRD induced more pronounced expression of HSPA1A/B and HSPB1 in 
cadmium treatment and the effect persisted throughout a 3-h recovery period (Figure 4B in 
II). Together these results show that instead of being a modification required for 
transactivation capacity, hyperphosphorylation rather represses HSF1 activity. Moreover, 
this effect appears to be general, as the phosphorylation-mediated repression of HSF1 
transactivation capacity was detectable in both heat shock and heavy metal induced stress. 
Intriguingly, similar observations have been obtained also in human cancer cell lines, where 
IER5-PP2A-mediated dephosphorylation of HSF1 was shown to increase HSF1 
transactivation capacity (Asano et al., 2016) 
 
The difference between the levels of Hsps induced by the HSF1 WT and HSF1PRD, could 
be due to a decreased activation threshold of HSF1PRD. Previously, lowered heat-induced 
activation has been observed with HSF2 (Shinkawa et al., 2011). To study the propensity of 
the proteins to induce the heat shock response, we transfected Hsf1-/- MEFs with HSF1 WT 
and HSF1PRD, exposed the cells to different heat shock temperatures (39C, 40C, and 
41C) or cadmium concentrations (40 M and 60 M), and measured the induction of 
HSPA1A/B with qRT-PCR. We found that HSF1PRD indeed has a lower activation 
threshold than WT HSF1, as stronger HSF1PRD-mediated induction of HSPA1A/B was 
detected in milder stress conditions (Figure 5A and B in II). Moreover, HSF1PRD induced 
an increase in HSPA1A/B mRNA levels in shorter stress exposures (30 min at 41C). These 
results show that the lack of phosphorylation within the RD lowers the HSF1 activation 
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threshold and produces faster induction of the heat shock response in various stress 
conditions. 
 
We can only hypothesize on the possible reasons why HSF1PRD is a more potent 
transcription factor than WT HSF1. It is, however, widely accepted that phosphorylation 
modulates transcription factor activity often in concert with other PTMs (Filtz et al., 2014), 
and HSF1 RD has been shown to be subjected to multiple PTMs, including sumoylation and 
acetylation (Budzynski & Sistonen, 2017). Sumoylation of lysine 298 occurs only if the 
adjacent S303 residue is phosphorylated (Hietakangas et al., 2003) and is considered as a 
repressive modification (Hietakangas et al., 2006). Thus, lack of phosphorylation within the 
RD might inhibit stress-induced sumoylation of HSF1 and thus could retain HSF1PRD 
more active. Therefore, it would be interesting to examine whether reintroduction of S303 to 
HSF1PRD restores sumoylation and normalizes the transactivation capacity to the level 
of WT HSF1. Furthermore, K298 is also subjected to acetylation, which has been indicated 
as a stabilizing modification during stress (Raychaudhuri et al., 2014). Because we did not 
assess the stability of HSF1 WT or HSF1PRD during the heat shock time course, we 
cannot exclude the possibility that lack of S303 phosphorylation and subsequent impairment 
in K298 sumoylation enables more persistent acetylation on K298 and hence increases the 
stability of HSF1PRD. 
 
Another possibility is that phosphorylation regulates the protein interactome that is required 
for the normal HSF1 activation. As one of many examples of HSF1 interacting partners, 
HSF1 forms heterotrimes with HSF2 (Sandqvist et al., 2009) and this trimerformation has 
been shown to have an inhibitory effect on the expression of specific target genes during 
stress (Östling et al., 2007; El Fatimy et al., 2014) and in mitosis (Elsing et al., 2014). Though 
not directly mediating HSF oligomerization, lack of phosphorylation could prevent HSF1 
and HSF2 interaction and thereby enable unrestrained HSF1 activation. Co-
immunopurification experiments, assessing the interaction between endogenous HSF2 and 
exogenously expressed HSF1 WT and HSF1PRD, would provide insight into such a 
hypothesis. Heterotrimerformation has been implicated as a regulatory mechanism affecting 
HSFs activity in various stress, differentiation, and developmental conditions (Sandqvist et 
al., 2009). However, the mechanisms controlling the trimerformation are currently unknown 
and the proposed experiments could potentially provide important information about the 
post-translational regulation of HSF1-HSF2 trimers. 
 
2.3 Phosphorylation-deficient HSF1 can sense stress 
HSF1 RD has an intrinsic capacity to sense stress and, thus, can provide stress-inducibility 
to heterologous activatory domains, such as the activatory domain of herpes simplex virus 1 
VP16 (Newton et al., 1996). To assess whether hyperphosphorylation within the RD is 
necessary to provide heat-sensitive transactivation capacity also to heterologous activatory 
domains, the RDs of WT HSF1 and HSF1PRD were cloned into a Gal4-VP16 chimeric 
construct (Figure 6A in II). The constructs, as well as Gal4-VP16, were expressed together 
with a Gal4-driven luciferase reporter gene in HeLa cells and the relative luciferase activity 
in control and heat shock treatments was measured. In control conditions, cells expressing 
the Gal4-VP16-HSF1 WT displayed lower luciferase activity than cells expressing Gal4-
VP16 (Figure 6B in II). No statistically significant difference was observed between the 
luciferase activities of Gal4-VP16 and Gal4-VP16-HSF1PRD expressing cells (Figure 6B 
in II). After a 30-min heat shock and 5 h of recovery, cells expressing Gal4-VP16-HSF1 WT 
displayed equal luciferase activity to Gal4-VP16 expressing cells. In the same conditions, 
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however, Gal4-VP16-HSF1PRD expressing cells showed 60% higher luciferase activity 
denoting even more pronounced stress-inducible activation of transcription.  
 
These results are in line with a previous study and show that in control conditions, 
phosphorylation within the HSF1 RD represses the transactivation capacity of heterologous 
VP16 in a constitutively DNA-bound chimera, whereas lack of phosphorylation reverses this 
repression (Kline & Morimoto, 1997). Interestingly, the study further showed that the 
repression in control conditions is mediated mainly through phosphorylation of S303 and 
S307 residues, which could be confirmed by reintroducing those sites into HSF1PRD. By 
gaining a repressed phenotype in the control conditions, such protein could demonstrate that 
the intrinsic ability of the regulatory domain to sense stress is dependent on phosphorylation 
of these two serine residues. The observed difference in the stress-induced luciferase activity 
between HSF1 WT and HSF1PRD expressing cells cannot, however, be exclusively 
explained by reduced repression at the control conditions. Instead, the observation could also 
be related to more persistent activation. It has been reported that in K. lactis HSF 
phosphorylation promotes the return of the activated HSF to an inactive state (Høj & 
Jakobsen, 1994). Considering the time scale of our experiments (5 h after initial exposure to 
stress), it is fully possible that the increased luciferase activity in HSF1PRD expressing 
cells is indeed caused by impaired transcriptional attenuation. Interestingly, HSF1 
hyperphosphorylation is detected also during mitosis, where HSF1 DNA-binding activity is 
significantly reduced compared to freely cyclin cells (Vihervaara et al., 2013: Elsing et al., 
2014). These observations suggest that phosphorylation might regulate HSF1 displacement 
from the chromatin.  
 
Altogether, our findings show that phosphorylation within the RD is not required for nuclear 
localization or acquisition of DNA-binding and transactivation capacities of HSF1. 
Phosphorylation was, however, shown to regulate the HSF1 activation threshold and affect 
the magnitude of the heat shock response. Based on these results, we propose that 
phosphorylation might function as a fine-tuning mechanism and together with additional 
PTMs, create a distinct HSF1 signature that provides the factor with functional variability in 
a multitude of stress and disease conditions. Altered HSF1 activity has been particularly 
implicated in pathologies such as cancer and neurodegenerative diseases (see 3 HSFs in 
pathologies). Increased HSF1 activity often leads to more prominent cancer growth and 
HSF1 phosphorylation at S326 has been proposed as a marker for HSF1 activity in human 
cancers (Mendillo et al., 2012; Shah et al., 2016). In the study II of this thesis, we showed 
that HSF1 phosphorylation within the RD, including S326, is not required for HSF1 
transactivation capacity (Figure 4 in II). However, the role of phosphorylation was only 
examined in a non-transformed mouse cell line and thus we cannot fully conclude that HSF1 
activity is independent of phosphorylation in malignant human cells. It is plausible that the 
observed S326 phosphorylation denotes a cancer-specific HSF1 phosphorylation signature 
that is required for the distinct transcriptional program that HSF1 drives in malignant cells 
(Mendillo et al., 2012). To date, the importance of specific PTMs in HSF1 target gene 
selection or transactivation capacity has not been assessed in mammalian cells in a genome-
wide manner (e.g. with ChIP-seq or RNA-seq). Therefore, it would be interesting to examine 
in the fortcoming studies whether HSF1 has a specific PTM signature in human cancer cells 
and define whether specific modulation of HSF1 PTMs could serve as a novel platform for 
drug development.    
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3 HSF2 IN PROSTATE CANCER (III) 
Prostate cancer is the most commonly diagnosed cancer in males and the second leading 
cause of cancer-related deaths in Finland as well as in other western countries (Finnish 
Cancer Registry, Jemal et al., 2011). Since the introduction of the PSA (prostate specific 
antigen) -test in early 1980´s (Kuriyama et al., 1980), prostate cancer incidence has increased 
rapidly and the cancers are often diagnosed while still localized to the prostate tissue. Most 
of such tumors can be effectively treated by combining androgen deprivation therapies 
(ADT) (Huggins, 1967) to radical prostatectomy (i.e. surgical removal of the prostate gland), 
although such measures do not necessarily cure the disease. In approximately 7-10 % of the 
diagnosed prostate cancer cases, the disease progresses into castration resistant prostate 
cancer (CRPC), which no longer responds to anti-hormonal therapies (Ceder et al., 2016; 
Feldman & Feldman, 2001). This is mainly due to AR (androgen receptor) overexpression 
that has been shown to be sufficient for the disease to turn into CRPC (Chen et al., 2004). At 
this stage, the disease progression often includes metastasis formation in distant tissues, 
which eventually might cause patient death. 
 
Prostate cancers are a heterologous group of diseases and the patient outcome largely 
depends on good stratification systems and subsequent therapy decisions. Gleason scoring, a 
histology-based grading system, is currently used as the main tool to predict prostate cancer 
progression, though it is insufficient in classification of all prostate cancer subtypes. Gleason 
score (2-10) is assigned by combining the histological grades (1-5) of the most common 
tumor pattern with the most aggressive pattern observed in a given tumor biopsy (e.g. grade 
3 + grade 5 = Gleason score 8) (Gleason, 1966; Epstein et al., 2017). Grade 1 pattern tumors 
resemble closely the normal prostate tissue, with well differentiated and organized glandular 
structure. Appearance of degenerated glandular structures increases the grade and in the most 
aggressive grade 5 pattern the prostate tissue has none or only a few recognizable glands and 
mainly consists of neoplastic cells. The tumors with Gleason score 6 are considered indolent 
and have low risk of progressing into CRPC. In contrast, tumors with Gleason score ≥8 are 
highly aggressive and predictive for poor patient outcome. The most challenging group of 
tumors consists of Gleason 7 scored tumors that show intermediate tumor phenotype. Correct 
stratification of such tumors into prognostic groups is difficult and has significant 
implications for the patient outcome (Uemura et al., 2009). Thereby, detailed molecular 
characterization of mechanisms involved in prostate cancer progression is essential as 
identification of novel therapeutic targets and biomarkers is in high demand. 
 
HSF1 is a well-recognized promoter of cancer progression and pronounced HSF1 expression 
has been detected in a large selection of human cancers, including prostate cancer (Jiang et 
al., 2015). In breast cancer, high HSF1 level correlates with poor patient outcome and 
utilization of HSF1 expression has been proposed as a prognostic marker of specific breast 
cancer types (Santagata et al., 2011). In contrast, HSF2 has not been related to cancer 
progression and the importance of HSF2 in malignancies is unknown. Thereby, in the study 
III of this thesis, we investigated whether HSF2 has a role in cancer progression.  
 
3.1 HSF2 mRNA expression is decreased in aggressive prostate cancers 
This study was initiated by examining HSF2 mRNA expression in silico from Memorial 
Sloan-Kettering Cancer Centre (MSKCC) prostate cancer data set consisting of 216 prostate 
cancer specimens originating from both primary and metastatic tumors (Taylor et al., 2010). 
By comparing HSF2 mRNA expression in normal and cancerous prostate tissue, we found 
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that HSF2 levels are lower in primary prostate tumors and further decreased in metastatic 
tumors (Figure 1A in III). Specifically, HSF2 mRNA expression negatively correlated with 
the Gleason grading, as lower HSF2 levels were detected in tumors denoted with high 
Gleason grades (≥8) (Figure 1A in III). Furthermore, decreased HSF2 expression was 
associated with lymph node invasion, positive surgical margins (i.e. cancer cells can still be 
found in patients after surgical removal of the cancerous tissue), and seminal vesicle 
invasion, all indicative for aggressive and advanced prostate cancer (Figure 1A in III). These 
results indicated that a decline in HSF2 expression associates with aggressive prostate cancer 
phenotype.   
 
Since HSF2 was not previously connected to cancer progression, we next wanted to examine 
the relevance of our observations by comparing the observed HSF2 alterations to those 
detected with well-established tumor-suppressors PTEN and p53 as well as Myc oncogene 
and HSF1. We used a subset of 85 tumor specimens that had been analyzed for transcriptomic 
(mRNA and miRNA) and copy-number alterations as well as subjected to focused exon 
resequencing (157 high interest genes) (Taylor et al., 2010). HSF2 alterations were observed 
in 20% of the studied specimens and these alterations mainly consisted of HSF2 mRNA 
downregulations (18% of tumors) (Figure 1B and Supplementary Figure S1A in III). PTEN 
and p53 alterations were found comparable to those of HSF2, as 18% and 29% of the tumors 
displayed changes in these genes, respectively. Interestingly, HSF1 was also found altered in 
20% of the tumors so that 70% of those exhibited HSF1 mRNA upregulation (Figure 1B in 
III). Putative copy-number alteration assessment revealed that the decreased HSF2 mRNA 
expression was mainly associated with loss of heterozygosity, whereas PTEN alterations 
were associated with both loss of heterozygosity and homozygous deletions (Figure 1C in 
III).  
 
To explore if our findings have clinical relevance, we analyzed 23 metastatic prostate cancer 
samples and correlated HSF2 expression to patient survival. Intriguingly, the analysis 
showed that decreased HSF2 expression is predictive of poor patient outcome, albeit 
performed with limited number of tumor samples (only 23 tumors) (Supplementary Figure 
1B in III). Taken together, these results showed that the HSF2 expression is downregulated 
in aggressive prostate cancers in a frequency comparable to other tumor suppressors and that 
the decline in HSF2 levels correlates with poor patient survival. This indicated for the first 
time that, in addition to HSF1, also HSF2 might have a role in cancer progression. 
 
3.2 HSF2 expression is dynamic and reflects initiation of invasion 
The findings shown in Figure 1 (in III) proposed that HSF2 levels vary according to the 
severity of the disease and a decline in HSF2 expression correlates with aggressive cancer 
phenotype. To verify our observations in cells, we assessed HSF2 expression at both mRNA 
and protein levels in a selection of human prostate cell lines with variable degrees of 
malignancy. As shown in Figure 2A (in III), HSF2 expression was low in cells with low 
malignant potential (primary prostate epithelial cells, PrEC; immortalized prostate epithelial 
cells, EP156T), whereas high expression was observed in the cancerous cell types LNCap 
(prostate adenocarcinoma) and Du145 (prostate carcinoma) (Figure 2A in III). Importantly, 
HSF2 mRNA expression in the highly malignant and invasive PC-3 (prostate 
adenocarcinoma derived from bone metastasis) and PC-3M (PC-3 variant with high 
metastatic potential) cells was clearly reduced when compared to the less invasive cancerous 
cell lines. Similar results were obtained from HSF2 protein expression analysis (Figure 2B 
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in III), implying that a decline in HSF2 expression correlates with invasive growth phenotype 
also in cell lines.  
 
Cancer development is a multi-step process, during which the cancer must acquire novel 
properties, such as sustained proliferation and ability to avoid apoptosis, to enable the 
unrestricted neoplastic growth (Hanahan & Weinberg, 2011). A hallmark of cancer 
development is the ability to activate invasion and metastasis, which is a process strongly 
suppressed in normal epithelial tissue. To analyze whether the observed decrease in HSF2 
expression occurs concomitant with invasive behavior, we used 3D cell culture method to 
examine prostate cancer cell growth. The method presents a biologically more relevant model 
system to study cancer progression than conventional 2D cultures. In the 3D growth model, 
cells are placed between layers of gel (Matrigel in this study), which usually is composed of 
a selection of extracellular matrix constituents, such as collagens, laminins, and heparan 
sulfate proteoglycans (Hughes et al., 2010). This mimics the natural 3D cell environment and 
thus provides the cells with physiologically relevant cell-cell and cell-matrix contacts (Lee 
et al., 2007; Pampaloni et al., 2007). Previously, both normal and cancerous prostate 
epithelial cells have been shown to grow and form organoid structures in 3D cultures in a 
process often referred to as organoid development (Härmä et al., 2010). Moreover, gene 
expression profiling has demonstrated that the organoids undergo cancer-relevant epithelial 
differentiation and can activate invasion (Härmä et al., 2010). Multiple cell types are 
currently used as models to study prostate cancer and we chose the widely used PC-3 cells. 
When cultured in 3D, PC-3 cells first form well-differentiated and polarized organoids 
(around days 4-7), after which the organoids spontaneously de-differentiate (around days 8-
12) and give rise to invasive stellate structures (Härmä et al., 2010) (see also Figure 2C in 
III). We analyzed HSF2 mRNA expression in 3D-cultured PC-3 cells at days 4, 8, 13 and 15, 
as the days comprehensively cover the steps of organoid development. As shown in figure 
2D (in III), HSF2 mRNA levels were upregulated during spheroid polarization (day 4) but 
decreased concomitantly with de-differentiation and appearance of invasive structures (days 
8, 13, and 15). Similar results were obtained from protein analysis, which clearly 
demonstrated that HSF2 expression also decreases during PC-3 organoid development and 
co-occurs with the activation of invasion.  
 
3.3 Lack of HSF2 promotes invasive behavior of prostate cancer organoids 
Since fluctuating HSF2 expression has been previously connected to various differentiation 
and developmental processes, such as spermatogenesis and corticogenesis (Björk & 
Sistonen, 2010), it is possible that HSF2 downregulation only reflects the organoid 
differentiation state but does not directly regulate it. Therefore, we next examined the 
importance of dynamic HSF2 expression during PC-3 organoid development. HSF2 was 
silenced with siRNA and the cells were cultured in 3D for eight days and monitored for their 
morphology and invasive properties (Figure 3 in III). HSF2 silencing efficacy during the 
experimental course was examined with qRT-PCR (Supplementary Figure S3 in III). During 
the 8-day experiment, cells transfected with control siRNA progressed into well-
differentiated organoids and initiated invasive behavior similarly as reported earlier (Härmä 
et al., 2010) (Figure 3B in III). Surprisingly, HSF2 silencing accelerated the differentiation 
process, as invasive structures were observed already at day 7 of the organoid development 
(Figure 3B in III). In contrast, PC-3 cells where HSF1 was silenced failed to develop into 
well-differentiated organoids and exhibited apoptotic and non-invasive phenotype, 
supporting the previous results demonstrating that HSF1 is essential for cancer progression 
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(Dai et al., 2007). These results indicated that HSF2 directly impacts the organoid 
development.  
 
The observed differences between control and HSF2-depleted organoids were quantified 
with high-content automated morphometric image data analysis (AMIDA) software, which 
allows quantitative measurement of thousands of organoids with variable shapes and sizes 
(Härmä et al., 2014). AMIDA has been successfully used to examine growth phenotypes of 
a large selection of prostate and breast cancer cell lines (Härmä et al., 2014). AMIDA 
analysis of the spheroids confirmed that HSF2-depleted PC-3 cells exhibited decreased 
organoid roundness, increased roughness and length of the invasive structures, all indicative 
for pronounced metastatic potential (Figure 3E in III) (Härmä et al., 2014). In stark contrast, 
HSF1 silencing produced round and small organoids with decreased roughness, only a few 
invasive appendages and overall decrease in cell number (Figure 3E in III), suggesting that 
HSF1 and HSF2 might have an opposite effect on cancer progression. The HSF2-dependent 
phenotypic differences were further validated by rescue experiments, where shRNA-
mediated HSF2 downregulation was combined with overexpression of shRNA-resistant 
exogenous HSF2. As presented in Figure 4 (in III), re-introduction of HSF2 reversed the 
invasive phenotype detected with HSF2 silencing, strongly implying that HSF2 functions in 
a developmental switch involved in the maintenance of the well-differentiated epithelial 
phenotype and suppressing the initiation of invasive behavior of PC-3 organoids.  
 
Considering that the role of HSF2 in PC-3 organoid development was examined by silencing 
HSF2 expression with siRNA (Figure 3 in III), it is important to note that such a method can 
only induce transient changes in the expression of the desired gene. This means that in long-
term 3D cultures, e.g. the 8-day cultures used in this study, downregulation of HSF2 levels 
does not persist (Supplementary Figure S3 in III) but begins to be modulated according to 
the requirements of the cell. To be able to examine the importance of HSF2 during the whole 
course of organoid development, the HSF2 gene would have to be knocked out from the PC-
3 cells e.g. by CRISPR-Cas9-based gene-editing methods. However, in this study, we 
observed that HSF2 is dynamically regulated during the organoid development (Figure 2 in 
III). This indicates that PC-3 cells both upregulate and downregulate HSF2 expression when 
grown in 3D, which in turn suggests that high HSF2 expression is required for the initial 
development of well-differentiated organoids (at day 4), after which the levels decline to 
allow activation of metastatic behavior. Complete abolishment of HSF2 expression would 
thereby likely result in misregulated organoid development and disable the investigations 
addressing the role of HSF2 as a switch regulating the initiation of invasion. In fact, by using 
the transient siRNA-mediated downregulation of HSF2, we likely shift the invasive switch 
to be activated at an earlier time point, which results in accelerated development of invasive 
structures. A more accurate approach to study the impact of HSF2 in this invasive switch 
could be generation of a stable cell line, where HSF2 expression would be under an inducible 
promoter (e.g. Tet-ON, tetracycline-responsive promoter). Such a cell line would allow for a 
more precise upregulation of HSF2 expression at a specific time point in 3D cultures and 
thus could more precisely investigate whether HSF2 has the ability to maintain specific 
epithelial differentiation state.  
 
Dynamic HSF2 expression during the PC-3 organoid development suggests that cancer cells 
have an inherent ability to downregulate HSF2 levels. In fact, the regulation appears to be 
very precise, as disruption of the expression pattern resulted in accelerated appearance of 
invasive structures (Figure 3 in III). Moreover, forced HSF2 upregulation suppressed the 
invasive phenotype, altogether implying that, similarly to the normal mammalian 
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developmental programs, fluctuating HSF2 expression is a key determinant also during 
malignant progression. These results imply that the detected change in HSF2 levels is perhaps 
secondary to the initial developmental signal, which raises the question about the regulatory 
mechanisms behind dynamic HSF2 expression. As the alterations in HSF2 expression were 
detected also at the mRNA level, it is reasonable to hypothesize that the mechanism functions 
through regulating the synthesis or stability of mRNA. In testis, HSF2 expression is regulated 
through an mRNA-targeting miR-18 (Björk et al., 2010), which could be one of the 
mechanisms behind fluctuating HSF2 expression also in cancer. However, many 
developmental processes are characteristically driven by transcription factors acting in 
sequence, and it is tempting to speculate that HSF2 expression, during organoid 
development, is also regulated by modulating the activity of the HSF2 gene. Currently, little 
is known about HSF2 gene regulation and only a few factors have been shown to bind to the 
HSF2 promoter in mammalian cells. In rat, USF2 (upstream stimulatory factor 2) has been 
shown to bind to an E-box element 200 bp upstream of the transcription start site and appears 
critical for the HSF2 promoter activity in C6 rat neuronal cell line (Lee et al., 2003). In 
addition, by studying the target genes of the activated Wnt/-catenin/TCF4 pathway, it was 
found that -catenin can bind to the promoter of HSF2 and activate its transcription in Huh7 
(hepatocyte carcinoma), HEK293T (human embryonic kidney cells), and glioblastoma cells 
(Kavak et al., 2010). Interestingly, USF2 has been shown to have a suppressive role in 
prostate carcinogenesis (Chen et al., 2006), whereas the Wnt/-catenin-signaling is a well-
recognized positive regulator of prostate cancer development (Kypta & Waxman, 2012). 
Nevertheless, it remains to be established, whether these factors are responsible for the 
fluctuating HSF2 expression detected in this study. 
 
3.4 HSF2 affects genes related to cell invasion 
HSF2 is a potent DNA-binding factor that regulates gene expression in a stimulus-dependent 
manner. High expression of HSF2 has been shown to correlate with its DNA-binding activity 
and modulation of HSF2 levels is considered the main mechanism regulating HSF2 
transcriptional activity (see 2.4.1 Regulation of HSF2 activity). Therefore, we wanted to 
establish whether the observed phenotypic differences between control and HSF2-depleted 
organoids are mediated by HSF2-regulated alterations in the organoid gene expression 
profile. For this, control and HSF2 depleted PC-3 cells were cultured in 3D and organoids 
were collected at days 5 and 8 representing the critical time points of epithelial differentiation 
and initiation of invasive behavior. From the collected samples, total RNA was isolated, 
amplified, and used for in vitro synthesis of biotinylated cRNA (complementary RNA). 
Subsequently, cRNA was subjected to whole-genome microarray analysis through 
hybridization on Illumina Sentrix HumanHT-12 v4 Expression BeadChips and the relative 
gene expression changes were analyzed with limma and lumi R/Bioconductor packages. 
Gene set enrichment analysis (GSEA) is a bioinformatics tool that can be used to examine 
whether specific classes of genes are overrepresented in a given gene set. In this study, 
GSEA-analysis of the differentially expressed genes demonstrated that genes affected by 
HSF2 silencing were related to gene ontology (GO) terms associated with key cellular 
functions, such as RNA processing, ribosome biogenesis, and organelle homeostasis (Figure 
5A in III). Importantly, HSF2 silencing was also shown at both time points to affect genes 
associated with GO terms such as GTPase activity and signaling as well as actin cytoskeleton 
organization (Figure 5A and Supplementary Table in III). GTPases are a large family of 
proteins that can catalyze hydrolysis of GTP to GDP and have an important role functioning 
as molecular switches in cells. In addition to the heterotrimeric G-proteins associated with 
G-protein coupled receptors, the most well-known subclass of GTPases is the Ras 
 Results and Discussion  
 69
superfamily of GTPases, which is further divided into multiple subfamilies. From the 
subfamilies, especially the Rho family small GTPases have been implicated as important 
regulators of actin cytoskeleton dynamics and cancer cell motility (Parri & Chiarugi, 2010). 
Intriguingly, among the genes differentially expressed at day 5, members from the Rho-
family of GTPases (e.g. RhoA and Rnd3) were found affected by HSF2 downregulation. 
 
We used a DAVID analysis tool (Dennis et al., 2003) to perform a functional cluster 
annotation of the 300 most significantly changed genes at both time points. At day 5, enriched 
clusters were related to extracellular matrix interactions and cell adhesion and included genes 
from laminin, collagen, and integrin families (Figure 5C left panel in III). At day 8, the 
clusters were associated with small GTPase signaling, and more specifically to  Ras and Rho-
family of small GTPases, as well as actin cytoskeleton organization, and included genes such 
as ROCK2 (Rho-associated protein kinase 2) and WASF2 (Wiskott-Aldrich syndrome 
protein family member 2) and Cdc42BPB (Cdc42 binding protein kinase ), all important in 
regulating actin cytoskeleton dynamics (Olson & Nordheim, 2011) (Figure 5C in III). 
Moreover, ingenuity pathway analysis (IPA) showed alterations in pathways affecting, for 
example, focal adhesion assembly and actin polymerization in lamellipodia, suggesting for 
multi-level pathway alterations in HSF2-depleted cells at day 8 (Figure 5D in III). Taken 
together, these results indicated that by affecting genes related to small GTPase-mediated 
regulation of actin cytoskeleton, HSF2 is involved in the initiation of invasion in PC-3 
organoids.  
 
The Rho-family of small GTPases are a well-established family of proteins regulating actin 
cytoskeleton and cancer cell movement (Lamouille et al., 2014). In contrast to Ras, which is 
often found mutated in human cancers (Simanshu et al., 2017), mutations in Rho GTPases 
are rarely found. Instead, the detected alterations in Rho GTPases are mainly related to 
increased expression or increased activity (Parri & Chiarugi, 2010; Sahai & Marshall, 2002). 
To directly link HSF2 to GTPase-signaling, we analyzed the pathways at the molecular level. 
Protein expression analysis with immunoblotting demonstrated that HSF2 silencing leads to 
a prominent increase in the expression of GNA13, a stimulatory G-protein subunit 13 
(Figure 6A in III), which has been previously implicated as a factor essential for PC-3 
invasion, migration, and RhoA activation (Rasheed et al., 2013). In addition, expression of 
ARHGAP1 (Rho GTPase-activating protein 1) was decreased in HSF2-depleted cells, 
suggesting that lack of HSF2 may impact the GTP-binding and activation state of the Rho 
GTPases, rather than the expression of these signaling modulators (Figure 6A in III). 
Accordingly, Cdc42, another Rho-family GTPase, levels were not affected in HSF2 
downregulated cells (Figure 6A in III).  
 
To examine whether the putative alterations in GTPase activity are related to the observed 
HSF2-affected organoid development, a selection of chemical inhibitors were used to 
regulate the activity of key small GTPase effector proteins. In accordance with previous 
observations (Härmä et al., 2014), Y27632-mediated inhibition of the RhoA downstream 
effector protein ROCK resulted in highly invasive organoids as evidenced by increased 
roughness and loss of round shape (Figure 6B and 6C in III). Moreover, inhibition of the 
Rac1 downstream effector PAK (p21 activated serine/threonine kinase 1) with IPA3, 
prevented the initiation of the invasive behavior (Figure 6B and 6C in III). Intriguingly, when 
applied to the HSF2-depleted PC-3 organoids, IPA3 reversed the aggressive phenotype and 
resulted in organoids with increased roundness and reduced roughness (Figure 6B and 6C in 
III). These results propose that during PC-3 organoid development, downregulation of HSF2 
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expression affects genes associated with GTPase activity regulation and thereby impacts the 
organoidal ability to activate invasion. 
 
The dynamic reorganization of actin cytoskeleton via small GTPases is essential for the 
epithelial-mesenchymal transition (EMT) program, during which the cancer cells escape 
from organized epithelial structures and gain migratory mesenchymal properties (Parri & 
Chiarugi, 2010 and Lamouille et al., 2014). As the analysis of the HSF2-affected genes 
demonstrated prominent alterations in GTPase signaling and actin cytoskeletal 
reorganization (Figure 6 in III), we assessed whether the invasive phenotype observed with 
HSF2-downregulated organoids is associated with EMT. We analyzed a panel of EMT 
markers during the organoid development in 3D. One of the hallmarks of EMT is the 
downregulation of E-cadherin (CDH1) that reinforces the de-stabilization of adherens 
junctions characteristic to epithelial structures. Downregulation of E-cadherin is balanced by 
increased expression of N-cadherin (CDH2), through which the cells acquire affinity for 
other mesenchymal cells (Lamouille et al., 2014). As shown in Figure 6E (in III), HSF2 
silencing in PC-3 organoids resulted in decreased expression of CDH1 at day 8, whereas 
increase in CDH2 was detected at day 5 (Figure 6E in III). In addition, expression of Snail2 
(SNAI2), an important transcription factor inducing EMT, exhibited increased expression in 
HSF2 depleted organoids at day 5 (Figure 6E), indicative for accelerated EMT progression. 
Analyzing the mRNA levels of critical EMT-mediators further supported our observation, as 
significant downregulation of CDH1 and upregulation of the mesenchymal markers S100A4, 
fibronectin (FN1), and vimentin (VIM) was detected at the mRNA level (Figure 6B in III). 
Taken together, our results indicate that HSF2 downregulation is involved in the epithelial 
disintegration of tumor cells leading to a motile and invasive mesenchymal phenotype.  
 
Transcriptional regulation of EMT involves complex cooperation of signaling pathways that 
together function to repress epithelial and activate mesenchymal phenotypes via multiple 
different target genes (Lamouille et al., 2014). In prostate cancer, the molecular events 
leading to EMT are mainly mediated by activation of androgen receptor and TGF--signaling 
pathways and may lead to metastasis formation and acquisition of therapeutic resistance 
(Montanari et al., 2015). Our results show that HSF2 is tightly connected to the gene 
expression changes related to prostate cancer invasion and EMT, and thereby it would be 
interesting to examine the impact of these signaling pathways in the regulation of HSF2 
expression. At this point, it is important to note that the PC-3 cells used in this study are 
aggressive prostate cancer cells that have been originally isolated from patient bone 
metastasis and, thus, have likely undergone EMT. Nevertheless, PC-3 cells are a widely used 
model system to study prostate cancer EMT and it has been proposed that the cell line has 
also undergone MET (mesenchymal to epithelial) program (reviewed Kong et al., 2011). To 
conclusively show that HSF2 levels are specifically regulated during EMT, it would be 
important to assess how non-tumorigenic cell lines regulate HSF2 expression e.g. in response 
to TGF-. Moreover, as TGF- is one of the main signaling molecules secreted by the cancer 
associated fibroblasts (CAFs) (Scherz-Shouval et al., 2014) and CAFs have been shown to 
promote invasive properties of prostate cancer organoids (Åkerfelt et al., 2015), the 
importance of trans-cellular tumor signaling as a regulator of HSF2 expression would be 
intriguing to elucidate. 
 
3.5 Lack of HSF2 promotes tumor growth and invasion in vivo 
In the human body, the tumor microenvironment contains a selection of different cell types, 
such as the above-mentioned CAFs, endothelial cells, and immune cells. Hence, cancer 
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progression is by no means a sole outgrowth of a single cell type, whereas it requires a 
coordinated network of complex cell-cell interactions. Various in vivo model systems are 
often used in cancer research to more accurately mimic the tumor microenvironment in 
patients. In this study, we used the chicken chorioallantoic membrane (CAM) model system 
as a platform to examine HSF2 capacity to affect tumor development in vivo. The CAM is 
based on the ability of the highly vascularized chorioallantoic membrane to support cancer 
cell growth, and due to the natural immunodeficiency of chicken embryos, it has been 
successfully used as a model for tumor growth and invasion (Dagg et al., 1956; Kunzi-Rapp 
et al., 2001). In contrast to immunocompromised mice (e.g. Nude, RAG, NOD/SCID strains), 
which currently are the most frequently used as in vivo models, the CAM presents a more 
rapid and cost-efficient growth model, albeit being of non-mammalian origin.  
 
For the CAM experiments, HSF2-depleted PC-3 cells were mixed with Matrigel and 
implanted on the CAM. Cell growth was followed for three days. During this time, control 
transfected PC-3 cells had developed into large cell masses with uneven borders (Figure 7B 
in III), reflecting the high metastatic capacity of PC-3 cells. Intriguingly, cells lacking HSF2 
exhibited enhanced tumor growth and clearly larger tumors nearly covering the whole 
implantation area (7 mm) were detected. Moreover, in line with the previous results presented 
in this and other studies, HSF1 silencing inhibited PC-3 tumor growth, as significantly 
smaller tumors were observed with HSF1-depleted cells (Figure 7B, C in III). Histological 
analysis of the paraffin embedded hematoxylin-eosin-stained tumors revealed that HSF2-
depleted cells, similarly to the control transfected cells, developed into adenocarcinoma-like 
tumors with abnormally large and uneven nuclei (Figure 7D in III). More cells escaping the 
primary implantation site were detected in HSF2-depleted tumors when compared to the non-
transfected or control transfected PC-3 tumors (Figure 7D in III). In stark contrast, tumors 
derived from HSF1-depleted cells were fibrotic, had only a few cancer cells, and mainly 
consisted of chicken tissue (Figure 7D in III). Increased metastatic potential of the HSF2-
depleted cells was confirmed by immunohistochemical staining of MMP-14, which is one of 
the metalloproteinases required for extracellular matrix degradation and prostate cancer 
invasion (Littlepage et al., 2010). In HSF2 depleted tumors, MMP-14 localized to the tumor 
edges and exhibited strong staining at cell membranes, whereas more cytoplasmic 
localization was detected in the control cells (Figure 7E). Since strong MMP-14 expression 
has been detected in aggressive prostate cancers (Wang et al., 2009), these results imply that 
HSF2-depleted PC-3 tumors mimic the aggressive tumor phenotype in vivo in CAM.  
 
3.6 Expression of HSF2 target genes is decreased in human cancers 
Having established that HSF2 silencing from 3D cultured PC-3 cells affects a specific set of 
genes related to GTPase signaling, focal adhesion, and actin cytoskeleton reorganization, we 
next wanted to analyze whether the same genes are also altered in the MSKCC prostate 
cancer data set (Taylor et al., 2010). Analysis of selected genes affected by HSF2 
downregulation in PC-3 organoids, including COL6A3 (collagen 6), FLNA (filamin A), 
WASF2, and ROCK2, revealed a correlation between HSF2 and the putative target gene 
expression, as similar mRNA patterns with lower expression levels in more advanced disease 
were detected (Figure 8A in III). In fact, all of these genes were clearly downregulated in 
metastatic prostate cancer samples vs. normal prostate tissue. More detailed analysis of the 
individual tumors (Taylor et al., 2010) demonstrated a strong co-occurrence or mutual 
exclusivity between HSF2 and the target genes, indicating that HSF2 directs similar genetic 
programs also in the clinical prostate cancer samples (Figure 8B in III). Finally, we extended 
the study by analyzing HSF2 mRNA expression in other human malignancies (Rhodes et al., 
 Results and Discussion  
 72
2004) of both epithelial and non-epithelial origin. Excitingly, decreased HSF2 expression 
was observed in a large variety of human malignancies, such as breast cancer, small-cell lung 
carcinoma, embryonal carcinoma, and glioblastoma (Figure 9 in III). Therefore, low HSF2 
expression is not only restricted to prostate cancer, as it appears as a characteristic feature of 
a large variety of human cancer types.  
 
Taken together, this study expands our knowledge on HSFs in cancer by revealing for the 
first time that HSF2 is an important regulator of cancer progression. In contrast to HSF1, 
HSF2 suppresses prostate cancer progression, which indicates that the factors have opposing 
roles during malignant growth. In this study, HSF2 expression was found to be dynamically 
regulated during PC-3 organoid development, whereas HSF1 expression remained stable 
(Figure 2 in III). HSF2 interacts with HSF1 through heterotrimer formation and modulating 
the relative abundance of HSF1 and HSF2 has been implicated as a mechanism regulating 
transcription in response to distinct stimuli (Sandqvist et al., 2009). Thus, it is likely that the 
functions of HSF1 and HSF2 in cancer are not entirely separate and it would be interesting 
to examine, whether the dynamic expression of HSF2 has a role in the regulation of HSF1 
activity. Dynamic HSF2 expression also suggests for inherent HSF2 regulation in PC-3 cells 
and proposes that HSF2 acts as a switch maintaining the epithelial phenotype and suppressing 
activation of invasive behavior. These results are, however, limited by the utilization of a 
single highly malignant PC-3 cell line and should be further confirmed with other cell lines.  
 
The whole-genome microarray analysis demonstrated that HSF2 affects genes related to 
GTPase signaling and actin cytoskeleton plasticity, and thus connected HSF2 to the key 
cellular pathways required for cell motility (Figure 5 in III). Modulation of the GTPase 
effector proteins implicated that HSF2 affects the activity of GTPases during the invasive 
switch, though the direct mechanism remains to be uncovered. As this study only examined 
the gene profile at the level of mRNA expression, utilization of more direct methods to assess 
HSF2-regulated genes during cancer progression would be beneficial. For example, 
performing HSF2 ChIP-seq at different stages of PC-3 organoid development would yield 
more information on the genes directly regulated by HSF2 in cancer. To date, only two 
individual studies have reported for ChIP-seq-based analysis of genome-wide HSF2 binding 
sites. One of these was performed in non-adherent K562 cells (Vihervaara et al., 2013), 
whereas the other examined HSF2 binding in mouse testis (Korfanty et al., 2014). Albeit 
revealing essential information about the importance of HSF2 in those cells and tissues, the 
results cannot be directly applied to adherent human organoids.  
 
In this study, we found that lack of HSF2 alters the expression of specific EMT-markers 
(Figure 6 in III). This places HSF2 in the very center of cancer-specific de-differentiation 
and suggests that HSF2, among other factors, impacts the transition from epithelial to 
mesenchymal phenotype. In vivo growth analysis in CAM further confirmed that lack of 
HSF2 promotes invasive properties of PC-3 cells (Figure 7 in III). CAM has been previously 
used as an in vivo model for prostate cancer growth (Kunzi-Rapp et al., 2001). However, 
CAM is a non-mammalian model system and thus it would be important to confirm our 
findings in e.g. mice xenografts. For such experiments, generation of a stable cell line with 
inducible HSF2 expression would be essential, since transient downregulation is not 
sufficient to maintain low HSF2 levels in long-term mouse experiments.  
 
Finally, by analyzing in silico the HSF2 mRNA expression in clinical prostate cancer 
specimens, we showed that low HSF2 expression correlates with high Gleason score (Figure 
1 in III). Together with the other findings reported in study III, this indicates that HSF2 
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functions as a suppressor of prostate cancer progression. Downregulation of putative HSF2 
target genes was also detected in the clinical samples, proposing that the HSF2 affected 
genetic program might serve as a starting point for the development of novel therapeutics. 
Considering the challenge of correct patient stratification presented in the very beginning, 
our results propose that similarly to the HSF1 expression that can be used as a biomarker to 
predict the outcome of specific breast cancer types (Santagata et al., 2011), detecting HSF2 
levels in prostate cancer biopsies might have a prognostic value in the clinics. 
 
 
4 HSF2 IN PROLONGED PROTEOTOXIC STRESS (IV) 
From the mammalian HSFs, HSF1 is considered as the master regulator of inducible HSP 
expression and it has been shown to be essential for cell viability upon a variety of acute 
proteotoxic stress conditions (Gomez-Pastor et al., 2018). In contrast, HSF2 is negatively 
regulated during acute heat stress (Ahlskog et al., 2010), and albeit localizing to the HSP70 
promoter, its impact on gene expression is only modulatory (Östling et al., 2007). 
Interestingly, in response to proteasome inhibition, HSF2 is activated and acquires DNA-
binding capacity (Kawazoe et al., 1998; Mathew et al., 1998), indicating that the factor can 
respond to distinc types of proteotoxic stressors. However, it has been clearly shown that 
only HSF1 is required for proteasome inhibition induced upregulation HSP70 (Pirkkala et 
al.,  2000; Rossi et al., 2014) and thus the role of HSF2 during proteotoxicity has remained 
elusive. 
 
The eukaryotic 26S proteasome is a multiprotein complex that consists of a 20S core particle, 
responsible for peptide cleavage, and a 19S regulatory particles required to recognize the 
ubiquitinated substrate proteins (Tomko & Hochstrasser, 2013). The ubiquitin-proteasome 
system is one of the main cellular mechanisms regulating protein turnover and thus it affects 
multiple aspects of cell physiology, such as signal transduction and apoptosis (Hershko et 
al., 1998; Varshavsky, 2012). Due to its key role in cell physiology, the proteasome complex 
has emerged as an important target for anti-cancer therapy and subsequently led to the 
identification of multiple proteasome inhibiting drugs (Deshaies, 2014). One of the most 
well-known drug to inhibit proteasome activity is called Bortezomib (PS-341, 
VELCADE), which is currently used as a standard treatment in multiple myeloma and 
other hematological malignancies (Chen et al.,  2011). Bortezomib is a dipeptide boronic 
acid derivative that targets the chymotrypsin-like activity of the 26S proteasome (Kisselev et 
al., 2006). Bortezomib does not fully inhibit the activity of the proteasome and thereby causes 
prolonged proteotoxic stress upon long-term treatments (Chen et al., 2011; Goldberg, 2012). 
Intriguingly, in human blood-derived primary cells Bortezomib treatment has been shown to 
result in a remarkable upregulation of HSF2 at both mRNA and protein levels (Rossi et al., 
2014), suggesting that HSF2 plays a role in the cellular response to prolonged Bortezomib-
induced proteotoxicity. However, although HSF2 was shown to localizes to distinct stress-
responsive promoters together with HSF1, only HSF1 was required for the Bortezomib-
induced expression of these genes (Rossi et al., 2014). Nevertheless, proteasome inhibition 
has been shown to be severely toxic to both HSF1- and HSF2-deficient mouse embryonic 
fibroblasts (Lecomte et al., 2010), proposing that HSF1 and HSF2 have unique roles in the 
cellular protection against proteasome inhibition. Thereby, this study aimed at identifying 
the role of HSF2 and the unique HSF2-dependent gene expression profile during prolonged 
proteasome inhibition. 
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4.1 HSF2 is specifically regulated during proteasome inhibition  
This study was initiated by examining how human osteosarcoma U2OS cells respond to 
prolonged proteotoxic stress induced by Bortezomib. U2OS wild-type (WT) cells were 
treated with different concentrations of Bortezomib (BTZ) for 6 and 22 h and the HSF2 
protein expression levels were examined with immunoblotting. As shown in figure 1A (in 
IV) HSF2 protein levels were modestly upregulated already after 6 h treatment, whereas a 
prominent increase in HSF2 levels was detected after 22 h treatment (Figure 1A in IV). HSF2 
localization was examined with indirect immunofluorescence, which showed that HSF2 is 
predominantly nuclear already under normal growth conditions and that BTZ treatment 
further enhances the nuclear accumulation of HSF2 (Figure 1B in IV). These results are well 
in line with the observations made by Rossi and co-workers (2014) in human blood-derived 
primary cells and indicate that HSF2 is a specific responder to BTZ treatment, as both its 
protein expression levels and nuclear accumulation are enhanced in cells exposed BTZ-
induced proteotoxic stress.  
 
4.2 Lack of HSF2 predisposes U2OS cells to Bortezomib 
Due to the marked upregulation of HSF2 in cells exposed to prolonged BTZ treatment, we 
asked if HSF2 is required for cell survival during BTZ-induced proteotoxic stress. To study 
that, we generated, to the best of our knowledge, the first human HSF2 knockout (KO) cell 
line, by mutating the first exon of HSF2 gene in human osteosarcoma (U2OS) cells with 
CRISPR-Cas9 mediated genome editing. This genetic ablation led to a full depletion of HSF2 
protein in the U2OS HSF2 KO (2KO hereafter) cell line, whereas the expression of HSF1 
remained intact (Figure 1C in IV).  The sensitivity of these cells to proteasome inhibition 
was examined by treating both WT and 2KO cells with different concentrations of 
Bortezomib (BTZ) and analyzing the effects with microscopy. Already at this stage, we 
observed dramatic differences in the viability of WT and 2KO cells, as cells lacking HSF2 
exhibited de-attached and apoptotic appearance in concentrations were the WT cells were 
still adherent (Figure 1D in IV). The detected differences were quantified by measuring the 
cell viability with Calcein AM based fluorometric assay, which confirmed that the 2KO cells 
are more sensitive to BTZ and die in concentrations ineffective to their WT counterparts 
(Figure 1E in IV). Moreover, the 2KO cells accumulated more cleaved PARP-1 upon BTZ 
treatment, indicating that the cells die through apoptosis (Figure 1F in IV). To confirm that 
the observed decrease in the 2KO cell survival is caused by proteasome inhibition, we 
repeated the above-described experiments with a well-established proteasome inhibitor 
MG132 (Figure Supplement 1A-C). The obtained results revealed that the 2KO cells are 
extremely sensitive also to MG132-induced proteotoxic stress (Figure Supplement 1A-C) 
and thus verified that HSF2 is required to protect cells during prolonged proteasome 
inhibition. Importantly, as lack of HSF2 has been previously shown to sensitize HSF2-
deficient mouse embryonic fibroblasts (MEFs) to MG132 and to thermal stress of febrile-
range (Lecomte et al., 2010; Shinkawa et al., 2011), we propose that HSF2 is an important 
cell survival factor during prolonged proteotoxic stress in both murine and human cells. 
 
Although an efficient and sequence-specific genome editing tool, the guide RNA combined 
CRISPR-Cas9 nuclease can have off-target effects at sites that closely resemble the on-target 
sequence (Kim et al., 2015). Thus, to verify that the decreased survival of the 2KO cells is 
not caused by CRISPR-Cas9 off-target effects, HSF2 was transiently downregulated from 
the WT cells by transfecting the cells with HSF2 shRNA encoding expression plasmids 
(described in Östling et al., 2007). Intriguingly, transient downregulation of HSF2 also 
sensitized the WT cells to BTZ and resulted in impaired cell viability (Figure 1G in IV). 
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Moreover, HSF2 downregulation enhanced the BTZ-induced accumulation of cleaved 
PARP-1 (Figure 1H in IV), indicating that the cells are more apoptotic than the WT cells. 
These results strongly imply that HSF2 is a key cellular survival factor during prolonged 
BTZ-induced proteotoxic stress.  
 
It is, however, important to note that our results only describe the effect of HSF2 
downregulation on one single U2OS cell line. To elucidate if HSF2 downregulation also 
sensitizes other cell types to BTZ-induced proteotoxic stress, we transfected K562 and PC-3 
cells with HSF2 shRNA encoding plasmids and exposed the cells to BTZ. However, we were 
not able to completely disrupt the expression of HSF2 in these cells (data not shown) and 
thereby did not observe any impairment of cell viability upon BTZ treatment. These 
observations likely reflect the strong ability of BTZ to induce upregulation of HSF2 at the 
mRNA level (Rossi et al., 2014), which might override the capacity of shRNA to fully 
deplete HSF2 mRNA molecules. Thereby, targeting HSF2 at the mRNA level might not be 
suitable for demonstrating the importance of HSF2 during proteotoxicity in all cell types.  
Interestingly, Clift and co-workers recently described a novel method to downregulate 
protein expression at the protein level (Clift et al., 2017). The method is called Trim-Away 
and it is based on TRIM21 E3 ubiquitin ligase, which has high affinity for the Fc-domains 
of antibodies and thus can rapidly direct the degradation of antibody-bound complexes 
through the ubiquitin-proteasome system. Since TRIM21 is widely expressed in a variety of 
cell types, including U2OS and HEK2893T cells (Clift et al., 2017), the key requirement of 
this method is the transfection of target-specific antibodies to the cells e.g. by electroporation. 
Thus, it would be useful to examine, whether Trim-Away-based transient depletion of 
functional HSF2 protein can sensitize a broader selection of cell types to BTZ treatment.  
 
Proteasome inhibition is a well-known inducer of heat shock response, which is mounted to 
alleviate the proteotoxic damage through HSF1-mediated expression of HSPs (Gomez-Pastor 
et al., 2018). Recently, Shah and co-workers reported that expression of HSF1 as well as its 
phosphorylation on serine 326 are required for the survival of myeloma cells during BTZ-
induced proteasome inhibition (Shah et al., 2016). To determine whether the decreased 
viability of 2KO cells is caused by impaired HSF1 expression or phosphorylation on S326, 
we treated the WT and 2KO cells with BTZ and MG132 and analyzed the levels and the 
phosphorylation status of HSF1 S326 by immunoblotting with specific antibodies. 
Intriguingly, we observed no differences in HSF1 expression levels or the phosphorylation 
status of serine 326 between WT and 2KO cells (Figure Supplement 1D in IV). These results 
suggest that albeit HSF1 is essential for HSP expression and cell survival during acute stress, 
it is unable to solely protect cells from apoptosis during prolonged BTZ-induced 
proteotoxicity. Furthermore, the results propose that HSF1 and HSF2 might provide 
protection against proteotoxic stress through two different mechanisms. 
 
4.3 HSF2 disruption does not compromise inducible survival programs  
Similarly to other surveillance transcription factors, such as the DNA-damage sensitive p53 
(Kubbutat et al., 1997) or the oxidative stress sensitive Nrf2 (Kobayashi et al., 2004), HSF2 
is an unstable protein under normal growth conditions (Ahlskog et al., 2010) and regulation 
of its protein expression levels is considered the key mechanism determining its DNA-
binding activity (Mathew et al., 1998; Sarge et al., 1994). Due to the prominent upregulation 
of HSF2 and localization to the nucleus upon BTZ-treatment, we next asked if the decreased 
survival of HSF2-depleted cells could be caused by misregulation of HSF2 target genes. To 
study that, we decided to perform a whole genome transcriptome analysis with RNA-seq, on 
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samples generated form U2OS WT and 2KO cells treated with DMSO or with 25 nM BTZ 
for 6 or 10 h (Figure 2A in IV). These time points were selected to represent such proteotoxic 
conditions, where the cell viability is not yet compromised (Figure Supplement 2A in IV). 
Before proceeding into RNA-extraction the 2KO phenotype and the functionality of the 
treatment was confirmed by analyzing the expression levels of HSF2, HSF1, and Hsp70 with 
immunoblotting. As evidenced by Figure Supplement 2B (in IV), we observed no HSF2 in 
samples generated from 2KO U2OS cells. Moreover, the 2KO cells exhibited equal HSF1 
levels and inducible Hsp70 expression compared to WT cells in response to BTZ treatment 
(Figure Supplement 2B in IV). From the verified samples, the poly-A containing mRNA 
molecules were purified with poly-T oligo magnetic beads and fragmented under elevated 
temperatures. RNA fragments were reverse transcribed to cDNA after which the cDNA 
molecules were ligated to Illumina TrueSeq indexing adapters to generate the cDNA library. 
Samples were sequenced with the Illumina HiSeq 3000 and the raw sequences were aligned 
against the hg38 human genome assembly. After normalization, the statistical testing 
between the sample groups was performed with Bioconductor R package Limma (Ritchie et 
al., 2015) and the differentially expressed genes were filtered using fold change (FC) ≥3 and 
false discovery rate (FDR) <0.001 as cutoff. Correlations between the quadruplet samples 
were determined with Spearman´s metrics (Figure Supplement 2C in IV). According to the 
analysis, both WT and 2KO U2OS cells responded to BTZ treatment with significant 
upregulation and downregulation of distinct genes (Figure 2B and Table supplement 1 in IV). 
The table supplements 1 and 2 can be accessed through the following link, which will be 
available until June 18th, 2018: https://bit.ly/2EQKyyu. 
 
To identify the putative HSF2-mediated transcriptional survival program, we first compared 
the genes that were inducibly upregulated and downregulated in WT and 2KO cells in 
response to BTZ. To our surprise, the inducible gene expression profiles were highly similar 
between the cell types (Table supplement 1 in IV) and the GO-term analysis of biological 
processes did not reveal any processes that would be significantly misregulated in the 2KO 
cells (data not shown). To specifically search for the survival programs that would be altered 
in the 2KO cells, we next addressed whether induction of autophagy or unfolded protein 
response would be affected in the 2KO cells. Both processes are known to be induced in 
response to BTZ (Hideshima & Anderson, 2012) and inhibition of their activity has been 
linked to reduced cell survival during BTZ treatment (Chang & Wang, 2016). Immunoblot 
analysis of LC3B-II, a ubiquitin-like molecule widely used as a cellular readout for 
autophagy levels (Barth et al., 2010; Hansen & Johansen, 2011), revealed nearly equal levels 
of accumulating LC3B-II (Figure 16), indicating that the BTZ-induced autophagy is not 
hampered in the 2KO cells. Moreover, the normalized gene expression data was used to 
examine the expression kinetics of distinct target genes associated with the UPR (Walter & 
Ron, 2011), which clearly showed that the lack of HSF2 does not impair the inducible 
expression of ER-stress related target genes (Figure 17).  
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Figure 16. Lack of HSF2 does not affect BTZ-induced autophagy. U2OS WT and 2KO cells were 
treated with indicated concentrations of BTZ for 22 h and the expression of LC3B-II was examined 
with immunoblotting. GAPDH was used as a loading control.   
 
 
 
Figure 17. HSF2 disruption does not compromise the induction of the unfolded protein 
response upon BTZ treatment. mRNA expression levels of selected ER-stress related genes. 
Normalized ene expression data for ERN1 (IRE1), XPB1 (XPB1), ATF4 (ATF4), ATF3 (ATF3), DDIT3 
(CHOP), PPP1R15A (GADD34), HSPA5 (GRP78), DNJAC3 (p58IPK), and DNAJB9 (ERdj4) was 
used to analyze the expression kinetics of these genes in control (C) and BTZ-treated (6 or 10 h) WT 
(black lines) and 2KO (blue lines) cells. The data is presented as mean values ± SEM relative to WT 
control sample that was set to 1.  
 
Yet another key consequence of proteasome inhibition is the cytosolic accumulation of 
misfolded and damaged proteins and subsequent initiation of the heat shock response (Bush 
et al., 1997; Mitsiades et al., 2002). In contrast to acute heat shock, which predominantly 
activates HSF1, proteasome inhibition activates all members of the HSF family (Kawazoe 
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et., 1998). Therefore, we also wanted to determine whether the BTZ-induced activation of 
the heat shock response would be affected in the 2KO cells. We used the normalized 
expression data to study the inducible expression patterns of all human molecular chaperone 
genes (Kampinga et al., 2009) and found that the BTZ-inducible chaperone expression 
profiles between WT and 2KO cells are nearly identical (Figure 2C in IV). Only DNAJ12 
and DNAJC18 displayed clearly different expression patterns (Figure 2C in IV). A closer 
examination of selected HSP genes (HSPA1A, HSPA6, HSPB1, and HSP90AA1), revealed 
that the expression of these genes is equal or even higher in the 2KO cells when compared 
to the WT cells (Figure 2D in IV). HSF2 has been previously shown to negatively regulate 
the stress-inducible expression of distinct Hsp target genes (Elsing et al., 2014; Östling et al., 
2007), which likely explains the higher expression levels of HSPB1 and HSP90AA1 observed 
in here. In addition to Hsps, HSF1 and HSF2 bind also to the promoters of Hsp90 co-
chaperones and polyubiquitin genes in response to heat stress (Vihervaara et al., 2013). To 
study whether HSF2-depletion would impact the expression of such genes upon BTZ-
treatment, the expression of Hsp90 co-chaperones PTGES3 (p23) and AHSA1 (AHA1), and 
the polyubiquitin genes UBB and UBC was analyzed. Similarly to Hsps, we observed no 
significant differences in the levels of these genes between the BTZ-treated WT and 2KO 
cells (Figure 2E in IV), and thereby conclude that the heat shock response is not impaired in 
cells lacking HSF2. Of note, although HSF2 has been previously shown to be dispensable 
for the transcriptional induction of specific heat shock genes (Mathew et al., 1998, Rossi et 
al., 2014), this is the first study to demonstrate the HSF2 is not required for the global 
induction of heat shock response during proteotoxic stress. 
 
Decreased expression of proteasome subunits has been previously proposed as one of the 
mechanisms causing the decreased survival of HSF2-deficient MEFs during MG132-induced 
proteasome inhibition (Lecomte et al., 2010). To examine if the proteasome subunits are 
significantly downregulated in the HSF2-depleted U2OS cells and thereby contribute to the 
sensitivity of the cells to BTZ, we used the normalized gene expression data to analyze the 
mRNA expression of all human proteasome subunits in control and BTZ-treated WT and 
2KO U2OS cells. In contrast to the results by Lecomte and co-workers (2010), no significant 
downregulation of proteasome subunits (either 20S or 19S) was detected in the 2KO cells 
(Figure 18), suggesting that HSF2 disruption does not predispose U2OS cells to BTZ 
treatment through misregulated expression of proteasome subunits. Interestingly, reduced 
expression of the 19S particles has been shown to also protect human cancer cells from 
proteasome inhibiting treatments (Acosta-Alvear et al., 2015; Tsvetkov et al., 2015). 
Although the expression of proteasome subunits was modestly decreased in the 2KO cells, it 
did not provide any survival advantage to the 2KO cells upon exposure to BTZ. Thereby it 
is unlikely that misregulated expression of proteasome subunits would cause the drastic 
survival differences detected between the WT and 2KO cells upon BTZ treatment (Figure 
1B in IV). Nevertheless, as RNA-seq only examines the expression of specific genes at the 
mRNA level, it would be beneficial to determine the expression of proteasome subunits also 
at the protein level or the overall functionality of the proteasome with a proteasome activity 
assay.    
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Figure 18. Expression of proteasome 
subunits is not compromised in HSF2 KO 
cells. U2OS WT and 2KO cells were treated 
with 25 nM BTZ for 6 or 10 h. Control cells were 
treated with DMSO. Gene expression changes 
were analyzed with RNA-seq. Differentially 
expressed genes in each comparison pair, were 
determined with Bioconductor R package 
Limma (Ritchie et al., 2015) (FC≥3, 
FDR<0.001).  Normalized expression data for all 
human proteasome subunit genes was used to 
calculate the fold change of each gene in 
relation to respective expression in WT control 
sample. The data is presented as heatmap of 
log2 transformed fold changes and it was 
generated with GraphPad Prism.
Altogether these results propose that the inducible survival programs are not impaired in the 
2KO cells and thereby it remains to be established why HSF2 is so prominently upregulated 
upon BTZ treatment. Since this study mainly relies on analyzing large gene sets that were 
acquired with stringent cutoff criteria, it fails to unveil the importance of single genes or 
genes that are more subtly changed in response to BTZ. Moreover, as HSF2 has been shown 
to act as both an activator and a repressor (Östling et al., 2007) it is possible that HSF2 has a 
highly complex target gene selection during proteotoxic stress. Since the current literature 
regarding the HSF2 target genes is fairly scarce, we can only speculate on the importance of 
distinct genes that were found misregulated in the 2KO cells. However, one gene worth 
mentioning is CDKN1A, which encodes a cyclin-dependent kinase inhibitor 1, p21, a well-
established p53 target gene required to arrest cell cycle (Fischer, 2017). Unlike other p53 
target genes, which were similarly regulated in BTZ-treated WT and 2KO cells, the 2KO 
cells failed to induce the expression CDKN1A upon exposure to BTZ (Figure 19). This might 
suggest that the 2KO cells are not able to regulate the progression of mitosis similarly to the 
WT cells. Considering the notion that HSF2 is downregulated during mitosis (Elsing et al., 
2014), it would be interesting to examine, if the pronounced upregulation of HSF2 is required 
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for stress-induced regulation of mitotic progression and thereby also for cell survival upon 
such conditions.  
 
      
 
 
4.4 HSF2 affects genes related to cell-cell adhesion 
To unravel the differences between the WT and 2KO cells, we next examined the 
significantly changed genes in 2KO:WT comparison pair at each experimental time point 
(control, 6 h, and 10 h) (Figure 3A in IV). Interestingly, absence of HSF2 resulted in 
significant misregulation of 819 genes (272 upregulated, 547 downregulated) already in 
control conditions, whereas after 6 and 10 h treatments 765 (250 upregulated, 515 
downregulated) and 688 (207 upregulated, 481 downregulated) genes, respectively, showed 
altered expression in 2KO cells (Figure 3B in IV and Table Supplement 1). GO term analysis 
of the misregulated (both up- and downregulated) genes in each time point revealed specific 
enrichment of terms related to cell adhesion and included terms such as biological adhesion 
and cell-cell adhesion via plasma membrane adhesion molecules (Figure Supplement 3A in 
IV). Notably, the terms between all studied comparison pairs were highly similar, strongly 
suggesting that the lack of HSF2 affects genes relevant to cellular adhesion properties both 
under normal growth conditions and upon exposure to BTZ-induced proteasome inhibition 
(Figure Supplement 3A in IV). 
 
To define the genes that are misregulated in 2KO cells in all experimental time points, we 
generated Venn diagrams of both upregulated and downregulated genes in each comparison 
pair with the BioVenn web tool (BioVenn, http://www.cmbi.ru.nl/cdd/biovenn/). In total of 
114 common genes were found upregulated and 277 common genes downregulated in all 
comparison pairs (Figure 3B in IV). Analysis of the 114 upregulated genes with DAVID 
functional cluster annotation tool (Dennis et al., 2003) revealed strong association to cell 
adhesion and included genes associated with extracellular matrix attachment, such as 
collagens (COL16A1, COL18A1), laminins (LAMB1 and LAMA5), and integrins (ITGB4) 
(Figure Supplement 3B in IV). Excitingly, the 277 downregulated genes were linked with 
GO terms such as cell-cell adhesion, and IPR (protein amino acid and sequence annotation) 
terms such as cadherin and N-terminal cadherin (Figure 3D in IV), suggesting for 
involvement of a specific type of cell-cell adhesion molecules, namely the cadherins. The 
cadherins are essential transmembrane adhesion molecules, which mediate Ca2+-dependent 
cell-cell adhesion via their highly conserved extracellular cadherin domains (reviewed in 
Hirano & Takeichi, 2012). The human genome encodes 110 cadherin genes, which together 
form a cadherin superfamily that can be further divided into distinct sub-families. The main 
role of cadherins is to mediate tissue integrity and they are essential for proper development 
of multicellular organism (reviewed in  Hirano & Takeichi, 2012). Intriguingly, the 
significantly downregulated genes included members from multiple different cadherin sub-
families, such as protocadherins (e.g. PCDHA1 and PCDHA7), desmosomal cadherins 
Figure 19. Upregulation of CDKN1A is impaired in cells 
lacking HSF2. Normalized gene expression data was used to 
analyze the expression kinetics of CDKN1A in control (C) and 
BTZ-treated (6 or 10 h) WT (black lines) and 2KO (blue lines)
cells. The data is presented as mean values ± SEM relative to
WT control sample that was set to 1.  
 Results and Discussion  
 81
(DSC2) and Fat-Dachsous cadherins (FAT2), indicating that the cadherin-mediated cell-cell 
adhesion is misregulated in 2KO cells at multiple levels (Figure 3D in IV). The most 
prominent sub-family was, however, the protocadherins, as 13 distinct protocadherin genes 
were found significantly downregulated in all examined comparison pairs (2KO:WT in 
control, 6 h and 10 h) (Figure 3D in IV).  
 
4.5 Abnormal expression of cadherins in cells lacking HSF2  
Due to the relatively stringent cutoff criteria used in this study (FC ≥3, FDR <0.001), the 
more subtly changed genes were automatically excluded from the analysis. Because 
cadherins appeared as a completely novel group of HSF2 target genes, we wanted to examine 
the expression of all the cadherin superfamily genes in WT and 2KO cells in more detail. 
Normalized gene expression data was used to generate a heat map governing all the currently 
known cadherin genes in the human genome (reviewed in Hirano & Takeichi, 2012). 
Surprisingly, by comparing the expression of each gene to the level detected in the WT cells, 
we observed extensive downregulation of the whole cadherin superfamily, as at least one 
member from all sub-families was markedly downregulated in 2KO cells (Figure 4A in IV). 
These included classical cadherins (CDH2 and CDH6), desmosomal cadherins (DSC2 and 
DSG2), CDH23-PCDH15 cadherins (CDH12), Fat-Dachsous cadherins (FAT2 and FAT4), 
Flamingo cadherins (CELSR1), and Calsyntenins (CLSTN2) (Figure 4A in IV). The most 
striking downregulation was detected in the sub-family of clustered -, -, and -
protocadherins, of which 92% were found abnormally expressed in the 2KO cells (Figure 4A 
in IV). These results indicated that HSF2 is a key regulator of multiple cadherin superfamily 
genes. 
 
The extensive downregulation of the cadherin genes raises important questions about the 
mechanism(s) by which HSF2 regulates the cadherin expression. HSF2 is a potent DNA-
binding factor and thus it is possible that HSF2 affects cadherin gene expression by directly 
binding to these genes. Previously, genome-wide HSF2 binding sites have been analyzed 
with ChIP-seq in human erythroleukemia K562 cells (Vihervaara et al., 2013) and in mouse 
testis (Korfanty et al., 2014), which are two very different model systems. The non-adherent 
K562 cells are deficient of endogenously expressed classical cadherins and specific 
protocadherins (Ozawa & Kemler, 1998) and, perhaps not surprisingly, HSF2 occupies only 
the CLSTN gene in normal growth conditions (Vihervaara et al., 2013). However, upon 
exposure heat stress, HSF2 binding is observed at members of classical cadherins (CDH4), 
desmogleins (DSG2), Fat-Dachous cadherins (DCHS2), Flamingo cadherins (CELSR2), and 
CDH23-PCDH15 cadherins (CDH23) (Vihevaara et al., 2013), indicating that multiple 
cadherin genes are direct HSF2 targets in human cells. Furthermore, in mouse testis, HSF2 
occupancy was observed at CDH15, CDH5, CDH7-11, CDH18, CDH20, CDH13, FAT1, 
FAT4, PCDH9, PCDH17, and PCDHA1 (Korfanty et al., 2014), demonstrating that multiple 
cadherin superfamily genes are direct HSF2 targets in both murine and human cells. Thereby, 
it is plausible that the altered cadherin expression observed in 2KO cells in this study, results 
from lack of HSF2 binding on those genes.  
 
However, as we did not examine the direct HSF2 targets in the U2OS cells, it is also possible 
that HSF2 affects cadherin gene expression indirectly via some other gene regulatory factors. 
For example, the expression of clustered protocadherins, which were the most extensively 
misregulated cadherin superfamily members in the 2KO cells, has been previously shown to 
be regulated by chromatin modifying factors such as CTCF (CCCTC-binding 
factor)/cohesin-complex (Golan-Mashiach et al., 2012), methyltransferase DNTMB3 (DNA 
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(cytosine-5-)-methyltransferase 3 beta) (Toyoda et al., 2014), and SETDB1 (SET domain, 
bifurcated 1) -repressor complex (Jiang et al., 2017). Interestingly, the expression of CTCF, 
cohesin-complex subunits SMC1A, SMC3, and RAD21 (Song & Kim, 2017), DNTMB3, or 
SETDB1 was not altered in the 2KO cells (Figure 20), proposing that the downregulation of 
clustered protocadherins is not caused by misregulation of these factors in the 2KO cells. 
Therefore, it would be important to determine (e.g. with ChIP-seq) if HSF2 can directly bind 
to cadherin superfamily genes in U2OS cells and explore the mechanism(s) by which HSF2 
regulates the expression of these genes. 
 
 
 
Figure 20. The expression of chromatin 
modifying factors, previously identified as 
regulators of protocadherin expression, is 
not altered in 2KO cells. Gene expression 
profile of WT and 2KO U2OS cells was 
analyzed with RNA-seq. Normalized gene 
expression data for CTCF, SMC1A, SMC3, 
RAD21, DNMT3B, and SETDB1 was used to 
calculate the fold change of each gene in 
relation to respective expression in the WT 
cells. The data is presented as mean values 
+SEM relative to WT sample that was set to 1.
To determine the biological relevance of the extensive cadherin downregulation, we next 
analyzed the protein expression levels of -protocadherins (Pan-PCDHA) and N-cadherin 
by immunoblotting. We observed that both -protocadherins and N-cadherin are 
downregulated also at the protein level in BTZ-treated 2KO cells (Figure 4B in IV). Since 
cadherins are essential in mediating Ca2+-dependent cell-cell adhesion (Hirano & Takeichi, 
2012), their functionality can be assessed with a cell aggregation assay, which measures the 
cellular ability to adhere to neighboring cells in liquid (Emond et al., 2011). For this, U2OS 
WT and 2KO cells were suspended in aggregation assay buffer supplemented with either 3 
mM CaCl2 or calcium chelator EDTA (ethylenediaminetetraacetic acid) and rotated for 2.5 
h at 37°C, 150 rpm. Following that, the cell aggregates were examined with microscopy. 
Intriguingly, when supplemented with Ca2+ the WT cells formed large cell aggregates, which 
were abolished in the presence of Ca2+ -chelating EDTA (Figure 4C in IV). In stark contrast, 
2KO cells were completely unable to form cell aggregates even in the presence of Ca2+, 
clearly demonstrating that the cells are deficient of Ca2+-dependent cell-cell adhesion 
molecules. Altogether, these results show that HSF2-depleted U2OS cells exhibit cadherin 
downregulation at both mRNA and protein levels, which results in functional inability to 
form relevant Ca2+-dependent cell-cell contacts.  
 
Considering the functional impairment of cadherin-mediated cell-cell adhesion in 2KO cells, 
it is tempting to speculate that the misregulation of cadherins is one of the molecular 
mechanisms behind the developmental defects, namely disrupted spermatogenesis and 
corticogenesis, observed in hsf2-/- mice (Kallio et al., 2002; Wang et al., 2003, Chang et al., 
2006). In testis, the seminiferous epithelium lining the lumen of the seminiferous tubules 
accommodates both the differentiating spermatocytes as well as the Sertoli cells that nurse 
the differentiating sperm cells. Interestingly, one of the key elements of correct sperm 
production is the various cell-cell contacts between the Sertoli cells and the differentiating 
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cells, which not only regulate the polarity of the cells but also direct the cell transport and 
release from the epithelium (reviewed in Gao & Cheng, 2016). As one of the most prominent 
spermatogenic defects in the hsf2-/- mouse is the accumulation of apoptotic cells, it is 
intriguing to hypothesize that the lack of appropriate cell-cell contacts leads to misregulation 
of sperm release and subsequently promotes apoptosis in the developing sperm cells. In 
addition to spermatogenesis, also corticogenesis is affected in hsf2-/- mouse and has been 
shown to be caused by defects in neuronal migration and positioning (Chang et al., 2006). 
Though protocadherins are fairly unexplored group of proteins, their role in brain 
development and neuronal migration has been implicated (Hayaishi & Takeichi, 2015). Since 
protocadherins were identified in this study as the main cadherin sub-family downregulated 
in HSF2 KO cells (Figure 4A in IV), it would be interesting to examine, whether the HSF2-
dependent misregulation of cell-cell contacts contributes to the defective corticogenesis in 
the hsf2-/- mouse. In support of this, both protocadherin 2A (PCDH2A) (Hirano et al., 2002) 
and HSF2 (Kallio et al., 2002) expression has been detected particularly in the ependymal 
cell layer forming the lining of lateral ventricles, indicating that the proteins share similar 
tissue expression patterns in mouse brain. Consequently, it would be extremely interesting to 
study, if lack of HSF2 results in cadherin downregulation also in hsf2-/- MEFs and in hsf2-/- 
mouse tissues and subsequently utilize the hsf2-/- mouse to define the physiological relevance 
of our results. 
 
4.6 Impaired cell-cell contacts predispose cells to chronic proteotoxic stress 
Albeit the importance of cadherins has been demonstrated in a variety of developmental 
systems, their role in the cellular resistance to proteotoxic stress has remained poorly 
understood. To elucidate if the cadherin-mediated cell-cell adhesions contribute to the 
cellular resistance against BTZ-induced stress, we re-introduced N-cadherin to the HSF2-
depleted cells aiming to restore cell-cell adhesion. As evidenced by figure 5A (in IV), U2OS 
2KO cells transfected with the Mock-plasmid displayed lower N-cadherin levels than the 
Mock-transfected WT cells, whereas in the 2KO cells transfected with the N-cadherin 
encoding expression plasmids, the levels were modestly increased (Figure 5A in IV). Of note, 
we were not able to fully rescue the expression to the level observed in the WT cells, which 
likely was caused by low transfection efficiency and cell survival after transfections (data 
not shown). Following the transfections, cells were let to recover for 24 h, after which they 
were counted and re-plated for BTZ treatments. Strikingly, when exposed to BTZ, the N-
cadherin transfected 2KO cells accumulated significantly less cleaved PARP-1 than the 
Mock-transfected cells (Figure 5B in IV), indicating that re-introduction of N-cadherin can 
increase cell survival during BTZ-induced proteotoxic stress. Since N-cadherin was not the 
only cadherin downregulated in 2KO cells, we next wanted to study if global destabilization 
of cadherin-mediated cell-cell contacts can sensitize the U2OS cells to BTZ. For that, U2OS 
WT and 2KO cells were first treated with 25 nM of BTZ for 20 h in serum free media (SFM) 
to induce accumulation of misfolded proteins inside the cells. Following day, the cadherin-
mediated cell-cell adhesion contacts were destabilized by depleting the extracellular Ca2+ 
with 3 mM EDTA (2 h) and the effect on cell viability was examined with Calcein AM assay 
(Figure 5C in IV). Intriguingly, Ca2+-depletion was found to enhance the apoptotic effects of 
BTZ, since the WT cells treated with both BTZ and EDTA exhibited significantly reduced 
cell survival and more apoptotic phenotype when compared to the EDTA-treated cells 
(Figure 5C in IV). In 2KO cells the effect of Ca2+-depletion was even more dramatic and 
resulted in nearly complete abolishment of living cells when combined to BTZ treatment 
(Figure 5C in IV). Altogether these results indicate, that destabilization of cadherin-mediated 
cell-cell contacts can predispose U2OS cells to BTZ-induced proteotoxic stress.  
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It is important to note that Ca2+-depletion does not only disrupt cadherin-mediated cell-cell 
contacts but affects a variety of cellular features. Thus, we cannot exclude the possibility that 
the observed results are caused by some other yet unidentified factors and for that it would 
be beneficial to inhibit the functionality of the cadherins with more specific methods. The 
challenge is, however, the simultaneous downregulation of multiple cadherin superfamily 
members in the 2KO cells, which makes e.g. siRNA-based downregulation methods 
unfeasible. Although not really assisting with the challenge of multiple cadherins, one way 
to specifically inhibit the function of distinct cadherins would be to use subtype specific 
antibodies to neutralize the cadherin extracellular domains. In principle, such method is 
highly similar to the Trastuzumab-based inhibition of the HER2 receptor, i.e. it utilizes a 
monoclonal antibody that specifically binds to extracellular domains of transmembrane 
proteins. In fact, N-cadherin targeting monoclonal antibody GC-4 (manufactured by Sigma-
Aldrich), has been successfully used to block N-cadherin-mediated cell-cell adhesion in bone 
marrow-derived mesenchymal stem cells (Dubon et al., 2017) and thus it would be important 
to examine, whether simultaneous treatment with GC-4 and BTZ also reduces the viability 
of WT U2OS cells.  
 
4.7 HSF2 protects cells against accumulation of misfolded proteins 
In this and other studies, HSF2 has been shown to function as a cellular responder to 
proteasome inhibition and mediate cell survival during proteasome inhibition induced 
proteotoxicity (Mathew et al., 2001; Lecomte et al., 2010; Rossi et al., 2014). However, it 
has remained unclear, if HSF2 activation is caused by proteasome inhibition in particular or 
if the factor functions as a more general responder to cytosolic protein damage. To study that, 
we exposed both WT and 2KO cells to amino acid analogue L-canavanine to induce 
accumulation of damaged proteins without directly affecting the proteasome. U2OS WT and 
2KO cells were first starved in L-arginine depleted growth media for 17 h, after which the 
cells were supplemented with L-canavanine, a structural analogue of arginine. Starvation of 
the cells for a particular amino acid stalls the translation at the ribosomes, whereas 
supplementing the cells with an amino acid analogue reinitiates the translation and leads to 
incorporation of the supplemented amino acid to the growing peptide chain. Incorporation of 
an incorrect amino acid disturbs the folding of the peptide chain and thus results in 
accumulation of misfolded proteins in the cytosol. After the treatments, the expression of 
HSF2 and PARP-1 was examined through immunoblotting and the cells were visualized with 
microscopy. Excitingly, the WT cells supplemented with L-canavanine displayed higher 
HSF2 expression than the untreated cells, indicating that the U2OS cells respond also to 
amino acid analogue-induced stress by upregulating HSF2 (Figure 21A). Moreover, the 2KO 
cells were found to be clearly more sensitive to L-canavanine, as they accumulated more 
cleaved PARP-1 and appeared more apoptotic than their WT counterparts (Figure 21A and 
B). These results show that, similarly to BTZ-induced proteasome inhibition, also amino acid 
analogue exposure results in upregulation of HSF2 and is more toxic to 2KO cells than to 
WT cells. As HSF2 DNA-binding activity has been detected during azetidine (a proline 
homologue) treatment (Sarge et al., 1993), it is tempting to speculate that HSF2 does not 
specifically respond to proteasome inhibition, but rather functions as a more general 
surveillance transcription factor monitoring the cytosolic protein folding state.   
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Figure 21. HSF2 is required for cell survival upon amino acid analogue induced proteotoxicity. 
(A) Cells were starved for 17 h in L-arginine free growth medium (A14431-01, Gibco) supplemented 
with 10% fetal calf serum and 100 μg/ml penicillin-streptomycin. Following that, L-Canavanine sulfate 
salt (C9758, Sigma) was applied to cells in indicated concentrations. Cells were treated for 3 or 6 h. 
Expression of HSF2 and cleaved PARP-1 was analyzed through immunoblotting with indicated 
antibodies. Hsc70 was used as a loading control. Cells were harvested and visualized with Leica 
phase contrast microscope. Scale bar 100 µm. 
 
In conclusion, this study revealed that HSF2 is an essential cellular survival factor during 
prolonged proteotoxic stress. By examining the gene expression profiles of wild-type and 
HSF2-depleted U2OS treated with BTZ, we found that HSF2 disruption does not impair the 
induction of classical heat shock response in BTZ-treated cells. Albeit HSF2 has been 
previously shown to occupy distinct gene loci upon proteasome inhibition, this is the first 
study to reveal that HSF2 is not required for the global induction of stress-responsive heat 
shock genes. Excitingly, by comparing the differentially expressed genes between the wild-
type and HSF2-depleted cells, we identified cell adhesion as the main biological process 
disrupted in cells lacking HSF2. Moreover, functional cluster annotation of the HSF2-
dependent genes proposed for involvement of a distinct type of cell adhesion molecules, 
namely the cadherins, which were found extensively downregulated in the HSF2-depleted 
cells. The most striking downregulation was observed with the clustered protocadherins, of 
which the great majority was found misregulated in cells lacking HSF2. To the best of our 
knowledge, this is the first study to identify HSF2 as a key regulator of cadherin gene 
expression.  
 
By examining the biological impact of cadherin downregulation with a cell aggregation 
assay, we demonstrated that disruption of cadherin expression results in functional 
impairment of cell-cell adhesion contacts. This result is particularly important when 
considering the developmental defects (disrupted corticogenesis and spermatogenesis) 
 Results and Discussion  
 86
observed with the hsf2-/-  mouse, which might at least partially be caused by misregulated 
cell-cell adhesion contacts. Thereby, it would be essential to determine in the future studies, 
whether HSF2-disruption leads to cadherin downregulation also in other cell types and in 
mouse tissues. During prenatal exposure to alcohol, HSF2 binding on its target genes is 
impaired, which leads to brain developmental defects associated with the fetal alcohol 
spectrum disorder (FASD) (El Fatimy et al., 2014). Recently, Laufer and co-workers 
examined the FASD specific DNA-methylation patterns and identified clustered 
protocadherins as one of the main genes affected in FASD diagnosed children (Laufer et al., 
2015). Thus, it would be interesting also to examine, whether these two observations are in 
fact connected and disturbed HSF2 binding is the molecular phenomenon leading to 
differential methylation pattern of protocadherin genes associated with FASD. 
 
In mammals, HSF2 occupies a great number of target genes (Korfanty et al., 2014; 
Vihervaara et al., 2013), whose importance in stress resistance has not been characterized. In 
this study, we re-introduced N-cadherin to HSF2-depleted cells and revealed that cadherin 
mediated cell-cell contacts are required for cell survival during prolonged proteasome 
inhibition. To the best of our knowledge, this is the first study to describe the importance of 
cell-cell adhesion in proteotoxic stress resistance. Moreover, the study demonstrated that 
HSF2 is not only important during proteasome inhibition but protects cells also against amino 
acid analogue induced proteotoxicity. Together these results suggested that HSF2 is an 
essential cellular surveillance factor, which by maintaining the correct cell-cell adhesion 
contacts, protects the cells against prolonged proteotoxicity. Considering the notion that the 
cellular inability to maintain proteostasis is a key feature of aging and neurodegenerative 
diseases (Douglas & Dillin, 2010), it is tempting to speculate that HSF2 might also contribute 
to the outcome of neuronal proteotoxicity. Intriguingly, by expressing a mutant 
polyglutamine construct (polyQ81-GFP) in Hsf2-/- CEFs (chicken embryonic fibroblasts), 
Shinkawa and co-workers have demonstrated that lack of HSF2 promotes the accumulation 
of polyQ-inclusions (Shinkawa et al., 2011). Moreover, in the same study, HSF2-null 
Huntington´s diseases mice were shown to contain more insoluble polyQ-aggregates in the 
striatum and have shorter lifespans when compared to the Huntington´s disease mice with 
wild-type HSF2 expression. These results suggest that HSF2 is required to protect neurons 
from gradual accumulation of damaged proteins.  
 
Finally, although BTZ was used in this study only as a tool to induce prolonged proteotoxic 
stress, we cannot ignore the clinical relevance of the molecule and thereby also the possibility 
that HSF2 might contribute to the outcome of BTZ treatment. Since HSF2 was shown in this 
study to protect malignant cells from BTZ-induced proteotoxic stress, inhibiting the 
functions of HSF2 might result in cellular sensitization to the drug. Hence, it would be 
important to elucidate, if downregulation of HSF2 predisposes also other types of cancer 
cells to BTZ. BTZ is predominantly used to treat multiple myeloma and mantel cell 
lymphoma, but it is not similarly effective towards solid tumors (Chen et al., 2011). 
Considering the observations made in this study, one might argue that the solid tumors are 
more resistant to BTZ because of their proper cell-cell adhesion contacts. Thereby, the 
possibility that destabilization of cell-cell contacts increases the efficacy of the drug should 
also be examined. Furthermore, in the third study of this thesis (III), we identified HSF2 as 
a novel regulator of prostate cancer progression and showed that downregulation of HSF2 is 
linked to the initiation of invasive behavior. Considering the observations made in this study, 
it is possible that the downregulation of HSF2 promotes the initiation of invasive behavior 
by destabilizing the cadherin-mediated cell-cell contacts. Although purely hypothetical, it is 
also interesting to speculate that if the initiation of invasion requires HSF2 downregulation, 
 Results and Discussion  
 87
perhaps it is the invasive cells that are the most sensitive to BTZ treatment. Since 90 % of 
the cancer-associated deaths are caused by metastases (Lambert et al., 2017), it would be 
essential to be able to target specifically the invasive tumor cells that have escaped from the 
original tumor site to the circulation or lymphatics (aka. circulating tumor cells, CTCs). 
Thereby, the future studies should define whether the invasion-related downregulation of 
HSF2 sensitizes metastatic cancer cells to BTZ-induced proteotoxic stress. 
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CONCLUDING REMARKS  
Sumoylation is an essential PTM and development of novel unbiased methodologies to study 
sumoylation is pivotal in our attempts to unravel the complex cellular sumoylome. In the 
beginning of this thesis work, the methods that were used to identify sumoylated proteins 
mainly relied on in vitro sumoylation reactions and cumbersome identification of putative 
target peptides by mass spectrometry. Such methods were often challenged by the biological 
and biochemical properties of sumoylation, which greatly hindered the detection of novel 
sumoylation substrates. In this thesis, we developed a novel method to study sumoylated 
proteins in vivo in cells. The method is based on engineered human SUMO1 and enables 
better purification and more accurate identification of both consensus and non-consensus 
sumoylation substrates. At the time of its publication, the method provided an important 
advancement to the sumoylation research and many of its biochemical details are still applied 
in the currently used sumo methodologies. 
 
The second study of this thesis focused on HSF1 phosphorylation, which was the first 
identified post-translational modification to co-occur with HSF1 activation. For years, 
hyperphosphorylation was considered as the main modification regulating HSF1 activity and 
multiple research groups published their studies regarding the importance of single-site 
phosphorylation in the regulation of HSF1. We aimed at elucidating the importance of HSF1 
hyperphosphorylation by generating a phosphorylation deficient HSF1 mutant and 
investigating its functionality during heat shock response. The study demonstrated that HSF1 
phosphorylation is not required for the inducible heat shock response, but functions as a fine-
tuning mechanism for the heat-inducible transcription of Hsps. Our observations are 
elementary to the HSF1-field and provide a conclusion to the reports implicating 
phosphorylation as a key requirement of HSF1 activity. However, many questions still 
remain open. For example, we do not understand how phosphorylation mediates the observed 
effects and whether these findings are applicable also in specific developmental and disease 
contexts.  
 
Due to its strong ability to enhance cell survival, HSF1 is a potent inducer of carcinogenesis 
and overexpression of HSF1 has been detected in multiple human cancer types. In contrast, 
the importance of HSF2 in cancer progression was not known prior to study III of this thesis. 
We showed that decreased HSF2 mRNA expression correlates with prostate cancer 
progression and that HSF2 downregulation occurs simultaneously with the initiation of 
invasive behavior of PC-3 prostate cancer organoids. By modulating HSF2 expression levels, 
we demonstrated that HSF2 maintains the epithelial phenotype in organoids and suppresses 
invasion. The study identified key cellular pathways affected by HSF2 in prostate cancer 
cells and proposed that decreased HSF2 expression in a general characteristic of human 
malignancies. As the levels of both HSF1 and HSF2 appear to be aberrant in cancer, it would 
be important to clarify how the expression of these factors is mechanistically regulated. From 
the clinical perspective, further studies are required to elucidate whether HSF2 could serve 
as a novel biomarker for prostate cancer progression.  
 
The final study of this thesis aimed at understanding the importance of HSF2 in the cellular 
response to prolonged proteotoxicity. Prior to this work, HSF2 had been shown to be 
activated in response to proteasome inhibition induced proteotoxic stress, but the 
mechanisms by which HSF2 protects cells were unknown. In this work, we utilized genome-
wide gene expression profiling (RNA-seq) to examine the differentially expressed genes 
 Concluding Remarks  
 89
between wild-type and HSF2-depleted U2OS cells and observed significant alterations in 
genes related to cell adhesion. More specifically, we found that the cadherin superfamily 
genes are the main genes misregulated in cells lacking HSF2 and demonstrated that 
disruption of proper cadherin-mediated cell-cell contacts predispose human cells to 
proteasome inhibiting treatments. By describing a previously unidentified class of HSF2 
target genes the study proposed a completely novel role for HSF2 in cellular physiology and 
identified a new determinant of stress resistance. Altogether, this work lays the ground for 
the future studies examining the molecular details behind HSF2-mediated developmental 
defects and thus provides essential information regarding the importance of HSF2 in human 
physiology and disease. 
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sumoylated proteins in cells and investigates the 
role of heat shock transcription factors (HSFs) in 
stress and disease conditions. Post-translational 
modifications, such as phosphorylation or sumoyla-
tion, mediate rapid signal-responsive alterations in 
protein function and have multiple target substra-
tes in mammalian cells. In this thesis, a modified 
human SUMO-1 is used as a basis for a method that 
can be used to identify novel sumoylation substra-
tes in cells. Phosphorylation, in turn, is examined in 
the context of HSF1, which is hyperphosphorylated 
in response to proteotoxic stress. On the contrary 
to the prevalent view, this thesis reveals that HSF1 
hyperphosphorylation is not essential for its activity 
but rather fine-tunes the HSF1-mediated transcrip-
tional response. In addition to HSF1, the mamma-
lian cells express another HSF-family member, HSF2, 
whose role in specific biological processes is still 
partially uncharacterized. In this thesis, HSF2 is iden-
tified as an important regulator of prostate tumori-
genesis and thereby this work describes a novel role 
for heat shock factors in human diseases. One of the 
main findings of this thesis presents HSF2 as a key 
survival factor upon proteotoxic stress and identifies 
not only a completely novel group of HSF2 target 
genes but also a previously unknown determinant 
of proteotoxic stress-resistance. Altogether the work 
presented in this thesis elaborates on HSF-mediated 
cellular survival pathways and lays a ground for fu-
ture studies regarding HSFs as important regulators 
of human physiology and disease.
